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Abstract 
 
Foot-and-mouth disease virus (FMDV) causes a highly infectious disease of 
cloven-hoofed livestock with economically devastating consequences. The political 
and technical problems associated with the use of FMDV vaccines make drug-
based disease control an attractive alternative. The FMDV genome is translated as a 
single polypeptide precursor that is cleaved into functional proteins by virally-
encoded proteases. Ten of the thirteen cleavages are performed by the highly 
conserved 3C protease (3C
pro
), making this enzyme an attractive target for anti-viral 
drugs (Curry et al., 2007a).  
This thesis describes the design, synthesis and evaluation of FMDV 3C
pro
 
inhibitors. A study of the activity of different FMDV 3C
pro 
mutants and a recently 
determined enzyme–substrate crystal structure provide an insight to the structure–
activity relationships of the target and provides a basis for the inhibitor design 
(Curry et al., 2007b; Sweeney et al., 2007). Taking the enzyme‘s specificity as a 
starting point (Birtley et al., 2005), a small peptide sequence corresponding to an 
optimal substrate has been modified at the C-terminus, by the addition of a 
warhead, making it able to irreversibly react with the active site of this cysteine 
protease. Several synthetic routes have been developed, one allowed easy 
modification of the peptidic component of the inhibitor, whereas a second was 
designed to enable the introduction of variation on the warhead moiety. After the 
expression and purification of the FMDV 3C
pro
, a FRET assay, developed to 
monitor changes on 3C
pro
 activity (Jaulent et al., 2007), was used to evaluate the 
inhibition of the enzyme by a range of potential synthetic inhibitors. The success of 
the inhibitor design has been demonstrated by the development of compounds that 
react as Michael acceptors with the enzyme active site. The investigation of the 
peptidic part of the inhibitor has highlighted key elements for inhibition which are 
supported by structural data. Finally, consideration of the bioavailability of these 
inhibitors, particularly in regard to membrane penetration, has led to use pro-drug 
approach in the further development of the inhibitors.  
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1 Introduction       
  
 
This introduction presents an overview of foot-and-mouth disease (FMD) and 
its current control measures, highlighting the need for FMD research after the 
recent outbreaks in the UK and worldwide. The causative agent, FMD Virus 
(FMDV), will be described in the context of its viral family. The mode of action of 
the virus is discussed along with current antiviral strategies which have revealed 
FMDV 3C protease (3C
pro
) as a valid target for antiviral therapy; such approaches 
offer an alternative control measure against FMD. An overview of proteases, 
including a comparative study of FMDV 3C
pro
 with its close relatives, places the 
specificity and structural characteristics of the enzyme in context. Finally, the aims 
and the structure of this thesis are outlined.  
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1.1 Foot-and-Mouth Disease 
FMDV is the causative agent of a highly contagious disease with a significant 
economic impact. FMD affects cloven-hoofed mammals, both wild and 
domesticated animals (such as cattle, sheep and swine), with the latter being more 
susceptible when intensively reared. There are seven FMDV serotypes and a 
spectrum of strains within each (section 1.2.1), but diseases caused by different 
serotypes are clinically indistinguishable.  
The clinical signs of the disease and their severity depend on the strain of the 
virus and the age and type of host. They typically include acute fever, profuse 
salivation and epithelial vesicles on the tongue, snout, teats and between the hoofs. 
These symptoms are rarely fatal for adult animals, but mortality is high among 
young individuals due to myocarditis. While the majority of the animals recover 
from the disease, it often leaves them weakened and debilitated (decreased weight, 
strength and milk production). Resulting in severe productivity losses, FMD 
represents a menace to the economy (James and Rushton, 2002). 
The disease spreads easily by inhalation, ingestion or skin penetration. Infected 
animals can carry FMDV for up to eight days before the clinical signs are evident, 
with viral particles being present in their tissues, natural secretions and excretions. 
Vaccinated animals or animals that have recovered from infection can host live 
viruses up to 5 years and may serve as carriers. Raw animal products and any 
contaminated material (e.g. equipment, vehicles and clothing) may also spread the 
disease. However, FMDVs are highly labile and rapidly lose infectivity at pH 
values lower than 7.0 (Brown and Cartwright, 1961).  
The infectivity and the economically devastating consequences of FMD have 
made it global problem. An overview on the present situation of FMD follows. For 
an extended review on foot-and-mouth disease refer to Grubman and Baxt (2004). 
1.1.1 Distribution of FMD  
FMD was first reliably described in 1514 (Fracastorius, 1514). Subsequently, 
outbreaks of FMD have occurred periodically in almost every livestock-containing 
region of the world. 
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FMD is placed on the A list of infectious animal diseases by the World 
Organisation for Animal Health (Office International des Épixooties: OIE). Given 
its highly contagious nature and economic importance for many countries, FMD is 
the first disease for which the OIE has established an official list of free countries 
and zones, with the latest update being found at http://www.oie.int. FMD is 
generally associated with low levels of development and it has become enzootic in 
areas of Africa, Asia, South America and the Middle East (Figure 1.1). Australasia 
and Indonesia, Central and North America and continental Western Europe are 
currently free of FMD; however, it occurs sporadically in typically free areas. Some 
recent examples are the outbreaks in Taiwan in 1997 and in the United Kingdom in 
2001 and again in 2007 (section 1.1.3). 
 
 
Figure 1.1 Distribution of FMD. 
Map compiled from the FMD outbreaks reported to the OIE for the period 2005–2007 (OIE, 2007). 
The OIE is responsible for granting FMD-free status, and all member states are required to report 
the event of an outbreak. 
With the globalisation of markets raising the risk of outbreaks, severe control 
measures allow only FMD-free countries to participate in the international trades of 
live animals and uncooked meat. Traditionally poor economies are consequently 
left without access to those markets, and their development remains severely 
1 Introduction 
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hampered. The presence of FMD also represents a menace to FMD-free countries. 
Therefore, the control and eventual eradication of the disease is in the interest of 
every economy (Kitching et al., 2007). 
1.1.2 Control of FMD 
In the event of a FMD outbreak, developed countries proceed with what is 
referred to as ―stamping-out‖ procedure (Sutmoller et al., 2003). Following the first 
detection of the disease, the immediate slaughter and safe disposal of the infected 
and in-contact animals is imposed together with the restriction of animal 
movement. Contingency plans may also include emergency vaccination which can 
be applied on top of the preventive vaccination that some countries use (Barnett 
et al., 2002; Toma et al., 2002).  
Rapid, sensitive and reliable diagnostic procedures are required for an 
immediate action against FMD. Clinical diagnosis alone may not be enough given 
the delay between infection and the appearance of clinical signs. Moreover, these 
can be indistinguishable from other viral diseases, like vesicular stomatitis and 
swine vesicular disease. Developments in recent years in virological and serological 
techniques (such as PCR, microarray and ELISA) have improved the speed and 
sensitivity of the analyses and have even allowed the identification of different viral 
strains (Remond et al., 2002). However, difficulties still remain to distinguish 
between infected and vaccinated animals (Clavijo et al., 2004). 
 Vaccination 
Vaccination has been traditionally used to control infectious diseases. A recent 
review on mass vaccination and herd immunity uses the control of Rinderpest, 
another viral disease affecting cattle, as an illustrative example (Roeder and Taylor, 
2007). Even though the use of FMDV vaccines has been successful in the reduction 
of outbreaks (Brown, 1992), preventive vaccination is not practised in the United 
States and Europe due to import/export restrictions in international trade regulation 
of animals and animal products and the lack of methods for the detection of carriers 
in vaccinated populations (Sutmoller et al., 2003).  
The control of FMD through vaccination strategies has been reviewed 
(Grubman and Mason, 2002; Doel, 2003). Some of the vaccines developed against 
 24 
 
FMDV include attenuated whole virus preparations, empty capsids and the use of 
proteins and peptides mimicking parts of the viral capsid, mainly VP1 (section 
1.2.4). However, given the considerable antigenic diversity of the virus (section 
1.2.1), the preparation of a universal vaccine is impracticable. Moreover, immunity 
will not develop for 4–5 days and will only last up to six months, adding to an 
already costly procedure to obtain the vaccines. Vaccine production requires 
inactivating whole-virus preparations in high containment facilities. There is good 
evidence that some FMD outbreaks had a vaccine origin due to incomplete 
inactivation prior to vaccine formulation (Sobrino et al., 2001). In addition, as seen 
in the recent FMD outbreak in the United Kingdom, there is the possibility of the 
virus escaping from such laboratories.  
1.1.3 FMD in the United Kingdom  
In the last decade FMD has hit the UK on two occasions: in 2001 and more 
recently in August 2007. The very different origins of these two outbreaks and the 
lessons learned from the hardship caused by the first have probably helped to 
reduce the consequences of the latter. 
 The 2001 outbreak 
In February 2001 the presence of pigs infected with FMD in an abattoir in 
South East England was confirmed. The pigs came from a fattening unit in 
Northumberland, near the Scottish border. The origin of the outbreak was attributed 
to the consumption of unprocessed waste food containing imported contaminated 
meat or meat products (Scudamore, 2002; DEFRA, 2005). Investigations also 
showed that the animals must have been infected at least 3 weeks before FMD was 
first reported, and that the viral strain involved was Type O, PanAsia. The nature of 
FMDV (see beginning of section 1.1), the lack of evident clinical signs in sheep 
when infected with the Pan Asia strain, and the huge animal movement taking place 
in the UK at that time of the year, contributed to the scale of the outbreak, which 
spread widely in the UK and reached France, Northern Ireland and the Netherlands.  
Given an initial reluctance to vaccinate and the rapid spread of the virus, the 
control of the disease was affected by slaughtering all contact or susceptible 
animals. In total, over 4 million animals were culled (Davies, 2002). Severe 
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questions and criticism were raised by farmers and the general public concerning in 
particular animal welfare. The total cost to the UK economy has been estimated at 
£8 billion (Thompson et al., 2002). Even though Thompson et al. have shown that 
the overall impact upon the GDP level in 2001 represents less than 0.2%, the losses 
incurred within particular sectors, which consequently were greatly affected. 
Temporary trade restrictions imposed on live animals and animal products caused 
severe losses for the agricultural and food sector, and the outbreaks and the related 
control measures had significant negative consequences for tourism.  
Soon after the crisis, a list of intentions was outlined in the International 
Conference on Control and Prevention of Foot and Mouth Disease (Commission, 
2001). With the ultimate goal of remaining FMD free without vaccination, the 
report included the need to revise the EC import policy. It also recognised the 
importance of rapid diagnosis and restriction of animal movement for effective 
disease management. Moreover, it stressed the need to encourage and adequately 
finance research, particularly the development of vaccines and diagnostic tests. It is 
beyond the scope of this introduction to review how the law has changed since. 
Nonetheless, the 2007 FMD outbreak has severely tested the contingency plans of 
the Department for Environment Food and Rural Affairs (DEFRA, 2005). 
 The 2007 outbreak 
On the 3
rd
 of August 2007 the UK authorities confirmed a FMD outbreak in a 
farm in Surrey, and immediately implemented measures in line with EC legislation 
(Council, 2003). After only one more outbreak a few days later and profuse 
sampling showing negative results for FMDV, the complete animal movement ban, 
the culling of animals and the establishment of protection and surveillance zones (3 
and 10 km around the first focuses) seemed to have been successful in stopping 
FMD. On the 8
th
 of September, 30 days after the completion of preliminary 
cleansing and disinfection, the UK authorities lifted the measures relating to the 
surveillance zone. However, on the 12
th
 of September a new FMD outbreak was 
confirmed 50 km away. The identification of five more outbreaks (the last one on 
the 30
th
 September) completes what is known as phase 2 of the 2007 FMD outbreak 
in the UK (Commission, 2007; IAH, 2007a). 
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Clinical signs alerted to the presence of FMD but action by DEFRA was taken 
after serological identification, which also helped in the recognition of 
asymptomatic infections in surveillance tests. Genetic fingerprint tests also allowed 
the classification of the viral strain involved in these events (O1 BFS) (IAH, 
2007a).  
Ironically, the causative agent of the outbreak was found to be most similar to 
strains used in diagnostic laboratories and in vaccine production, including those at 
the Pirbright site (5 km away from the first premises infected): Stabilitech Ltd., 
Merial Animal Health Ltd., and the Institute for Animal Health (IAH), where all 
tests relating to the outbreak were carried out (IAH, 2007b). The exact source of the 
virus and the way it escaped from the site remain unproven. However, in the report 
on possible security breaches, the Health and Safety Executive (HSE) suggested 
that some of the infrastructures and procedures at the site required revision (Logan, 
2007).  
These events highlight the need for alternative control methods, such as 
antiviral agents or vaccines that do not require infectious FMDV at any stage of 
their production (Grubman, 2005). By improving our understanding of the events 
taking place during viral infection at the molecular level, it is possible to identify 
potential targets for antiviral drugs.  
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1.2 Foot-and-Mouth Disease Virus 
At the end of the 19
th
 century, in what is seen as one of the first discoveries in 
the era of virology, Loeffler and Frosch demonstrated that FMD was caused by a 
filterable agent (Loeffler and Frosch, 1898). Ever since, not only are new viruses 
being discovered, but virology has benefited from technical advances that still 
today add to the comprehensive information on known viruses (Knipe et al., 2006). 
After many years of research in FMD, the way the virus finds its first target cells or 
tissues, how it is propagated, the different number of strains, the structure and 
function of the viral proteins and the events in the viral replication cycle have been 
unveiled (Brown, 2003). 
FMDV belongs to the Aphtovirus genus of the Picornaviridae (or picornavirus) 
family. This highly contagious viral family includes well studied human and animal 
viral pathogens, including human rhinovirus (HRV, the virus of the common cold), 
encephalomyocarditis virus (EMCV), hepatitis A virus (HAV) and poliovirus (PV). 
The picornavirus constitutes one of the simplest and smallest viral families (Figure 
1.2). The family is named after small (pico) and RNA, which refers to the 
characteristic that all the members in the family share: a small (approximately 
30 nm diameter) non-enveloped icosahedral capsid that contains a linear, positive 
sense RNA genome (+RNA) (Stanway, 1990).  
1.2.1 FMDV serotypes 
Due to a lack of error-correction mechanisms during genome replication, RNA 
viruses, and particularly FMDV, have high mutation rates (Holland et al., 1982). 
The mutations occurring within the capsid-coding region of the genome (region P1, 
section 1.2.2) are responsible for its significant antigenic variation and have been 
studied in detail (Knowles and Samuel, 2003).  
Traditionally, FMDVs had been classified according to the serological criteria 
by which they were classified on the basis of the lack of cross protection after 
infection or vaccination (Bachrach, 1968). The FMDV isolates can be grouped into 
seven distinct serotypes and are given the names of their areas of distribution. The 
Euroasiatic serotypes are A, O, C and Asia1, and the South African Territories 
serotypes SAT1, SAT2 and SAT3 (Knowles, 2007).  
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Figure 1.2 Schematic representation of the main viral families. 
In contrast with the size and complexity of some of the DNA and RNA viruses, the picornaviral 
particles (2nd from the bottom) are only composed of a protein shell surrounding a naked RNA 
genome. Taken from F. A. Murphy, School of Veterinary Medicine, University of California, Davis 
(Murphy, 2007). 
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 Viruses showing partial cross protection were assigned to the same serotype but to 
a different subtype. The availability of complete genome sequences have allowed 
the generation of phylogenetic trees that strongly correlate with the serotypical 
classification and have replaced the division into subtypes (Rodrigo and Dopazo, 
1995; Sobrino et al., 2001).  
Comparative genetic studies have been extended to other regions of the FMDV 
genome showing conserved motifs in the untranslated regions (UTR) and within the 
coding regions of the non-structural proteins L
pro
 and 3C
pro
 (van Rensburg et al., 
2002; Carrillo et al., 2005). This suggests that the development of a novel antiviral 
agent, with FMDV 3C protease as the drug target, may yield a drug that could work 
against a multitude of serotypes. 
1.2.2 The FMDV genome  
The FMDV genome is about 8500 bases long and it is constituted by two UTR, 
both at the 5′ and 3′ termini, and a single long open reading frame (ORF) (Figure 
1.3). The molecular basis of FMDV pathogenesis and the regulation of picornavirus 
gene expression have been reviewed recently (Mason et al., 2003; Bedard and 
Semler, 2004) and in this section only a short description of the roles of the two 
UTR and the ORF is presented.  
 
 
Figure 1.3 Schematic representation of the FMDV genome. 
The main elements of the 5′ and 3′ UTR (see below) are boxed and named. From the ORF only the 
two starting codons are highlighted here since it is illustrated further in section 1.2.3. Adapted from 
Vagnozzi et al. (2007). 
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 5′ UTR 
The 5′ UTR has a role both in genome translation and replication. One of the 
most striking differences between the positive strand RNA that constitutes the 
picornaviral genome and the host messenger RNA (mRNA) is that their 5′-terminal 
sequences are attached to protein VPg (virion protein, genome linked) also referred 
to as 3B. Whereas during translation the genome is free, during the replication 
events it is found to be covalently bound on its 5′ terminus to this 23–24 amino acid 
long protein.  
 FMDV 5′ UTR is bigger than most of its family members and hosts a unique 
combination of structural elements (Figure 1.3). The first feature is the highly 
structured S fragment, which is likely to be responsible for genome stability and it 
has been shown to interact with proteins that play a role in genome replication 
(Grubman and Bachrach, 1979; Barton et al., 2001). The Poly C track that follows 
is associated with cellular Poly C Binding Protein and could play a role in 
switching from replication to translation states, possibly due to interaction with the 
3′ UTR (Serrano et al., 2006). A series of pseudo knot structures (PKs) occur next, 
their function remaining unclear (Mason et al., 2003). The cis-acting replication 
element (cre) of FMDV (involved in genome replication) comes next; for a 
sequence always found within protein-encoding regions of the viral genome, to be 
situated within a UTR is very unusual. Finally, the internal ribosome entry site 
(IRES) can be found. This is probably the most significant element of this region of 
the genome, since the direct interaction of the IRES element with eIF4G 
(eukaryotic-translation initiation factor 4G) explains how picornaviral proteinases 
can keep translating their genome after host-cell protein synthesis shut-off (known 
as cap-independent translation).  
 ORF 
The open reading frame (ORF) section of the genome encodes all structural 
and functional proteins of the virus. It translates into a single polyprotein which, 
through different proteolytic events, will provide a series of intermediates and the 
final mature viral proteins (see following section and Figure 1.5). The mature viral 
proteins and the corresponding encoding regions of the ORF are named according 
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to the Rueckert and Wimmer nomenclature for picornaviral proteins (Rueckert and 
Wimmer, 1984).  
The ORF is divided in four parts according to the initial cleavage products of 
the polyprotein (Figure 1.5). The L (leader) region, which contains two in-frame 
AUG initiation codons, provides two different forms of leader protease, Lab and 
Lb. However, only Lb, originated from the second AUG codon (AUG2 in Figure 
1.3), seems to be biologically functional and accounts for the function of the 
protease referred to as L
pro
 in vivo (Cencic et al., 2007). The P1 region encodes the 
four structural proteins VP4, VP2, VP3 and VP1 also known as 1A, 1B, 1C and 1D 
respectively. The P2 region encodes the non structural (NS) proteins: 2A, 2B and 
2C. Finally, the P3 region encodes for the non structural proteins: 3A, three copies 
of 3B (or VPg), 3C protease (3C
pro
) and 3D polymerase (3D
pol
).  
 3′ UTR 
The 3′ UTR of the FMDV genome follows from the ORF termination codon 
and is constituted by a short stretch of RNA, which folds into two stem-loop (SL) 
structures, and a poly (A) tract. It is thought to function in translation and 
replication of the RNA and it may involve both RNA-protein interactions and 
bridging of the 3′ and 5′ ends. At least two distinct strand specific long range RNA-
RNA interactions have been described between the 3′ UTR and the S region and the 
IRES element of the 5′ UTR (Serrano et al., 2006).  
1.2.3 The FMDV cycle  
Picornavirus replication cycle occurs entirely in the cell cytoplasm (Knipe 
et al., 2006) (Figure 1.4). After binding to host-cell receptors, the RNA genome is 
uncoated through several structural changes on the viral capsid and enters the 
cytoplasm. The RNA is then translated to a polyprotein that is cleaved nascently to 
provide viral proteins essential for genome replication and the production of new 
viral particles. Genome replication occurs on small membranous vesicles that are 
induced by several viral proteins (Knox et al., 2005) and starts with the generation 
of a negative copy from the input positive RNA, as an intermediate to synthesise 
additional positive copies. During the early stages of infection, the newly 
synthesised RNA supports translation; however, once there are enough capsid 
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proteins is encapsidated to form new virions. Finally, after a cycle that lasts 
between 4–6 h (depending on temperature, pH, host cell etc.) the newly synthesised 
viral particles are released from the cell by lysis.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Schematic representation of the picornavirus life cycle in a cell. 
All events take place in the cytosol of the host cell: 1) attachment, 2) uncoating, 3) translation, 4) 
protein processing, 5) genome replication, 6) assembly and 7) cell lysis. By stopping protein 
processing (4), viral replication can potentially be inhibited. Adapted from (Knipe et al., 2006). 
 FMDV polyprotein processing 
The presence of proteinases within picornavirus polyproteins allows 
polyprotein processing with both co-translational and post-translational proteolytic 
cleavages. Two co-translational primary cleavages take place very rapidly to 
provide the P1-2A precursor and the full-length polyprotein is not detected in native 
polyprotein processing (Knipe et al., 2006).  
In FMDV the P1-2A precursor comes from the release of L
pro
 as the 
polyprotein grows and from the cleavage of the 2A/2B junction at its C-terminus. 
The FMDV leader protein is the only picornaviral leader protein known to possess 
proteolytic activity. The cleavages involving the P1/P2 junction also vary among 
the different picornaviruses (Ryan and Flint, 1997). In entero- and rhinoviruses, 2A 
protease frees the P1 intermediate by cleaving itself at the N-terminus, in 
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cardioviruses 2A
pro
 generates a P1/2A precursor by cleaving its own C-terminus 
instead, and the equivalent position is cleaved in hepatoviruses by 3C
pro
. FMDV is 
thought to follow the cardiovirus pattern, providing the P1-2A precursor and the 
2B-2C-P3 polyprotein (Figure 1.5); however, the proteolytic activity of 2A has 
been questioned and other mechanisms, like a putative ribosome skip during 
translation, have been suggested for this step (Donnelly et al., 2001b).  
Secondary cleavage events take place to provide the mature proteins through 
further intermediates. Except for the last step, known as the maturation cleavage (at 
the VP4/VP2 junction), which occurs during RNA encapsidation and whose 
mechanism is still unknown (Curry et al., 1997), all remaining cleavages have been 
attributed to 3C protease. Being responsible for 10 out of a total of 13 cleavages in 
FMDV polyprotein processing (Figure 1.5), 3C
pro
 has a crucial role in virion 
formation, which makes this enzyme a potential drug target for preventing viral 
replication (section 1.3.2).  
 
  
Figure 1.5 Schematic representation of the FMDV genome and its translation products. 
The polyprotein obtained from the direct translation of the ORF from the viral +RNA (A); B) Partial 
cleavage intermediates generated during processing of the polyprotein; C) Mature viral proteins. The 
different protease cleavage sites are indicated with 3C
pro
 being the enzyme responsible for most of 
the proteolysis. Adapted from (Grubman and Baxt, 2004).  
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C) A) B) 
1.2.4 FMDV proteins 
The ihibition of virally encoded enzymes essential for virus replication that 
differ enough from cellular enzymes should allow cessation of viral replication at 
various stages of the cycle. Thus, an understanding of the roles of the viral proteins 
in the replication cycle is fundamental to develop antiviral therapies. 
 The leader protease (Lpro) 
The L
pro
 is a papain-like protease (Seipelt et al., 1999) that actively participates 
in processing FMDV polyprotein. It releases itself from the growing peptidic 
polyprotein (Figure 1.5) and it also has the ability to cleave host cell eukaryotic 
initiation factors (eIF), primarily eIF4G (Gradi et al., 2004), resulting in 
shutting-off of host cap-dependent mRNA translation. Subsequently, due to the 
presence of the IRES in the 5′ UTR of the FMDV genome (see above), host cell 
protein synthesis machinery can be used for cap-independent viral protein 
production. 
 The structural proteins 
The four structural proteins VP1, VP2, VP3 and VP4, encoded in the P1 region 
of the ORF, self-assemble into a protomer, five protomers will form a pentamer, 
twelve of which will constitute a mature capsid of an icosahedral symmetry (Mateo 
et al., 2003) (Figure 1.6).  
 
 
 
 
 
 
 
Figure 1.6 Structures of the mature type O1BFS FMD virion. 
Viral proteins are coloured blue (VP1), green (VP2) and red (VP3). VP4 (yellow) is buried within 
the particle and cannot be seen from the surface. A) Organisation of the capsid proteins. B) A 
pentamer positioned on the virion looking down the fivefold axis. C) The organisation of the entire 
virion (Grubman and Baxt, 2004). 
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VP1, VP2 and VP3 are surface-oriented, whereas VP4 is internal and has an N-
terminal myristic acid (Chow et al., 1987). Virus attachment, entry, protective 
immunity and serotype specificity are associated with the amino acid residues 
exposed in the surface of the capsid, and particularly the very prominent G-H loop 
of VP1 (Jackson et al., 2003).  
 The 2A, 2B and 2C proteins 
The 2A, 2B and 2C proteins are encoded in the P2 section of the FMDV 
genome (Figure 1.5). 2A has been identified as a protease in other picornaviruses, 
but the 2A peptide in FMDV is much smaller (only 18 amino acids instead of the 
150 from cardiovirus), and its proteolytic activity has been questioned (Donnelly 
et al., 2001a) (see polyprotein processing above). Both 2B and 2C proteins have 
been shown to enhance membrane permeability and to block protein secretion, 
which may induce cytopathic effects in FMDV infected cells (Moffat et al., 2007). 
 The 3A and 3B proteins 
The 3A and 3B proteins are involved in RNA replication and selectivity of host 
infection (Pacheco et al., 2003). The 3B protein (VPg), as described in section 
1.2.2, is covalently attached to the 5′ terminus of the genome and serves as a 
peptide primer for the synthesis of the RNA. Unlike other picornaviruses, the 
FMDV genome, encodes three redundant copies of 3B (3B123 in Figure 1.5). The 
presence of three nonidentical copies in FMDV has yet to be understood, but it has 
been suggested that it might be related to the pathogenic potential and the broad 
host range of FMDV (Mason et al., 2003). 
 The 3D polymerase (3Dpol) 
3D
pol
 is mainly involved in RNA replication and is one of the most highly 
conserved virally encoded proteins between FMDV strains and among the different 
picornaviruses (Stanway, 1990; Carrillo et al., 2005). Initiation starts with the 
uridylylation of a tyrosine in VPg, which involves 3D
pol
 and its 3CD precursor 
(Nayak et al., 2005; Ferrer-Orta et al., 2006). Just as in other picornaviruses, 3D
pol
 
is also responsible for elongation of the nascent RNA chains (Ferrer-Orta et al., 
2007).  
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 The 3C protease (3Cpro) 
3C is the only enzyme common to all picornaviruses that has been identified as 
a protease (Klump et al., 1984). Although the primary role of 3C
pro
 is processing of 
the viral polyprotein (section 1.2.3), the enzyme also cleaves host proteins involved 
in transcription and translation. 3C
pro
 removes 20 amino acids from the histone H3 
N-terminus (Falk et al., 1990) and it has been reported to cleave initiation factors 
eIF-4G (just like L
pro
) and eIF-4AI (Belsham et al., 2000; Li et al., 2001). 3C is 
also thought to have a non-proteolytic role in viral RNA replication. During 
uridylylation of VPg, the first step for obtaining a positive strand from the negative 
RNA template (see above), the interaction of the 3C moiety of the 3CD precursor 
with RNA is believed to be essential (Nayak et al., 2006). 
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1.3 Antiviral Agents 
It is essential that the battle against virus proliferation extends beyond 
traditional vaccination. As discussed in section 1.1.2 not only can it be dangerous to 
work with active viral particles, but the diversity between ever diverging serotypes 
due to mutation signifies the need for a range of ever growing vaccine formulations. 
Ideally, targets that are conserved through serotypes can be tackled by a drug-based 
approach (De Clercq, 2004). Table 1.1 shows examples of antiviral drugs, some of 
which are in current clinical use, that target different stages of the virus cycle of a 
diverse group of viruses.  
 
Virus cycle step Drug Chemical Structure Target virus Reference 
Entry into cell Enfuvirtide* -Helix peptide HIV 
(Veiga et al., 
2004) 
Reverse 
transcription 
AZT* Nucleoside analogue HIV 
(Furman and 
Barry, 1988) 
DNA replication ACV* Nucleoside analogue HSV (Elion, 1993) 
RNA replication Enviroxime 
Benzimidazole 
derivative 
PV, HRV 
(Heinz and Vance, 
1995) 
Polyprotein 
processing 
Ruprintrivir Peptide analogue HRV 
(Matthews et al., 
1999) 
Virus release Zanamivir* Sialic acid derivative 
Influenza 
Virus 
(von Itzstein et al., 
1993) 
Table 1.1 Antiviral drugs inhibiting different steps of the virus cycle. 
Table adapted from a mini-review on inhibitors of virus replication (Magden et al., 2005). HIV: 
Human Immunodeficiency Virus; HSV: Herpes Simplex Virus; AZT: Azidothymidine or 
Zidovudine and ACV: Acyclovir. *Commercially available drugs.  
Enfuvirtide is a structured peptide that inhibits the entry of HIV. AZT and 
ACV are nucleoside analogues that, following intracellular phosphorylation, act as 
chain terminators of HIV reverse transcription and HSV DNA replication 
respectively. Enviroxime is believed to stop RNA synthesis by interacting with 
replicase protein 3A. Ruprintrivir is a peptidyl derivative that stops polyprotein 
processing by inhibiting HRV 3C
pro
. Finally, a sialic acid derivative, Zanamivir, 
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stops virus release by inhibiting the neuraminidase from influenza virus 
(responsible of hydrolysis of terminal sialic acid residues from carbohydrate 
moieties). 
1.3.1 Efforts towards FMDV inhibition 
In contrast to emergency vaccination, a potent and selective antiviral agent may 
provide almost immediate protection against infection and thus constitute an 
important alternative to contain viral outbreaks such as those caused by FMDV. 
There have been some limited attempts to affect specific FMDV targets. One 
naturally occurring peptide (Meliacine) was reported to inhibit FMDV uncoating 
(Wachsman et al., 1998) and some cysteine protease inhibitors showed some effect 
against FMDV proliferation (Kleina and Grubman, 1992); however, the latest 
antiviral drug therapy efforts against FMDV have concentrated on interfering with 
the nucleic acid machinery.  
 Nucleoside analogues 
Nucleoside analogues known to inhibit viral replication (for a review see 
Simons et al., 2005) have also been applied against FMDV with some success. 
Chain-terminating nucleoside analogues such as 2′-C-methylcytidine are converted 
in cells to the corresponding triphosphates and incorporated by the viral polymerase 
into nascent nucleic acid chains. They prevent the incorporation of the next 
nucleotide resulting in the formation of incomplete, nonfunctional RNA or DNA 
products. 2′-C-Methylcytidine has been shown to exhibit antiviral activity against 
all seven FMDV serotypes (Goris et al., 2007). 
Another approach that has also been applied to FMDV uses the error-prone 
RNA viral replication to induce mutagenesis to a level at which the virus loses 
infectivity (Pariente et al., 2005). The use of nucleoside analogues to drive RNA 
viruses to extinction (entry into error catastrophe) has become an area of intensive 
research in recent years. Mutagenic base analogues 5-fluorouracil (FU) and 5-
azacytidine (AZC) were shown to increase mutation rates in FMDV in vitro 
replication and to have the greatest effect on the 3D
pol
 coding region, which is 
highly conserved among FMDV serotypes (Sierra et al., 2000). However, 
extinction was only observed occasionally. Ribavirin, a broad-spectrum antiviral 
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agent also known as Virazole (Sidwell et al., 1972), has been shown to have an 
effect on FMDV (de la Torre et al., 1987; Goris et al., 2007). Its mechanism of 
action is still under discussion (Feld and Hoofnagle, 2005), but this nucleoside 
analogue, first synthesised in 1970, is also thought to induce mutagenesis fatal to 
the virus.  
 Oligonucleotides and analogues 
Sense and antisense oligonucleotides are widely known for their potential 
inhibitory effects on gene expression in vitro as well as in vivo (Cohen, 1991; van 
Aerschot, 2006). The antisense sequence is made complementary to the messenger 
or positive RNA (the sense sequence) of a target gene in a cell or virus. The access 
to the native genetic material is blocked and its normal function stopped. Instead 
small interfering RNAs (siRNA) are small double stranded RNAs that serve as a 
guide sequence that instructs the multicomponent RNA-interfering silencing 
complex to destroy specific mRNAs (Bass, 2000; Mello and Conte, 2004; Schlee 
et al., 2006). The research in this field has also produced oligonucleotide analogues 
containing nuclease-resistant backbones. Although many oligonucleotides 
reportedly demonstrated activity against various viral targets, Vitravene
TM
 (an 
antisense oligonucleotide analogue used against cytomegalovirus by 
immunodepressed patients) is the only oligonucleotide drug that has been approved 
for routine therapeutic use (Azad et al., 1993). 
Research into FMDV therapeutics has also benefitted from this approach. 
Sense and antisense RNAs, and antisense DNA-like analogues have been used to 
target the untranslated regions of the FMDV genome showing inhibition of viral 
replication (Gutierrez et al., 1994; Bigeriego et al., 1999; Rosas et al., 2003; 
Vagnozzi et al., 2007). Small interference RNAs, designed from regions of the 
genome encoding 3B and 3D (Kahana et al., 2004), VP1 (Chen et al., 2004) and 2B 
(de los Santos et al., 2005), could also inhibit virus replication. However, this 
technology has not yet been extended to susceptible animals.  
 Protease inhibitors 
Protease inhibitors have been applied successfully against a number of viruses 
and several have made their way through to commercialisation. Attempts to inhibit 
FMDV viral proteases began in 1992 when the use of the cysteine protease 
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inhibitor E-64 (Hanada et al., 1978) and its membrane permeable analogue E64-d 
were shown to inhibit the proteolytic activity of L
pro
 both in vitro and in cell culture 
resulting in a 1,000-fold reduction in virus yield (Kleina and Grubman, 1992). 
Inhibition of L
pro
 autocatalytic activity generated the unprocessed L/P1/2A 
polyprotein (Figure 1.5), which stopped virus capsid assembly by presumably 
masking or altering the 3C
pro
 cleavage sites and, in the absence of the VP4 N-
terminus, blocking myristoylation. 
The unavailability of structural data of viral protease targets has probably been 
one of the reasons for lack of progress in this field. Recent structure determinations 
of FMDV proteases essential for polyprotein processing L
pro
 (Guarné et al., 1998) 
and 3C
pro
 (Birtley et al., 2005; Sweeney et al., 2007), might therefore boost the 
discovery of protease inhibitors. However, this is clearly a difficult road since the 
structures of HRV (Matthews et al., 1994), HAV (Allaire et al., 1994) and PV 
(Mosimann et al., 1997) 3C proteases were determined over 10 years ago and have 
yet to yield commercially viable antiviral drugs for the associated diseases. In the 
case of FMDV, the enormous economic impact of the disease, coupled with the 
problems associated with vaccine use and the fact that drugs might be used 
prophylatically to control outbreaks, may yet stimulate further investment in this 
direction. This thesis details work carried out on FMDV 3C protease inhibitors. 
1.3.2 FMDV 3Cpro as a viable drug target 
The central roles that FMDV 3C
pro
 plays in polyprotein processing and RNA 
replication are undoubtedly linked to the observation that it is one of the most 
highly conserved proteins in the viral genome. Sequence analyses have already 
shown that 3C
pro
 is 76% identical in amino acid sequence across all serotypes 
(appendix 7.5; Carrillo et al., 2005). This genetic variation can be mapped on to the 
surface of the protease; if this is done for the sequence variation from all seven 
serotypes, it becomes evident that amino acid variation in 3C
pro
 between different 
strains of FMDV is largely confined to the surface of the enzyme with the 
substrate-binding site being one of the most highly conserved features of the 
enzyme (Figure 1.7). Therefore, in marked contrast to vaccines (which are 
serotype-specific), FMDV 3C
pro
 inhibitors are likely to be active against different 
strains of the virus. Not only do the function and conservation of this enzyme make 
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FMDV 3C
pro
 an attractive target for antiviral drug development but the information 
available regarding this target sets important groundwork for inhibitor design 
(Curry et al., 2007a; Curry et al., 2007b). 
 
 
 
 
Figure 1.7 Mapping of sequence conservation in 3C
pro
 from all seven serotypes of FMDV. 
Variable regions are orange; darker shading indicates greater sequence variation, which was 
calculated with all 107 FMDV 3C
pro
 sequences reported (appendix  7.5; Carrillo et al., 2005). The 
P4–P1′ portion of the modelled PAKQL substrate is shown in stick representation to indicate the 
position of the peptide-binding cleft. Structures rendered using Pymol (DeLano, 2002) as found in 
Curry et al. (2007a).  
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1.4 FMDV 3C Protease  
FMDV 3C
pro
 offers the possibility of a new approach to FMD control. As seen 
in section 1.2.3 FMDV 3C
pro 
plays a crucial role in virus replication. Executing ten 
out of the thirteen processing cleavage sites on the polyprotein intermediate (Figure 
1.5), FMDV 3C
pro
 is responsible for the maturation of both structural and functional 
viral proteins indispensable for capsid formation and RNA transcription. FMDV 
3C
pro
 is an attractive target for drug design, since there are no known cellular 
homologues in susceptible hosts. It is well established that its functional role makes 
3C
pro
 coding regions highly conserved among and within the different FMDV 
serotypes (van Rensburg et al., 2002; Carrillo et al., 2005). Therefore it may be 
possible to develop protease inhibitors that have a broad activity against a range of 
different FMDV serotypes.  
 In the present section, after an overview of proteolytic enzymes, the 3C 
protease, which has an active site thiol, will be presented as a chymotrypsin-like 
protease providing an insight to its mechanism of action and describe some of the 
structural elements that are crucial for the work presented in this thesis.  
1.4.1 Proteases 
Proteases play a key role in important physiological processes in all living 
organisms, they are involved in cell growth and differentiation, apoptosis, immune 
response and protein turnover among other functions (Barret et al., 2004). 
Uncontrolled proteolysis can lead to many disease states including cancer, stroke, 
viral infections and arthritis. Given their importance as targets in medicinal 
chemistry proteases have been, and are still, widely studied. They constitute a large 
group of proteins that appear to be very diverse.  
There are proteases that act independently, whilst others are part of complex 
cascades, involving several distinct enzymes, controlled by ―limited proteolysis‖. 
The specificity and structure of proteases are equally varied. Some proteases show 
broad substrate specificity like trypsin and chymotrypsin that, as pancreatic 
digestive enzymes, need to hydrolyse a great variety of ingested proteins in the gut. 
However, many proteases display very narrow substrate specificity; for example, 
the isoprenylated protein peptidase carries out the proteolytic cleavage of the C-
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terminal tripeptide from a protein containing an isoprenylated cysteine residue in 
the fourth position from the C-terminus (Ma and Rando, 1992). Specificity of 
proteases is generally attributed to the topology of the residues adjacent to the 
catalytic site that determine the favourable enzyme–substrate interactions and, 
therefore, substrate discrimination. 
From a structural point of view, proteases present wide variations regarding the 
nature of their active site, their size, sequence and three dimensional structures. 
There are proteases as small as 19 kDa (Uria and Lopez-Otin, 2000) that show a 
minimal catalytic organisation and others that rely on very complex arrangements, 
such as the 20S proteasome, which is about 670 kDa and consists of 14 related 
subunits (Seemuller et al., 1995). Together with the five major catalytic types of 
protease, which are described later in the text, new catalytic mechanisms are still 
being discovered. Recently, the structure of a protease (scytalidoglutamic 
peptidase) containing a unique catalytic dyad with a glutamate and a glutamine 
residue has been elucidated (Fujinaga et al., 2004).  
 Hydrolysis of peptide bonds 
Proteases cleave peptides and proteins by the addition of a molecule of water to 
a peptide bond. In a sequence of amino acids, the bond that is hydrolysed is known 
as the scissile bond. Although the hydrolysis of amide bonds is thermodynamically 
favoured, such reactions are extremely slow. The hydrolysis of a typical peptide at 
pH 4–8 is estimated to have a half-life of between 500 and 1000 years (Milovic and 
Kostic, 2003) but in the presence of serine proteases the hydrolysis rate can 
increase by a factor of 10
5
 to 10
10
 (Creighton, 1993). 
 
R1
C
N
O
R2
H
H2O+ C
O
R1
O
R2 NH3 
+- +
 
Figure 1.8 Hydrolysis of amide bonds. 
The dotted line indicates the scissile bond. When R1 and R2 constitute a peptide the hydrolysis of 
the main chain amide bond can be catalysed by a protease generating a new C-terminus (R1-
carboxylate) and a new N-terminus (R2-amine). 
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Conventionally, the rate enhancement has been mainly attributed to the 
alternative mechanism offered by the catalyst, while substrate recognition has been 
associated with the shape and electrical distribution of the binding surface of the 
enzyme. However, these two aspects of enzyme catalysis cannot be considered 
separately and other factors in the enzyme–substrate interaction, like the proximity 
of the reactants, stabilisation of the transition state and changes in solvation and 
electrostatic environment, make an important contribution to the reduction of the 
activation barrier (Page and Williams, 1987).  
 Enzyme–substrate interactions 
Proteolysis takes place after molecular recognition. The peptide is 
accommodated in a cleft in the protein and the scissile bond is positioned at the 
active site (Figure 1.9).  
 
 
 
 
 
 
 
 
 
Figure 1.9 Representation of a protease with a substrate bound to its active site. 
According to the Schechter and Berger notation (Schechter and Berger, 1967), starting on the 
scissile bond (between the residues P1 [towards the amino terminus] and P1′ [towards the carboxy 
terminus]) the numbering increases with distance as shown and the substrate is divided into the P-
side and the P′-side. The residues from the enzyme interacting with the side chain of the 
corresponding peptidic residue constitute the binding pockets (S) and are numbered and labelled 
accordingly.  
There are two main enzyme–substrate interactions (substrate binding sites), 
common to all proteases, which ensure the precise alignment of the substrate: the 
polypeptide binding site and the binding pockets. The polypeptide binding site 
stretches the substrate into an adequate conformation for hydrolysis. It includes the 
main chain carbonyl oxygen atoms and amide protons from the enzyme 
N-terminus C-terminus 
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establishing hydrogen bonds with those from the substrate. Peptide recognition 
takes place in the extended β-strand conformation for all types of proteases; this 
homogeneity has been reviewed through 180 protease–inhibitor structures (Tyndall 
and Fairlie, 1999). The binding pockets are generally constituted by more than one 
enzymatic residue and interact mainly with the side chains of the substrate residues. 
They are the basis for substrate discrimination and according to the Schechter and 
Berger notation the different substrate residues (P) define, through these enzyme–
substrate interactions, the corresponding enzyme subsites (S) (Schechter and 
Berger, 1967; Figure 1.9). 
 Classification of proteases 
The terms ―protease,‖ ―peptidase‖ and ―proteinase‖ are used nowadays 
indiscriminately to name the enzymes that act to cleave amide bonds in sequences 
of amino acids constituting peptides or proteins. There has been much work on the 
classification of the different types of enzymes and on the systematisation of their 
nomenclature. According to the Nomenclature Committee of the International 
Union of Biochemistry and Molecular Biology (IUBMB, 1992) this group of 
hydrolytic enzymes would define the subclass ―EC 3.4‖, whilst ―EC 3‖ names the 
wider class involving all hydrolases. Regarding the position of the scissile bond 
hydrolysed in the peptide, proteases fall into two sub-categories. Exopeptidases 
(―EC 3.4.11–19‖) act near the N or C termini liberating either a single amino acid 
residue, a polypeptide (up to three residues) or modified terminal residues. 
Endopeptidases (―EC 3.4 21–99‖) catalyse the hydrolysis of peptide bonds from 
inner regions in peptide chains.  
Regarding the mechanism of hydrolysis, a different criterion for their 
classification has been generated. Generally, proteases facilitate nucleophilic attack 
at a relatively unreactive carbonyl group by using a twofold activation strategy. 
Firstly, the presence of a Brønsted base enables the activation of the nucleophile 
(Nu-H) by the release of its proton. Secondly, the interaction of the carbonyl group 
of the scissile bond with a Lewis acid enhances its electrophilicity (Barret et al., 
2004). Proteases can be classified according to the different nature of the elements 
that participate in this mechanism (the nucleophile and Brønsted base) and the 
corresponding three dimensional distributions. MEROPS is a widely used, 
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exhaustive database of proteases that uses structure-based classification (Rawlings 
et al., 2006).  
The mechanism-based main classes of proteases are: serine proteases, cysteine 
proteases, threonine proteases, aspartyl proteases (which have reactive Ser, Cys, 
Thr and Asp residues respectively) and metallo proteases (which contain a reactive 
metal ion). Accordingly, there are five variants for activation before water 
molecules attack and ultimately hydrolyse peptide bonds in protein substrates. Each 
of the catalytic types is further divided into distinct ―families‖. A family is defined 
as a group of peptidases shown to be evolutionarily related by the comparison of 
their amino acid sequence (Rawlings and Barrett, 1993). The structural similarities 
within a family of peptidases commonly reflect important similarities in catalytic 
mechanism. A set of families that have a common ancestor is further grouped into a 
―clan‖. Sometimes the tertiary structure of the proteins, the linear order of catalytic 
residues and the clusters of conserved amino acids around the catalytic site in 
different families are sufficiently similar as to indicate a distant relationship. So is 
the case of chymotrypsin-like proteases (Clan PA), which groups some serine and 
cysteine proteases (from clans PA(S) and PA(C) respectively), including FMDV 
3C
pro
.  
 Chymotrypsin-like proteases 
The expression ―chymotrypsin-like proteases‖ describes a group of both serine 
and cysteine proteases (including picornaviral 3C proteases) that share some 
characteristics in their three dimensional structure and catalytic mechanism. This 
term is adopted by convention since chymotrypsin is the most widely studied 
protease and its sequence and crystal structure were the first to be determined 
(Matthews et al., 1967).  
Traditionally, cysteine and serine proteases were regarded as unrelated enzyme 
classes. However, some evidence suggests that these two catalytic types of 
proteases may be evolutionary related (Neurath et al., 1984). For instance, the 
regions of 3C proteases around the catalytic Cys present considerable similarity to 
those surrounding the catalytic set of serine chymotrypsin-like proteases and bring 
3C and other picornaviral proteases closer to chymotrypsin than papain-like 
cysteine proteases (Gorbalenya et al., 1986; Barret et al., 2004).  
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1.4.2 Structure 
When no three dimensional structures of cysteine 3C proteases were available, 
sequence alignment studies and comparison of amino acid identity predicted 
similarities with tertiary structures of chymotrypsin-like proteases (Bazan and 
Fletterick, 1988; Gorbalenya et al., 1989). This prediction has been confirmed with 
the elucidation, by X-ray diffraction, of crystallographic structures of 3C proteases 
(Tong, 2002). 
 General fold 
Some of the structural features of chymotrypsin common to chymotrypsin-like 
proteases include two six-stranded β-barrels connected by a linker. The two barrels 
define a cleft that hosts the active site and the substrate binding sites. The catalytic 
triad is located at the interface between the two β-barrel domains. These overall 
structural motifs are found in the 3C
pro
 crystal structures of PV (Mosimann et al., 
1997), HRV (Matthews et al., 1994), HAV (Bergmann et al., 1997) and FMDV 
(Birtley et al., 2005) (Figure 1.10).  
Another structural feature common to 3C proteases is a β-sheet ribbon that 
folds over the peptide binding cleft of the enzyme. This β-ribbon corresponds to a 
similar feature in some bacterial chymotrypsin-like serine proteases (James et al., 
1980; Bone et al., 1989) and it has been observed in HAV, HRV and PV 3C
pro
 
crystal structures (Matthews et al., 1994; Bergmann et al., 1997; Mosimann et al., 
1997). Although it possesses a certain degree of flexibility, it appears to make 
important contributions to substrate–enzyme interactions and some direct contacts 
have been found in peptide sequences bound in the active site cleft of HRV 3C
pro
 
(Matthews et al., 1999).  
In FMDV, although the initial crystal structure of 3C protease (Birtley et al., 
2005) suggested that the two-strand β-ribbon was disordered, a more recent 
structure determination revealed that this β-ribbon is indeed conserved (chapter 2; 
Sweeney et al., 2007). The importance of this part of the enzyme on substrate 
specificity has been confirmed. We have shown how mutagenesis of Cysl42 at the 
apical tip of the β-ribbon has a significant impact on catalytic activity of FMDV 
(Sweeney et al., 2007). Moreover the recent substrate-enzyme crystal structure has 
shown that the β-ribbon is in contact with the P-side of the substrate (section 2.3.2). 
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Figure 1.10 Representation of the three dimensional structures of chymotrypsin-like proteases.  
A) FMDV 3C
pro
 (PDB ID 2J92; Sweeney et al., 2007), B) HRV 3C
pro
 (PDB ID 1CQQ; Matthews 
et al., 1999), C) HAV 3C
pro
 (PDB ID 2A4O; Yin et al., 2005) and D) chymotrypsin (PDB ID 4CHA; 
Tsukada and Blow, 1985). Highlighted in pink are the residues of the catalytic triad. The 
characteristic double β-barrel structure of chymotrypsin is present in all picornaviral 3C protease 
structures. The β-ribbon that can be clearly identified folding over the active site of HAV protease is 
also present in HRV and FMDV 3C proteases. Structures rendered using Pymol (DeLano, 2002). 
D) Chymotrypsin 
B) HRV 
C) HAV 
A) FMDV 
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 The catalytic site 
 The structural homology of FMDV 3C
pro
 to chymotrypsin is further observed 
in their respective active sites (Figure 1.11). Starting from the N-terminus the 
catalytic residues of chymotrypsin consist of histidine at the 57
th
 position (H57), 
aspartate on the 102
nd
 (D102) and serine on the 195
th
 (S195). The three catalytic 
residues have been identified in the sequences of chymotrypsin-like proteases and 
specifically on picornaviral 3C proteases. But previous to the FMDV 3C
pro
 structure 
determination (Birtley et al., 2005) the three dimensional distribution of other 3C 
proteases active sites was thought to deviate significantly from the classical Ser-
His-Asp triad configurations (Curry et al., 2007a; Curry et al., 2007b).  
The arrangement of the catalytic residues is stabilised by hydrogen bonds 
(Figure 1.11), which are part of an extensive hydrogen bond network that links the 
catalytic triad to the substrate binding sites. As catalysis proceeds, changes in 
bonding and charge at the scissile bond will propagate to more remote enzyme–
substrate interactions (Wilmouth et al., 2001). The hydrogen bonds are generally 
observed between the Asp102-His57-Ser195, but Ser214, which is part of the S1 
specificity pocket (Ash et al., 2000), also has an important contribution to the 
hydrogen bonding network and was once considered the ―fourth member‖ of the 
catalytic site (McGrath et al., 1992). This residue is also highly conserved in 
chymotrypsin-like proteases and often takes a very similar role (Barret et al., 2004). 
In picornviral 3C proteases the putative catalytic aspartate residue was either 
out of position, being directed away from the active site in HAV-3C (Bergmann 
et al., 1997), or replaced by glutamate, a substitution that is almost unknown in 
serine proteases but was observed in the HRV (Matthews et al., 1999) and PV 
(Mosimann et al., 1997) 3C
pro
 structures. These observations led to the suggestion 
that a dyad mechanism reliant on the Cys–His pair of active-site residues might be 
sufficient for proteolysis. However, the latest work on FMDV 3C
pro
 and HAV 3C
pro
 
(Birtley et al., 2005; Yin et al., 2005; Sweeney et al., 2007) showed how these two 
enzymes possess a Cys-His-Asp triad that is very similar in conformation to the 
Ser-His-Asp triad found in chymotrypsin-like serine proteases (Figure 1.11) 
suggesting a serine protease-like mechanism for hydrolysis. Furthermore, 
mutagenesis studies have shown that substitution of the third member of the triad is 
severely detrimental to proteolytic activity (Kean et al., 1993; Grubman et al., 
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1995). Despite this clarification, the catalytic mechanism of this unusual class of 
cysteine proteases remains uncertain. They appear to be distinct from papain-like 
cysteine proteases, since a Cys-His thiolate-imidazolium ion pair is not detectable 
in the active site (Sarkany et al., 2001) but clear evidence for a general base 
catalytic mechanism, as found for chymotrypsin-like serine proteases, has yet to be 
obtained (Sarkany and Polgar, 2003). 
 
A) FMDV B) HRV 
  
C) HAV D) Chymotrypsin 
  
 
Figure 1.11 Comparison of the active sites of 3C proteases. 
The catalytic residues are shown in pink and the heteroatoms correspond to oxygen (red), nitrogen 
(blue) and sulphur (yellow). The triad found in FMDV 3C
pro 
(PDB ID 2BHG) most closely 
resembles that found in the serine protease chymotrypsin. The other crystal structures shown are 
HRV 3C
pro 
(PDB ID 1CQQ), HAV 3C
pro
 (PDB ID 2A40) and chymotrypsin (PDB ID 4CHA). Due 
to the relevance of the S214 in chymotrypsin the homologous forth residue is highlighted in the 
other structures (grey). *The Cys163 side chain has been restored in the FMDV 3C
pro 
structure by 
modelling (since this is Ala in the crystal structure). Structures rendered using Pymol (DeLano, 
2002). 
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1.4.3 Catalytic mechanism  
In the core of the enzyme, the process of hydrolysis can be detailed in a large 
number of steps that constitute a catalytic cycle. The catalytic triad (see above), the 
oxyanion hole (below) and the substrate binding sites (section 1.4.1) all work in 
unison to achieve catalysis (Fersht, 1985). In the well known catalytic cycle of 
serine proteases (Figure 1.12), upon substrate binding the electrophilic carbonyl of 
the scissile bond is attacked by the Ser side chain with subsequent formation of the 
1
st
 tetrahedral intermediate. The 1
st
 tetrahedral intermediate then collapses to form 
the acyl–enzyme complex (acylation) and the amine product is released on 
protonation. The second part of the reaction, which completes hydrolysis, is similar 
to the 1
st
 addition elimination steps except a water molecule plays the nucleophilic 
role. Subsequently, the 2
nd
 tetrahedral intermediate collapses (de-acylation) to 
release the carboxylate product thus completing hydrolytic catalysis (Figure 1.12).  
Commonly in cysteine proteases the catalytic cysteine residue is accompanied 
by a histidine residue forming a catalytic dyad (Barret et al., 2004). In contrast to 
the thiolate-imidazolium ion pair of papain-like cysteine proteases, the imidazole 
assistance in 3C picornains is presumably a general base catalyst, as found in serine 
peptidases (Sarkany et al., 2001). In picornaviral 3C proteases the Cys thiol acts as 
the nucleophile and the imidazole group of His as the proton donor/acceptor, 
polarizing and deprotonating the sulfhydryl group. The extraction of a proton from 
a thiol (pKa ~ 8) to create a nucleophilic thiolate anion is more favourable than from 
a hydroxyl group (pKa ~ 15); therefore, the charge effect of the third member of the 
well known serine protease triad, with Asp providing electrostatic stabilisation to 
the imidazole of the His side chain, is not essential in cysteine proteases (Allaire 
et al., 1994). Nevertheless, Cys and His are often accompanied by Asp or Glu, as 
the third component of the triad. 
 The oxyanion hole 
The ―oxyanion hole‖ is a structural feature that has an important role in the 
catalytic cycle. This area contains a series of aligned dipoles, which compliment 
changes in charge distribution during catalysis (Cassidy et al., 1997). The 
interaction between these dipoles and the scissile bond carbonyl oxygen is thought 
to promote formation of the two tetrahedral intermediates and in turn increase the 
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rate of de-acylation of the acyl–enzyme complex. In chymotrypsin these dipoles are 
supplied by the main chain amide functions of Ser195 and Gly193 (Figure 1.12; 
Dorovska et al., 1972). Crystal structures of several transition state analogue 
complexes have confirmed these interactions (Bone et al., 1991). The oxyanion 
hole is conserved among 3C proteases, which also use the main chain amide 
functions of the catalytic Cys and G161 in FMDV or G145 in HRV (Curry et al., 
2007b). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.12 Mechanism of hydrolysis for chymotrypsin.  
The Ser195 and Gly193 residues, which form the oxyanion hole, are part of the charge relay system 
that begins at Asp102 and travels through His57 and the substrate to the oxyanion hole. This 
network of hydrogen bonds fixes all the components into favourable orientations and delocalises any 
charges, facilitating stabilisation (Birktoft et al., 1970; Cassidy et al., 1997).  
enzyme–substrate complex 
1st tetrahedral intermediate  2
nd
 tetrahedral intermediate  
acyl-enzyme intermediate 
acylation 
deacylation 
Asp-102
O
O
N N
His-57
H H
O
Ser-195
N N
His
O
H
Asp
O
O
N N
His
H
O
Ser
Ser
H
OH
Asp
O
O
N N
His
H
O
R2HN
O
R1
NH
NH
R1
H2O
R2NH2
H
N
R1
O
Ser
HO
O
NH
R1
OH
O
R1
H
N
R2HN O
Asp
O
O
H H
H
N
H
N
Gly-193
H
N
H
N
Gly
H
N
H
N
Gly
H
N
H
N
Gly
R2HN
O
R1
HN
1 Introduction 
53 
 
1.4.4 Substrate specificity 
Specificity of proteases is generally attributed to the topology of the residues 
adjacent to the catalytic sites and is primarily expressed by the value of kcat/KM, 
which allows comparison among different substrates for a given enzyme (section 
2.1.1). The nature of the binding sites determines the favourable enzyme–substrate 
interactions and, therefore, substrate discrimination.  
 As seen for many proteases, the S1 specificity pocket is highly discriminatory. 
Chymotrypsin requires a large hydrophobic residue at the P1 position for hydrolysis 
to occur at a reasonable catalytic rate (Schellenberger et al., 1991). However, the 
substrate specificity shown by 3C proteases is much more restrictive than found for 
chymotrypsin. Together with P1, other amino acids in the substrate sequence play 
important roles in the affinity for the protease. Picornaviral 3C proteases generally 
cleave peptide sequences with a hydrophobic residue at P4, Gln at P1 and a small 
residue (Gly, Ser, Ala) at P1′ (Blom et al., 1996; Seipelt et al., 1999). Although 
HRV and PV 3C
pro
 almost invariably cleave sequences with P1′-Gly, HAV 3Cpro 
tolerates larger residues at this position and, in addition, exhibits a preference for a 
small hydrophilic residue at P2. As we will see, FMDV 3C
pro
 shows similar 
variability at P1′. 
 FMDV 3Cpro natural substrates 
The primary sequences of the FMDV polyprotein variants are available in 
GenBank (Benson et al., 2005). With 3C
pro
 responsible for 10 of the 13 cleavages 
taking place in the polyprotein, some trends in enzyme specificity can be drawn 
from the alignment of the known 3C
pro
 cleavage junctions.  
For over 100 different strains reported (Carrillo et al., 2005) and all the 3C
pro
 
cleavage sequences within each strain, two major groups of substrates can be 
identified: those with Gln at P1 or those with Glu (Figure 1.13). Sequences with P1-
Gln typically also have P2-Lys and a hydrophobic residue at P1′ (Leu, Ile, Thr); in 
contrast, in sequences with P1-Glu the preference for P2-Lys is reduced, but there 
is strong selectivity for a small amino acid (Gly or Ser) at P1′. This suggests that 
interactions between different subsites in the peptide binding cleft of FMDV 3C
pro
 
may be important for specificity (Curry et al., 2007b). 
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Figure 1.13 FMDV 3C
pro
 substrate sequences and residue conservation. 
The table shows the sequences of the naturally occurring polyprotein junctions cleaved by 3C
pro 
in 
FMDV A1061. The sequence logos, generated using Weblogo (Crooks et al., 2004), are the result of 
the alignment of the sequences from over 100 strains of FMDV (Carrillo et al., 2005) split into two 
groups (P1-Gln and P1-Glu). The overall height of each stack indicates the sequence conservation at 
that position (expressed in bits), whereas the height of symbols within the stack reflects the relative 
frequency of the corresponding amino or nucleic acid at that position (Curry et al., 2007b). 
Experimental data supports these observations, with FMDV 3C
pro
 cleaving 
sequences with both P1-Gln and P1-Glu. Analysis of the naturally occurring 
cleavage junctions from the FMDV A1061 strain (Figure 1.13), 3C
pro
 showed 
preference for the VP1/2A junction sequence, revealing KIIAPAKQ↓LLNFDLLK 
as the optimal substrate. Furthermore, an alanine scan of the individual positions 
within this sequence also highlighted the importance of P4, P2, P1 and P4′ positions 
(Birtley et al., 2005).  
To date, no co-crystal structures of picornaviral 3C proteases with bound 
peptide have been reported, and there are only a handful of reports of complexes 
containing peptide-like inhibitors (Bergmann et al., 1997; Matthews et al., 1999; 
Dragovich et al., 2002a; Yin et al., 2006). Efforts should continue in order to 
understand the structural basis for selectivity of P1-Gln in most 3C proteases, since 
the residues that apparently specify P1-Gln in PV, HRV and HAV 3C
pro
 are also 
conserved in FMDV 3C
pro
 (Birtley et al., 2005), which can accommodate Gln or 
Glu at this position. Nonetheless, recent work has helped to elucidate the details of 
Junction Sequence (P8↓P8′) 
VP2/VP3 AGELPSKE↓GIFPVACA 
VP3/VP1 LPIDPRTQ↓TTTTGESA 
VP1/2A KIIAPAKQ↓LLNFDLLK 
2B/2C DLERAEKQ↓LKARDIND 
2C/3A SSHPIFKQ↓ISIPSQKS 
3A/3B1 AEDQPQAE↓GPYSGPLE 
3B1/3B2 RAKLPQQE↓GPYAGPME 
3B2/3B3 VKAPVVKE↓GPYEGPVK 
3B3/3C ARNLIVTE↓SGAPPTDL 
3C/3D VDPEPHHE↓GLIVDTRD 
Bits 
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3C
pro
 specificity (chapter 2) and the information available regarding the structure 
and specificity of FMDV 3C
pro
 provide valuable basis for the design of potential 
inhibitors which is the main objective of the present thesis. 
1.4.5 Protease inhibitors  
Proteases have been widely targeted given their ubiquity and their role in many 
biologically relevant processes (section 1.4.1). Hence, protease inhibitors have the 
ability to assist in regulating undesirable protease activity and have also been a 
useful tool in the characterisation of binding sites, catalytic functional groups and 
transition-state geometries of proteases. Moreover, the design of highly selective 
inhibitors makes it possible to investigate the physiological function of a particular 
class of enzymes within an organism. 
Viral proteases have been shown to be an absolute requirement in the life cycle 
of many viruses by cleaving host cell proteins or viral-protein precursors (section 
1.2.3). Therefore, targeting virally encode proteases without equivalent in the host 
cell has been one of the routes to tackle viral infection. Some viral protease 
inhibitors have been demonstrated to be clinically efficient antiviral drugs and 
exploration of natural inhibitors and synthesis of peptidomimetic molecules has 
provided many promising compounds (Fear et al., 2007). 
 HIV protease  
Albeit problems related to drug resistance in RNA viruses, the battle against 
HIV is an example of the success of antiviral drug discovery (Tomasselli, 2000). 
Some of the anti-HIV drugs currently on the market are HIV protease specific 
inhibitors. HIV
pro
 is an aspartyl protease that, like FMDV 3C cysteine protease 
(section 1.2.3), is essential for viral maturation. The design of inhibitors against 
HIV
pro
 has benefited considerably from years of research for the development of 
renin inhibitors for the treatment of hypertension, which produced a large number 
of substrate-based peptidomimetic compounds that were ready to be tested against 
HIV
pro
. On the other hand, HIV
pro
 selectivity for P1′-proline served as the basis for 
the rational design of selective inhibitors. Substitution of proline by decahydro-
isoquinoline led to Saquinavir, the first protease inhibitor to enter the market, and 
substitution by pyridylmethyl-piperizine to Indinavir. Finally, Ritonavir exploited 
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the dimeric nature of HIV
pro
 to maximise inhibitor-protease interactions. The 
structures of these protease inhibitors can be seen in Figure 1.14. 
 
 
Figure 1.14 Structures of HIV-protease inhibitors: Saquinavir, Indinavir and Ritonavir. 
The peptidic origin of these inhibitors can hardly be identified but their original polymeric nature 
can be recognised. Ritonavir, longer than the other two compounds and with a certain degree of 
symmetry, was designed to exploit the dimeric nature of HIV
pro
.  
 HRV 3C protease 
Human rhinovirus (HRV) is a member of the picornavirus family and is 
responsible of the common cold. HRV 3C
pro
 is highly conserved among the over 
100 different HRV serotypes (Binford et al., 2005) and, just like FMDV 3C
pro
 
(section 1.2.4), is essential for viral replication.  
Much work to formulate HRV 3C
pro
 inhibitors has been successfully 
undertaken by the teams of Dragovich and Matthews (Pfizer-Agouron 
Pharmaceuticals, Inc.), for an overview see Patick (2006). Inhibitor design was 
derived from HRV 3C protease 2C/3A polyprotein junction sequence after a 
synthetic version of this sequence displayed the highest level of substrate 
specificity in vitro (Cordingley et al., 1989) and the importance of the P4–P2′ 
region of the substrate was identified (Cordingley et al., 1990). This route led to 
some potent HRV 3C
pro
 inhibitors (Figure 1.15). Ruprintrivir (AG7088) is an 
irreversible inhibitor is that delivered locally into the nasal cavity has been found to 
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be effective, both as a prophylactic and a therapeutic drug (Hayden et al., 2003). 
Moreover, a novel orally bioavailable HRV 3C
pro
 inhibitor (known as Compound 1) 
has been described recently (Dragovich et al., 2003; Patick et al., 2005).  
These kinds of inhibitor are essentially modified versions of the P4–P1 
substrate with a Michael acceptor replacing the P1′ residue, a common warhead for 
cysteine proteases (section 3.1, Figure 3.3). The α,β-unsaturated ethyl ester was 
preferred after comparison with over 50 other species (Dragovich et al., 1998a). 
The peptidic part of the inhibitor was also customised (Dragovich et al., 1998b). 
Optimisation included making the molecule less peptide-like and introducing 
rigidity into the final compound (Compound 1 in Figure 1.15). P1-Gln was 
converted to a lactam (Dragovich et al., 1999), the aromatic ring on the P2-Phe side 
chain substituted by an alkyne, P3-Leu merged into the back bone as part of a 
pyridine (Dragovich et al., 2002a; Dragovich et al., 2002b) and the P4-Thr was 
replaced by an iso-oxazole (Dragovich et al., 2003). Both compounds went into 
clinical trials (phase II for Ruprintrivir and phase I for the latter) but currently no 
further clinical developments are planned (Patick, 2006). Nonetheless, the efforts 
on drug development against HRV may also impact other diseases caused by 
picornaviruses, like PV or FMDV, as has done with families with homologous 
proteins like SARS-CoV 3CL protease (see below). 
 SARS-CoV 3CL protease 
The battle against severe acute respiratory syndrome (SARS) has its origins in 
the aftermath of an outbreak that started in Asia in late 2002. The incident had 
worldwide dimensions with around 8,000 cases of infection and more than 700 
deaths. Its causative agent was identified as a new coronavirus (CoV) in 2003 (Rota 
et al., 2003). Like other coronaviruses, SARS-CoV contains a virally encoded 
cysteine protease, 3CL, which is responsible for crucial cleavage events during 
viral polyprotein processing. Numerous compounds have been reported to inhibit 
the SARS-CoV 3CL protease (Liang, 2006). Coronavirus 3CL
pro
 are similar to 
picornavirus 3C proteases, not only in their function but also in their structure. This 
similarity anticipated that 3C
pro
 inhibitors would be effective against 3CL
pro
 
(Matthews et al., 2004). With a HRV 3C
pro
 inhibitor (Figure 1.15) as a starting 
point, Yang et al. have developed a potent 3CL
pro
 inhibitor (TG-0205221) which 
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has antiviral activity against SARS-CoV (Yang et al., 2006). A structure based 
virtual screen has also been developed to estimate the activity of inhibitors against 
SARS-CoV 3CL
pro
 (Tsai et al., 2006). Despite these fast advances there are 
currently no effective drugs for the treatment of SARS-CoV. Nonetheless, 
following the example of SARS-CoV the battle against FMDV could potentially 
also benefit from the research into HRV inhibition.  
 
 
Figure 1.15 Structures of HRV and SARS-CoV inhibitors. 
The dotted arrows indicate that both inhibitors Compound 1 (HRV 3C
pro
) and TG-0205221 
(SARS-CoV 3CL
pro
) are derived from the potent HRV inhibitor Ruprintivir. Compound 1 represents 
an improvement to the inhibition of HRV in that it is an orally available drug. The HRV 3C
pro
 
inhibitor was adapted for the inhibition of the structurally related 3CL
pro
 resulting in TG-0205221. 
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1.5 Project Outline 
The main objective of this thesis was to find FMDV 3C
pro
 inhibitors with view 
to developing potential antiviral agents. In order to do so it was necessary to 
provide the required tools for the design, synthesis and assessment of potential 
FMDV 3C
pro
 inhibitors. Subsequently, the inhibitory activity of the compounds 
synthesised was used to establish the structure-activity relationships for inhibition 
and refine the inhibitor design. 
1.5.1 Structure of this thesis 
Chapter 1: The first chapter introduces FMD, the mode of action of its 
causative agent in vivo and different strategies used to stop its replication. FMDV 
3C
pro
 is presented as a viable drug-target followed by a discussion of the structure 
and specificity of picornaviral 3C
pro
 and a section on viral protease inhibitors.  
Chapter 2: In order to assist inhibitor design the structural requirements for 
substrate binding are presented in this section. The method to assess protease 
activity is enhanced by analysing the limitations of existing procedures and 
exploring potential alternatives. The method used to obtain recombinant FMDV 
3C
pro 
is also presented. Finally, the activity of several FMDV 3C
pro
 mutants 
together with an enzyme–substrate co-crystal structure is analysed. 
Chapter 3: Taking the work on HRV 3C
pro
 inhibition as a starting point this 
chapter describes the inhibitor design. The synthetic routes developed to access 
different Michael acceptor derivatives are also presented, together with the 
experimental techniques and conditions developed to investigate inhibitory activity 
against FMDV 3C
pro
. 
Chapter 4: The requirements of the peptide moiety for inhibition are analysed 
in detail in this chapter. The antiprotease activities of the different compounds 
synthesised, supported by the structural information available were used to derive 
structure-activity relationships, which, together with considerations of membrane 
permeability, led the inhibitor design. Modifications were introduced to the parent 
compound to identify the minimal size for inhibition and explore the requirements 
of the P2 position. The identification of the absolute requirement for a positive 
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charge on P2, led to the investigation of a pro-drug approach. Finally, the 
compounds that presented antiprotease activity were further assessed in antiviral 
cell-based assays.  
Chapter 5: The main conclusions drawn from the work are presented and 
potential directions for future investigation are summarised in this section.  
Chapter 6: This chapter records the experimental methods used throughout the 
thesis. 
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2 FMDV 3Cpro Structure Activity 
Relationships    
 
 
In this chapter, the assay developed in our lab to monitor FMDV 3C
pro 
proteolysis, the production of recombinant protease and the effect of C142 
mutations on protease activity are presented. A recently obtained crystal structure 
of a FMDV 3C
pro
 substrate–enzyme complex will be discussed highlighting key 
substrate–enzyme interactions. This chapter, therefore, establishes the basis the 
inhibitor the design (chapter 3) and the assay used for the evaluation of potential 
FMDV 3C
pro
 inhibitors (chapter 4). 
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2.1 Assay to Monitor FMDV 3C
pro
 Activity 
Evaluating the activity of a protease inhibitor requires a comparison of enzyme 
activity in the presence or absence of the potential inhibitor by monitoring protease 
hydrolysis of a substrate. When assessing protease activity in a bimolecular 
enzyme–substrate reaction it is common to use the Michaelis-Menten plot to 
determine the kinetic parameters of the system. Generally, the initial velocity or 
initial rate (v) of hydrolysis is plotted against the substrate concentration [S] 
(Cornish-Bowden, 2004). In order to determine the initial rate, hydrolysis should be 
monitored with time. Classically, peptides known to be substrates of the protease 
are synthesised and the progress of their cleavage in the presence of the enzyme is 
monitored by following the appearance of the two hydrolysis products on a HPLC 
trace. However, this is a non-continuous method and very time consuming. Instead, 
a fluorogenic substrate, which is a modified peptide that emits fluorescence upon 
cleavage, can be used. By recording the increase of fluorescence with time, 
hydrolysis can then be monitored in a continuous and sensitive manner. 
Fluorogenic substrates were developed long ago (Zimmerman, 1977) and are still 
widely used (Diamond, 2007). After a brief introduction to the Michaelis-Menten 
kinetics the assay used to monitor FMDV 3C
pro
 is presented through the design, 
synthesis and evaluation of two different fluorogenic substrates. 
2.1.1 Michaelis-Menten kinetics 
Hydrolysis of the peptide bond by chymotrypsin-like proteases involves three 
kinetic steps (Figure 2.1, A). When acylation is the rate determining step, 
hydrolysis can be depicted in the more general Michaelis-Menten form (Figure 2.1, 
B). The fundamental principles of Michaelis-Menten kinetics separate enzyme 
catalysis into 2 distinct processes. Firstly, the substrate (S) binds to the enzyme (E) 
in a reversible interaction where the free species (E + S) are in equilibrium with the 
enzyme–substrate complex (ES). Secondly, the enzymatic reaction, which can only 
occur after formation of the complex, takes place irreversibly to release the enzyme 
and the products (E + P).  
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Figure 2.1 Kinetic scheme of enzymatic hydrolysis. 
A) Chymotrypsin-like proteases complete hydrolysis through three main steps. B) Generalised 
expression of enzyme activity according to principles of Michaelis-Menten kinetics, where E = 
protease, S = peptide and P = hydrolysis products. k1 = association constant, k–1 = dissociation 
constant and k2 = turnover constant.  
 The Michaelis-Menten equation 
 The Michaelis-Menten equation can be derived from the reaction scheme in 
Figure 2.1 (B) and is used to determine the kinetic constants. As the hydrolysis 
proceeds, the enzyme, the substrate and the product concentrations vary. However, 
if the substrate concentration is much larger than the enzyme concentration, 
substrate consumption can be neglected and [S] ≈ [S]0. Moreover, at any given time 
the enzyme concentration can be expressed in terms of the known initial 
concentration and the concentration of the intermediate, thus [E] = [E]0 –[ES].  
 
 
 
 
 
Assuming that a steady state is reached, the concentration of the intermediate is 
constant as d[ES]/dt = 0 (Equation 2.1) and Equation 2.2 would apply. If we 
consider that the rate of the reaction (v) is determined by the limiting rate constant 
(k2) then v = k2[ES] and Equation 2.3 is obtained. Equation 2.4, known as the 
Michaelis-Menten equation, comes from redefining k2 as kcat and grouping 
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(k-1 + k2)/k-1 into KM (Cornish-Bowden, 2004). kcat is the catalytic constant, also 
known as the turnover number, and has the properties of a first order rate constant. 
KM is named the Michaelis constant. Another expression of the Michaelis-Menten 
equation (Equation 2.5) can be derived by substituting kcat[E]0 with Vmax which is 
the limiting rate for a particular system and is dependent on the initial enzyme 
concentration. Equation 2.5 defines a curve that corresponds to a rectangular 
hyperbola through the origin (Figure 2.2), where KM corresponds to the substrate 
concentration for which the hydrolysis rate is equal to half the limiting rate 
(v = Vmax/2).  
 
v =
𝑘2 E 0 S 
 
𝑘−1 + 𝑘2
𝑘1
 +  S 
 v =
𝑘cat  E 0 S 
𝐾M +  S 
 v =
Vmax  S 
𝐾M +  S 
 
Equation 2.3 Equation 2.4 Equation 2.5 
 
A specific enzyme–substrate system can be characterised with the method of 
initial rates which, by plotting the initial hydrolysis rate (v) of increasing substrate 
concentrations ([S]) for a given enzyme concentration and fitting the experimental 
data to the Michaelis-Menten equation (Equation 2.5), provides the kinetic 
constants Vmax and KM. However, saturation kinetics cannot always be achieved 
and when the working substrate concentration is well below KM ([S]<<KM) only the 
initial slope of the curve is well defined. Nonetheless, the slope of this straight line 
corresponds to Vmax/KM (or kcat[E0]/KM). Hence, knowing the initial enzyme 
concentration kcat/KM, known as the performance constant (or specificity constant), 
can be determined.  
Once an enzyme–substrate system is characterised by defining its kinetic 
parameters, the introduction of permutations to this system can be evaluated by 
comparing the parameters resulting from the use of a different substrate (i.e. to 
evaluate enzyme specificity) or a closely related enzyme (i.e. to evaluate the effect 
of a mutation on enzyme activity). The kcat is generally associated with the catalytic 
rate and the KM with the affinity of the enzyme for the substrate. Hence, kcat/KM 
will be a combination that increases as the enzyme shows a higher affinity for the 
substrate (lower KM) and/or higher catalytic rates (higher kcat). Thus, the higher the 
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kcat/KM value the better is the overall performance of the enzyme for a specific 
substrate. Separate analyses for kcat and KM are used to characterise a given 
enzyme–substrate system; however, in systems where the individual constants 
cannot be easily determined the combined term kcat/KM is particularly useful since it 
would summarise in one constant the net advantage or disadvantage of a 
permutation introduced the enzyme–substrate system (Koshland, 2002). 
 
Figure 2.2 Graphical representation of the Michaelis-Menten equation. 
This method of ―initial rates‖ is used to calculate kinetic parameters of a substrate–enzyme system 
using Equation 2.5. For small [S] values KM >> [S] and the initial slope corresponds to Vmax/KM. As 
[S] reaches enzyme saturation the hydrolysis rate tends to the limiting rate Vmax. 
2.1.2 Design of fluorogenic substrates 
Whereas an HPLC-based assay was used by S. Knox in previous work to 
analyse the 3C
pro
 cleavage sites within FMDV polyprotein (Birtley et al., 2005), a 
fluorescence resonance energy transfer (FRET) assay was used in the work 
presented in this thesis to continuously monitor FMDV 3C
pro
 hydrolysis. This 
assay, originally developed by A. Jaulent, A. Fahy et al. in order to provide a fast 
method that would permit the rapid screening of potential FMDV 3C
pro
 inhibitors 
(Jaulent et al., 2007), was adapted to evaluate the activity of the FMDV 3C
pro
 
inhibitors presented in this thesis (chapters 3 and 4). Moreover, as an attempt to 
overcome some of the limitations of the FRET substrate used, mainly its poor 
solubility and the inner filter effect characteristic of this type of substrate (see 
following sections), a different type of fluorogenic substrate (peptidyl-AMC) was 
v 
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designed and evaluated for its potential applicability to monitor FMDV 3C
pro
 
hydrolysis.  
 FRET substrates 
FRET-based assays have been used successfully to monitor protease activity 
by modifying a peptide sequence that is recognised and cleaved by the cognate 
protease. First described to monitor the activity of HIV protease (Matayoshi et al., 
1990), many examples can be found today of the use of FRET substrates with 
proteases. Some examples of substrates used to monitor 3C-related proteases 
include work on PV 3C
pro
 (Weidner and Dunn, 1991; Hata et al., 2000), HRV 3C
pro
 
(Brill et al., 1996; Kati et al., 1999) and more recently the extensive work on 
SARS-CoV 3CL
pro
 (Blanchard et al., 2004; Liu et al., 2005; Hamill et al., 2006).
 
To build a FRET substrate, a complementary pair of molecules, a fluorescence 
donor (fluorophore) and a fluorescence acceptor (quencher), are placed on the 
peptidic substrate at either side of the scissile bond. In the unprocessed substrate, 
the fluorescence of the donor is quenched intramolecularly by resonance-energy 
transfer. During this phenomenon a photon is transferred without any release of 
energy. For this to occur, the fluorescence emission spectrum of the donor must 
overlap the absorption spectrum of the acceptor and it is necessary that they are in 
close proximity, since the distance between a donor–acceptor pair will influence 
quenching. The minimal distance recommended is the Förster distance R0, which is 
specific for a given donor-acceptor pair (Haugland, 2002). After cleavage, the 
donor and acceptor are physically separated and the fluorescence of the donor 
group is thereby restored. Due to the distance-dependent nature of FRET, the 
likelihood of intermolecular photon transfer increases with concentration of the 
FRET substrate, a phenomenon known as the inner filter effect (Haugland, 2002). 
Nonetheless, proteolytic activity can be monitored by measuring the increase of 
fluorescence with time (Figure 2.3 and Figure 2.8).  
The EDANS/DABCYL pairing is commonly used due to the excellent energy 
overlap of the donor and quencher emission/absorption spectra. EDANS absorbs at 
341 nm and emits fluorescent radiation at 471 nm whilst DABCYL absorbs at 
453 nm without emitting fluorescence (Matayoshi et al., 1990). The FRET 
substrate for FMDV 3C
pro
 was built based on the sequence of the FMDV 
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polyprotein VP1/2A junction, KIIAPAKQ↓LLNFDLLK (where ↓ represents the 
scissile bond), which is the naturally occurring sequence with the highest level of 
specificity towards FMDV 3C
pro
 identified from the peptide cleavage assays 
(section 1.4.4; Birtley et al., 2005). The substrate with the optimal relative 
positions of the donor-acceptor pair within the sequence corresponded to the P5–
P8′ peptide with DABCYL on the N-terminus and EDANS on the P3′ position: 
DABCYL-APAKQ↓LLD(EDANS)FDLLK (compound 1; Figure 2.3; Jaulent et al., 
2007).  
 
 
 
Figure 2.3 DABCYL-APAKQ↓LLD(EDANS)FDLLK (1): optimised FMDV 3Cpro FRET–substrate. 
DABCYL, the fluorescence acceptor, is incorporated at the N-terminus of the peptide on the P-side, 
while the fluorescence donating EDANS is incorporated into the P′-side attached to the side chain of 
an Asp residue. Upon irradiation EDANS (λ ex = 341 nm; λ em = 471 nm) emission is quenched by 
proximal DABCYL (λ maxAbs = 453 nm). After hydrolysis separation of the P and P′ sides results in a 
recordable increase in fluorescence.  
 AMC substrates 
The use of 7-amino-4-methyl coumarin (AMC) peptide substrates in 
proteolytic assays is a well established method (Zimmerman, 1977) and is a very 
popular tool for studying protease activity and specificity. For instance, AMC-
substrates are the fluorogenic substrates of choice when assessing the activities of 
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serine and cysteine proteases and are widely used to map protease P-specificity 
(Gosalia et al., 2005; Choe et al., 2006).  
AMC is highly fluorescent on its free form, but upon conjugation to the 
C-terminal carboxyl of a peptide its fluorescence is essentially quenched. For the 
determination of cleavage rates, modified substrates are incubated with its target 
protease. Specific cleavage of the anilide bond between AMC and the conjugated 
peptide, placed on what would be the scissile bond of a peptidic substrate, liberates 
the AMC group resulting in a large increase in fluorescence, which can be detected 
at 441 nm upon excitation at 342 nm (Figure 2.4). 
 
 
 
Figure 2.4 Ac-APAKQ-AMC (2): potential FMDV 3C
pro
 AMC-substrate. 
The fluorogenic substrate is designed with an AMC group attached to the C-terminus of the P side of 
the peptidic substrate taking up the position of the P1′ residue. After irradiation at λ ex = 342 nm the 
AMC conjugated peptide should essentially be non-fluorescent (quenched substrate), whereas upon 
hydrolysis a noticeable increase in fluorescence should be recordable at 441 nm.  
In this type of substrate the AMC group occupies the P1′ position, which in a 
natural substrate sequence would be an amino acid. Many proteases are highly 
P1-specific but accept a wide range of amino acids at the P1′ position. In general, 
many serine and cysteine proteases hydrolyse AMC-substrates efficiently. 
However, despite their extensive use in other systems, there is no example where 
AMC-substrates have been used with 3C or 3C-like proteases. FMDV 3C
pro
 has a 
narrow P4–P1 specificity but unlike other viral 3C proteases, which only accept 
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Gly on the P1′ position, seems to have a more relaxed P1′ specificity and besides 
P1′-Gly also hydrolyses peptides with Leu, Ile, Thr, Ser and Cys in this position 
(Knox, 2006), see section 1.4.4. Therefore, AMC-peptides could potentially be 
viable fluorogenic substrates for FMDV 3C
pro
. In order to explore this possible 
alternative to the FRET-substrate a potential fluorogenic substrate for FMDV 3C
pro
 
was conceived by modifying the P-side of the VP1/2A junction sequence with an 
AMC group attached to its C-terminus and the peptidyl-AMC (2) (spanning P5–P1) 
was synthesised (Figure 2.4). 
2.1.3 Synthesis of fluorogenic substrates 
Like most peptide syntheses performed nowadays, the fluorogenic substrates 1 
and 2 were synthesised by SPPS. An overview on the technique and details of the 
synthesis and characterisation of the peptidyl derivatives can be found in the 
experimental chapter (sections 6.2.2 and 6.2.3). 
 FRET substrate synthesis 
The FRET substrate DABCYL-APAKQ↓LLD(EDANS)FDLLK (1) was 
synthesised by automated SPPS on Fmoc-K(Boc)-Wang resin (3a) following the 
Fmoc/tBu protection scheme (Figure 2.5). The synthesis required the use of the 
modified amino acid Fmoc-Asp(EDANS)-OH (4), which was synthesised 
beforehand following a pre-established method (Taliani et al., 1996). This amino 
acid was introduced into the sequence manually by pausing the automated 
synthesis of the peptide chain (growing from the C-terminus) after four amino acids 
had been coupled and the N-terminus of the pentapetide had been deprotected. In 
order to use the minimal amount of Fmoc-Asp(EDANS)-OH, instead of the usual 
five-fold excess of HOBt/HBTU used in all the rest of the couplings a two-fold 
excess of (4) was used in conjunction with a HOAt/HATU coupling-reagent pair. 
The automated synthesis was then resumed and the remaining amino acids were 
introduced. Finally the DABCYL group was also coupled manually on the 
N-terminus of the complete sequence. Purification of the FRET peptide (1) was 
achieved with reverse-phase HPLC. To ensure all collected fractions contained the 
required fluorophore and quencher only fractions that were red (indicating presence 
of DABCYL) and which contained material absorbing at 335 nm (EDANS 
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absorbance) were collected. The overall yield was generally around 50%, which is 
very good taking into account the length of the peptide and the introduction of two 
manual steps.  
 
 
 
Figure 2.5 Synthesis of the FMDV 3C
pro
 FRET substrate (1). 
The peptide, spanning P5–P8′ residues of the polyprotein VP1/2A junction sequence, was grown on 
Wang resin (3) preloaded with Fmoc-L-Lys(Boc)-OH (3a) using automated SPPS with two manual 
steps for the coupling of the Fmoc-L-Asp(EDANS)OH (4) and DABCYL-OH. 
 AMC-substrate synthesis 
AMC-substrates are easier and faster to synthesise since they are much smaller 
and, unlike the FRET substrate, they can be obtained directly by automated SPPS 
without the introduction of manual steps. The peptidyl derivative Ac-APAKQ-
AMC (2) was synthesised from a commercially available Rink amide resin (5) 
(Figure 2.6). This resin used was pre-loaded with a glutamate that is modified on its 
C-terminus with the AMC group and attached to the solid support via the 
carboxylic acid function of its side-chain. The remaining peptide was grown on its 
N-terminus by automated SPPS (Figure 2.6), which, after the final acidic cleavage 
conditions, led to a peptide modified on its C-terminus and with a glutamine on the 
P1 position. The final product was obtained with a yield of 55% and gave 
satisfactory HPLC, MS and NMR characterisation data (section 6.2.3).  
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Figure 2.6 Synthesis of peptidyl-AMC (2). 
The peptide, spanning the P5–P1 residues of the polyprotein VP1/2A junction sequence, was grown 
on a preloaded Rink amide AM resin (5) using automated SPPS.  
N
H
Nle
O
O
HN
OMe
H
N
AMC
O
O
RA(AM)
NH2
H
N
AMC
O
O
SPPS
APAKAc
MeO
Fmoc
5 
2 
2 FMDV 3C 
pro 
SAR 
73 
 
2.1.4 Comparison of AMC and FRET substrates 
As mentioned earlier, the AMC substrate was designed to overcome some of 
the limitations of the FRET substrate, mainly the limited solubility of compound 1 
and the inner filter effect, which is characteristic of this type of substrate (section 
2.1.2).  
The solubility of the AMC derivative was noticeably enhanced. Whereas the 
FRET substrate (1) required a stock solution of 5 mM in pure DMSO for it to be 
used in the assay conditions (section 2.1.5), the AMC-substrate (2) was soluble in 
water. This is a key factor in the determination of kinetic parameters, since, when 
higher substrate concentrations can be used in the working conditions, the chances 
of reaching saturation kinetics increase. Thus, not only can the kcat/KM ratio be 
defined, but the two separate parameters could potentially be determined for the 
AMC substrates.  
In order to investigate the applicability of the novel fluorogenic substrate two 
experiments were carried out. Firstly, for a range of different concentrations, the 
fluorescence of the two modified peptides was compared with the fluorescence of 
their fluorescence donor groups (Figure 2.7). In the case of the FRET substrate, the 
fluorescence of the fluorophore was also monitored in the presence of an equimolar 
amount of the quencher, to mimic the effect that would be observed upon 
hydrolysis of the FRET substrate, since each of the two hydrolysis products would 
be bearing either a fluorophore or a quencher. Secondly, the fluorescence for the 
two peptidyl derivatives 1 and 2 was recorded in the presence of FMDV 3C
pro 
(Figure 2.8).  
When comparing the two fluorophores (Figure 2.7) it could be established that 
for the same range of substrate concentrations the fluorescence of the AMC group 
was one order of magnitude larger than the EDANS group. More importantly, the 
increase of fluorescence when comparing the intact substrate with the 
corresponding free AMC and DABCYL + EDANS (both at 80 µM) was of 
5376 AFU and 230 AFU respectively. However, the background fluorescence was 
also noticeably higher for the peptidyl-AMC (2) and, as opposed to the FRET 
substrate, it increased with concentration, varying from 10 AFU to 230 AFU at the 
maximal concentration assessed (100 µM). Nonetheless, in the event of comparable 
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levels of hydrolysis, the AMC-substrate should function with lower amounts of 
protease and fluorogenic substrate, which would be greatly beneficial in cost.  
The inner filter effect, which manifests‘ increasingly with concentration, could 
also be clearly observed in this experiment (Figure 2.7). Whereas the fluorescence 
of free EDANS displayed a linear behaviour with concentration, in the presence of 
equal amounts of DABCYL the linearity was lost. On the other hand, the relation of 
fluorescence with concentration was also observed to lose linearity for increasing 
amounts of free AMC, even in the absence of a quencher. However, the inner filter 
effect was much lower for AMC than for the EDANS–DABCYL pair, which could 
be advantageous especially considering that the AMC was about 10 times more 
fluorescent.  
 
 
    
 
   
Figure 2.7 Characterisation of the fluorogenic substrates and their fluorophores. 
Fluorescence (F) in arbritrary fluorescence units (AFU) for the FRET (left) and AMC (right) 
substrates at different concentrations ([S]) and their corresponding fluorophores (EDANS and AMC). 
Note the tenfold difference in the AFU scale. As a result of inner filter effect the fluorescence of 
EDANS decreased in the presence of equimolar amounts of DABCYL (DABCYL + EDANS curve) 
and the fluorescence from increasing concentrations of AMC lost linearity.  
When fluorescence readings for the FRET (1) and AMC (2) substrates were 
taken upon incubation with FMDV 3C
pro
 under the same working conditions 
(Figure 2.8) increase of fluorescence with time could only be observed for the 
FRET substrate. Since the fluorescence remained constant for the mixture 
containing peptidyl-AMC it was concluded that even if the protease hydrolyses a 
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range of substrates with different residues at the P1′ position (section 1.4.4), the 
truncated version of the a FMDV 3C
pro
 substrate where the P1′ position was taken 
by the AMC group was not hydrolysed. This is a striking result since this type of 
substrate is successfully used for other cysteine proteases and closely related serine 
proteases. However, it confirms the importance of the P1′ position in FMDV 3Cpro, 
as with all other 3C proteases, in contrast with the primarily P-specificity of other 
enzymes such as chymotrypsin, papain or caspase (Barret et al., 2004).  
 
 
 
              
 
Figure 2.8 Hydrolysis of fluorogenic substrates. 
Plots of fluorescence (F) over time from the incubation of FRET and AMC substrates at four 
different concentrations with FMDV 3C
pro
 at 0.6 μM. A) The FRET substrate (1) showed an 
increase of fluorescence of at least 50 AFU after 1h of incubation initial hydrolysis rates can be 
determined from these plots taking the slope of the linear part of the curve (red line) during the first 
minutes of incubation. B) Under the same conditions (section 2.1.5) no increase in fluorescence 
could be observed for the peptidyl-AMC (2) indicating no substrate hydrolysis.  
2.1.5 The FRET assay 
The FRET substrate (1) is the only substrate available to monitor FMDV 3C
pro
 
activity and, despite its limitations, the substrate has been characterised (Jaulent 
et al., 2007) and has been successfully used in the assessment of the activity of 
different FMDV 3C
pro
 mutants (section 2.3.1) and the evaluation of potential 
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FMDV 3C
pro
 inhibitors (chapter 4). Moreover, the assay has been successfully 
miniaturised to be used in a 384-well plate for potential high-throughput screening 
(HTS) by S. McElroy and M. Deakin from the ―Assay Evaluation for HTS” 
department at the Scottish Hit Discovery Facility in Dundee, UK (personal 
communication). The following sections explain the conditions used for the assays 
performed in a 96-well format.  
 Assay parameters  
pH and temperature. Enzyme–peptide solutions were incubated at 37 °C in 
phosphate buffer made up to pH 7.4, reflecting biological pH and temperature in 
which native FMDV 3C
pro
 is known to operate (Li et al., 2001). Biological 
conditions were used to optimise peptide hydrolysis and, more importantly, provide 
an environment that potential FMDV 3C
pro
 inhibitors would encounter in vivo.  
Buffer components. All assays were performed in an aqueous phosphate buffer 
solution containing: Na2HPO4–NaH2PO4 (1:1, 100 mM), EDTA (1 mM), TCEP 
(1 mM) and glycerol (5% v/v). EDTA, a well known chelating agent, was present 
to avoid the interaction of residual metal ions with FMDV 3C
pro
 or peptide 
derivatives. TCEP, a phosphine reducing agent, was present to prevent protein 
aggregation and disulphide bridge formation with the active site Cys nucleophile, 
which would drastically lower or terminate catalytic activity. 
Enzyme and substrate concentrations. In order to keep the final DMSO 
concentration below 5% (so that the DMSO did not interfere with the fluorescence 
of the substrate) substrate concentrations used were below 100 μM, limiting the 
determination of the kinetic parameters to kcat/KM (section 2.1.1). Absolute enzyme 
concentrations are difficult to determine as they depend on purity and activity, 
which may be reduced if a proportion of the enzyme is denatured. Concentration 
was estimated from the total amount of protein based on absorbance at 280 nm 
(section 6.3.1), taking into account purity as observed on analytical SDS PAGE 
(typically only one band was observed for these enzyme preparations indicating 
apparent homogeneity).  
Assay product analysis. From the raw data directly obtained from monitoring 
substrate hydrolysis with time, the initial slope of the hydrolysis curve was used for 
the determination of the performance constant (Figure 2.7). In each instance these 
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initial rates (v), expressed in AFU/second, were transformed into the appropriate 
M/s units as indicated in the following section. The specificity constants (kcat/KM) 
were then calculated from the transformed initial rates using the Michaelis-Menten 
plot discussed in section 2.1.1 (Koshland, 2002).  
 Calibration curve and correction factor 
A calibration curve was necessary to convert hydrolysis rates from AFU units 
to concentration units. Moreover, due to the inner filter effect, a correction factor 
was required to compare rates observed at different substrate concentrations, which 
was essential for the determination of the kinetic parameters of an enzyme–
substrate system. However, a correction factor is not required when comparing 
relative rates in experiments where the initial substrate concentration remains 
constant, which was the case in the inhibition assays (section 3.3). In order to 
record true fluorescence readings, the correction factor was determined 
experimentally from two calibration curves (Figure 2.7). Fluorescence readings 
were taken for a range of EDANS concentrations that coincided with the working 
substrate concentrations, in this case 0–90 μM. This was also undertaken, over the 
same concentration range, for equimolar solutions of EDANS + DABCYL. The 
correction factor (C) for the inner filter effect was calculated experimentally for 
every substrate concentration ([S]) using Equation 2.6, where FEDANS was the 
fluorescence value observed for the fluorophore on its own and FDABCYL+EDANS was 
the value observed in the presence of the quencher. After applying the correction 
factor to hydrolysis rate readings (for every concentration: AFUcorr = C[S]∙AFUexp) 
the AFU values were transformed to product concentration through the linear 
regression from the AFUs vs [EDANS] plot (Equation 2.7). Both the calibration 
curve and the correction factor were established for every set of experiments for 
which they were required.  
C[S] =
F𝐸𝐷𝐴𝑁𝑆
F𝐸𝐷𝐴𝑁𝑆+𝐷𝐴𝐵𝐶𝑌𝐿
 AFU = slope  EDANS + background 
Equation 2.6 Equation 2.7 
 78 
 
2.2 Recombinant FMDV 3C
pro
 Mutants 
With a method of assessing FMDV 3C
pro
 hydrolysis in hand it was important 
to have access to the enzyme to be able to use it in the activity and inhibition 
assays. This was achieved by reproducing a previously established method (Birtley 
et al., 2005). The actual FMDV 3C
pro
 expressed corresponded to the A1061 viral 
strain, however; in order to allow the crystallisation and assessment of the 
recombinant protease, two mutations (C95K and C142S) had been introduced to 
the wild type protease to enhance enzyme solubility.  
As seen in the first FMDV 3C
pro
 crystal structure (PDB ID 2BHG; Birtley 
et al., 2005) the 95
th
 residue is located far from the active site whereas the 142
nd
 
residue is situated on a disordered region of the structure (―missing loop‖) (Figure 
2.9). However, as indicated in section 1.4.2, in the recently published FMDV 3C
pro
 
structure (PDB ID 2J92; Sweeney et al., 2007), where a new mutation (K51Q) had 
been introduced to favour a different crystal form, this missing loop (residues 138–
150) appears ordered, forming a β-ribbon folding onto the peptide binding cleft 
(Figure 2.9). The 142
nd
 residue sits at the tip of this loop in close proximity to the 
active site. Preliminary HPLC-based peptide cleavage assays indicated that the 
C142S substitution had no effect on substrate specificity but did reveal a very 
significant loss of enzyme activity (of about 2 orders of magnitude; Birtley et al., 
2005). Therefore, the precise effect of the 142
nd
 residue on protease activity was 
studied (section 2.3.1; Sweeney et al., 2007). 
The method used to obtain the FMDV 3C recombinant protease is explained in 
the following sections and is illustrated with the Mutant A (Table 2.1), which was 
the protease used for the inhibition assays (section 3.3 and chapter 4). Further 
details can be found in the experimental chapter (section 6.1) and appendix 7.2 and 
7.3. The construct presented here provided the active FMDV 3C
pro
 mutant 
necessary for the evaluation of potential inhibitors, but was also used to provide the 
C142 mutants assessed in section 2.3.1 (Sweeney et al., 2007). On the other hand, 
inactive protease suitable for crystallisation, used for the production of the 
enzyme–substrate crystal structure (section 2.3.2), was obtained by P. Zunszain 
from a slightly different vector but using a similar method and will not be discussed 
here.  
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Figure 2.9 FMDV 3C
pro
 crystal structures. 
A) Top view and B) front view of the first FMDV 3C
pro
 crystal structure (PDB ID 2BHG; Birtley 
et al., 2005). The recombinant protein has two mutations to enhance solubility (C142S and C95K) 
and a C163A mutation to rend the protease inactive. The active site residues H46, D84 and A163 
are highlighted in pink. The C95K mutation is far from the active site whereas C142S mutation 
cannot be identified in this structure since is in the missing loop (residues 141–147, inclusive). C) 
Second FMDV 3C
pro
 crystal structure (PDB ID 2J92; Sweeney et al., 2007) where an extra mutation 
(K51Q, also far from the active site) was introduced for crystallisation purposes and where C142S 
can be identified on the tip of the β-ribbon. Structures rendered with Pymol (DeLano, 2002). 
A) 
B) 
missing loop 
A163 
H46 
D84 
active site 
K95 
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S142 
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2.2.1 Over-expression and purification of FMDV 3Cpro 
The original expression vector (pET-FMDV3CXS) corresponded to a pET-28b 
plasmid (Novagen; appendix 7.3) modified by the insertion of a fragment of DNA 
coding for FMDV 3C
pro
. The plasmid, which was provided by C. Proud (University 
of Dundee) and had been shown to allow the over-expression of the active form of 
FMDV 3C
pro
 (Li et al., 2001), was modified by J. Birtley by introducing the 
mutations C95K and C142S mentioned above. The pET-28b vector contained a 
kanamycin resistance marker and was constructed in such a way that the 3 naturally 
occurring copies of the FMDV 3B genes (3B1, 3B2 and 3B3) were cloned 
immediately upstream of the 3C
pro
 gene (illustrated in Figure 2.10; Birtley and 
Curry, 2005).  
 
 
 
 
 
 
 
 
 
 
Figure 2.10 Autoprocessing of the expressed 3C
pro
. 
The correct processing of the pET-28b over-expressed 35 kDa protein results in a 23 kDa C-
terminally 6 ×  His tagged protein (shown in grey). The 3Cpro cleaves at its N-terminus releasing the 
3B genes (coloured blue) and 6 ×  His tag.  
Over-expression of the active protein from the pET-28b vector takes place 
using competent BL21(DE3)pLysS E. coli cells (see below), resulting in a 323 
amino acid (35 kDa) fusion protein (Figure 2.10). The first 45 amino acids to be 
translated included an N-terminal 6 ×  His tag and a linker region. The next 65 
amino acids were composed of the three 3B genes of FMDV whilst the remaining 
3C protease processing 
 6×His+linker 
  6×His      3C protease 
23 kDa 
 3B2 
 3B3 
 3B1 
N-t C-t 
35 kDa 
 3B1  3B2  3B3   6×His      3C protease  6×His+linker 
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213 amino acids belonged to the recombinant 3C
 
protease (23 kDa). Of the 213 
residues the last six wild-type C-terminal amino acids (208–213), PEPHHE, were 
substituted to His resulting in a polyhistidine tag on the C-terminus. Upon 
translation of the 323 amino acid product in E. coli, correctly folded material would 
be processed by the 3C
pro
 to liberate the 3B proteins and its authentic N-terminus 
(Figure 2.10). 
 Design of C142 mutants 
In order to probe the molecular basis of the effect of the 142 residue side chain 
and to attempt to produce a soluble enzyme with an activity closer to wild type than 
C142S, alternative substitutions of C142 were engineered and the resulting 
enzymes were assessed using the FRET assay (section 2.1.5). The mutation to 
serine (Mutant S) had been conceived as the amino acid structurally closest to 
cysteine, which is the 142
nd
 residue found in wild type FMDV 3C
pro
 and is strictly 
conserved among the different viral strains. Instead, the residues threonine (Mutant 
T), alanine (Mutant A), valine (Mutant V) and leucine (Mutant L) were chosen to 
increase bulk and hydrophobicity at this position to match the characteristics of 
residues found at the equivalent position in PV, HAV and HRV 3C proteases 
(Table 2.1, Figure 2.11). The plasmids for these mutants were generated by T. 
Sweeney using the Quikchange PCR method (Stratagene, 2007).  
 
 
Table 2.1 Recombinant 3C
pro 
mutants. 
Mutants from the A1061 viral strain of 
FMDV. These recombinant proteases 
were obtained from the pET vector by 
over-expression in E. coli. *The mutants 
are named after their 142
nd
 residue but 
they all also contain a second mutation 
C95K. 
Figure 2.11 Amino acids at 142. 
Structures of the residues at the 142 position in the 
mutants of Table 2.1. Cys corresponds to wild type 
residue, its closest relative is Ser followed by Thr. 
The appearance of other small alkyl chains in 
homologous positions in other 3C proteases lead to 
increase the side-chain length by the introduction 
of Ala, Val and Leu. 
Name* C142 Mutation 
Mutant C none 
Mutant S C142S 
Mutant V C142V 
Mutant T C142T 
Mutant A C142A 
Mutant L C142L 
   
Cys Ser Thr 
 
 
 
Ala Val Leu 
H
N
O
HS
H
N
O
HO
H
N
O
OH
H
N
O
H
N
O
H
N
O
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 Restriction Digest  
The mutations created in this study were designed so that they also introduced 
a new restriction site into the DNA sequence (cleaved by a specific endonuclease). 
In the plasmid provided, mutations had been introduced in the following manner: 
the wild type (WT) was mutated to Mutant S (C95K + C142S) with the 
introduction of EcoRV and NcoI restriction enzyme sites; Mutant A (C95K + 
C142A), which was the mutant used in the evaluation of potential inhibitors, had 
been obtained from Mutant S keeping the EcoRV restriction site from the C95K 
mutation but losing the NcoI site corresponding to the C142S mutation. An 
example of the restriction digest of plasmid DNA confirming the C95K mutation is 
shown in Figure 2.12. 
 
 
    Figure 2.12 Representative restriction digest of plasmid DNA. 
    Lane L contains a DNA ladder from which the most significant 
    bands are highlighted on the kilo base (kb) scale. Lane 1 is  
    undigested plasmid DNA. Lane 2 is the plasmid DNA of Mutant 
    A digested with EcoRV, the appearance of two bands indicates 
    the presence of the two EcoRV sites (pET-28b backbone site  
    and C95K mutation site). 
 
 DNA Sequencing  
 Even if the introduction of mutations is monitored by restriction digests, it is 
necessary to check that each clone has the authentic DNA sequence. Therefore, the 
plasmids were sequenced prior to their use for protein over-expression. The 
fragments corresponding to the FMDV 3C
pro
 encoding regions for the wild type 
and Mutant A are shown in Figure 2.13. The engineered mutations (highlighted in 
yellow) can be identified: the wild type C95 codon (TGC) was mutated to K95 
(AAG), the translationally silent EcoRV restriction enzyme site (GATATC) had 
been introduced by altering the D98 codon (from GAC to GAT) and the C142 
codon (TGC) was mutated to A142 (GCT). Characterisation of the sequences 
(section 6.1.3) for the rest of the 142 mutants confirmed that they all contained the 
C95K mutations and the corresponding C142 mutation (Table 2.1). 
  L       1       2    
 
3 - 
 
 
1 - 
 
0.5 -  
kb 
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A) DNA Sequences 
 
B) Protein Sequences 
Figure 2.13 DNA and protein sequences of recombinant FMDV 3C proteases. 
Sequence alignment of the encoding regions of the wild type (WT) and Mutant A (MA) (Table 2.1), 
from the FMDV A1061 strain 3C
pro
. A) Fragment extracted from the sequencing of the pET-28b 
vectors used for the expression of the recombinant protein. B) Translated amino acid sequences. 
Highlighted in yellow are the engineered mutations: C95K, the silent mutation on D98 and C142A. 
The EcoRV restriction enzyme site (GATATC) is shown in red. The incomplete codons are shown in 
blue with the unidentified bases represented by N and the corresponding ―untranslated‖ amino acids 
by blue Xs. The stop codon TGA is highlighted in red. Translation and alignments were performed 
using the ExPASy tools at http://www.expasy.ch/ (Gasteiger et al., 2003). 
 
WT 
dM 
 
AGTGGTGCCCCACCGACCGACTTGCAGAAGATGGTCATGGGCAACACAAAGCCTGTTGAGCTTATCCTC           
AGTGGTGCCCCACCGACCGACTTGCAGAAGATGGTCATGGGCAACACAAAGCCTGTTGAGCTTATCCTC             
WT 
dM 
 
GACGGGAAGACAGTAGCCATCTGCTGTGCTACTGGAGTGTTCGGCACTGCTTACCTCGTGCCTCGTCAC 
GACGGGAAGACAGTAGCCATCTGCTGTGCTACTGGAGTGTTCGGCACTGCTTACCTCGTGCCTCGTCAC 
 
WT 
dM 
 
CTTTTCGCAGAGAAGTATGACAAGATTATGTTGGACGGCAGAGCCATGACAGACAGTGATTACAGAGTG 
CTTTTCGCAGAGAAGTATGACAAGATTATGTTGGACGGCAGAGCCATGACAGACAGTGATTACAGAGTG 
 
WT 
dM 
TTTGAGTTCGAGATTAAAGTAAAAGGACAGGACATGCTCTCAGACGCGGCACTCATGGTGCTTCACCGT  
TTTGAGTTCGAGATTAAAGTAAAAGGACAGGACATGCTCTCAGACGCGGCACTCATGGTGCTTCACCGT 
 
WT 
dM 
 
GGGAACTGCGTGAGAGACATCACGAAACACTTTCGTGATACAGCAAGAATGAAGAAAGGCACCCCCGTC  
GGGAACAAGGTGAGAGATATCACGAAACACTTTCGTGATACAGCAAGAATGAAGAAAGGCACCCCCGTC 
 
WT 
dM 
 
GTTGGTGTTGTCAACAACGCCGATGTTGGGAGACTGATTTTCTCTGGTGAGGCCCTTACCTACAAGGAC 
GTTGGTGTTGTCAACAACGCCGATGTTGGGAGACTGATTTTCTCTGGTGAGGCCCTTACCTACAAGGAC 
 
WT 
dM 
 
ATTGTAGTGTGCATGGATGGAGACACCATGCCCGGCCTCTTTGCCTACAAAGCCGCCACCAAGGCTGGC 
ATTGTAGTGGCTATGGATGGAGACACCATGCCCGGCCTCTTTGCCTACNAAGCCGCCACCAAGGCTGGC 
 
WT 
dM 
 
TACTGTGGAGGAGCCGTTCTTGCCAAGGACGGGGCTGACACATTCATCGTCGGCACTCACTCTGCAGGT 
TACTGTGGAGGAGCCGTTCTTGNCAAGGANNGGGCTGACACATTCATCGTCGNNNCTCACTCTGCNNNN 
 
WT 
dM 
 
GGCAATGGAGTTGGATACTGCTCATGCGTTTCCAGGTCCATGCTTCAAAAGATGAAGGCTCACGTCGAG 
GGCAATGGAGTTGGATACTGNTNNTGNGTTTCCAGGTCCATGCTTCNAANNANNANNNNTCNCGTCNAG 
 
WT 
dM 
 
CACCACCACCACCACCACTGA 
CANCACCACCACCACCACTGA 
 
WT 
dM 
 
SGAPPTDLQKMVMGNTKPVELILDGKTVAICCATGVFGTAYLVPRHLFAEKYDKIMLDGR 
SGAPPTDLQKMVMGNTKPVELILDGKTVAICCATGVFGTAYLVPRHLFAEKYDKIMLDGR 
WT 
dM 
 
AMTDSDYRVFEFEIKVKGQDMLSDAALMVLHRGNCVRDITKHFRDTARMKKGTPVVGVVN 
AMTDSDYRVFEFEIKVKGQDMLSDAALMVLHRGNKVRDITKHFRDTARMKKGTPVVGVVN 
WT 
dM 
 
NADVGRLIFSGEALTYKDIVVCMDGDTMPGLFAYKAATKAGYCGGAVLAKDGADTFIVGT 
NADVGRLIFSGEALTYKDIVVAMDGDTMPGLFAYXAATKAGYCGGAVLXKXXADTFIVXX 
 
WT 
dM 
 
HSAGGNGVGYCSCVSRSMLQKMKAHVEHHHHHH 
HSXXGNGVGYXXXVSRSMLXXXXXXVXHHHHHH 
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 DNA amplification  
The genetic material provided (Mutant A plasmid) was sub-cloned in order to 
ensure it was in a good condition and make a stock of DNA encoding FMDV 3C
pro
. 
DNA amplification was performed in the competent E. coli cell line XL-10. The 
plasmid was introduced into E. coli by heat shock; in the same way 
BL21(DE3)pLysS cells, which allow over-expression of toxic proteins, were 
transformed for production of FMDV 3C
pro
 (see below). XL-10 cells were then 
incubated on agar plates containing kanamycin in order to select for colonies with 
the kanamycin resistant marker and, therefore, the target plasmid. Generally, three 
different colonies were taken for a small overnight culture. DNA from each culture 
was recovered and purified using a Miniprep/Qiagen kit (Qiagen, 2006). The 
success of the cloning was verified with an EcoRV restriction enzyme digest by 
confirming the presence of the C95K mutation in the recovered DNA.  
 Preparation of recombinant protease  
Transformation of BL21(DE3)pLysS cells by the incorporation of the plasmid 
was accomplished by heat shock. Given that BL21(DE3)pLysS cells are resistant to 
chloramphenicol the bacteria were selected for FMDV 3C
pro 
encoding plasmid by 
incubation on agar plates containing both kanamycin and chloramphenicol. Prior to 
the large-scale protease production a small-scale over-expression was performed in 
order to make sure a chosen colony had a good level of protein expression. Several 
mini cultures were set simultaneously using five different single colonies. After 
induction, the level of target protein was monitored by SDS-PAGE. According to 
the vector design, a new band appeared at around 23 kDa corresponding to the 213 
residues of FMDV 3C
pro
 (Figure 2.14). Once the production of the protease was 
confirmed a large-scale preparation was started with a colony that had shown high 
levels of over-expression and was achieved following the previously optimised 
conditions (Birtley et al., 2005). Briefly, the cells were incubated at 37 °C in LB-
broth and when an OD of 0.6 at 600 nm was reached protein expression was 
induced with IPTG at a final concentration of 1 mM. After 4 h of induction the 
cells were collected by centrifugation and kept at –80 °C prior to purification. Full 
details can be found in the experimental chapter (section 6.1.4). 
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 TALON purification 
As mentioned earlier the presence of the His-tag at the end of the protease 
allowed purification by metal affinity resin. The TALON
®
 resin uses Co
2+
 ions 
fixed through a tetradentate metal chelator. Under physiological pH (7.4), histidine 
binds by sharing the electron density of the imidazole nitrogen with the electron-
deficient orbitals of the metal ion, filling the two remaining coordination sites of 
the metal. Once the His-tagged protein is bound to the resin, any impurities are 
removed by repeated washings, and the target protein is recovered by elution with 
imidazole. The result of the purification was then analysed by SDS-PAGE (Figure 
2.14). Some 3C protease (band at 23 kDa) was present in the unbound fraction, but 
most of it was eluted with the first wash with 100 mM imidazole buffer (E100). The 
gel shows how the washes prior to elution contained minimal protein, indicating 
high selectivity of the beads for the tagged protein.  
 
               
 
Figure 2.14 Over-expression and purification of recombinant FMDV 3C
pro
. 
 A) SDS-PAGE from an over-expression of the FMDV 3C
pro
 Mutant A. A new band at around 23 
kDa can be observed after 4 h of IPTG induction. B) SDS-PAGE showing the progress of TALON 
purification. The 3C
pro
 band can be followed throughout the process. The molecular weight marker 
is represented by L = ladder and the analysed fractions as follows: UI = uninduced; 4 h = sample 
after 4 h of induction; Y = lysate; P = pellet; UB = unbound material; A1 and A2 = washes with 
buffer A; E5, E100 and E250 = elutions with buffer A + imidazole at 5, 100 and 250 mM respectively. 
 Gel filtration 
Fractions from the TALON purification containing pure 3C
pro
 (E100 and E250) 
were pooled together and dialysed overnight to remove the imidazole. 3C protease 
was then further purified by gel filtration. The use of a Superdex 75 column 
A) 
 
B) 
20 - 
kDa 
 
- 23 kDa - 
 
 
L     UI    4h 
 
Y      P      L    UB  A1   A2  E5   E100   E250     
30 - 
40 - 
50 - 
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allowed separation by size-exclusion of preparative amounts of sample for proteins 
by elution with buffer A (section 6.1.5). Fractions were selected using absorbance 
at 280 nm to follow the presence of protein. The fractions around the main peak, 
which was obtained when 60–75 mL of buffer had passed through the column, 
were analysed by SDS-PAGE and the band corresponding to 3C
pro
 (at 23 kDa) 
could be observed (Figure 2.15). The fractions containing pure 3C protease were 
pooled together and the final purified yield (calculated by absorbance at 280 nm) 
was 8 mg/L of culture.  
 
 
 
Figure 2.15 Typical gel filtration chromatogram of the purification of 3C
pro
. 
The gel filtration of the Mutant A was monitored by UV detection at 280 nm. The 3C
pro
 eluted from 
a Hi Load 16/60 Superdex 75 column (60 cm × 16 mm) after 60–75 mL of buffer had passed 
through at a rate of 0.75 mL/minute. The red lines indicate the beginning of the collection of a 1 mL 
fraction and fractions 1–49 are numbered. The fractions collected around the peak (26–35) were 
analysed on SDS-PAGE and a scan of the corresponding gel is shown on the insert where the 
numbers correspond to the fractions collected shown in the chromatogram and L = ladder (see 
Figure 2.14). 
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2.3 Structure Activity Relationships 
With access to a suitable substrate established, and with a method to assess 
protease activity in hand, we were in a position to evaluate, as described in sections 
2.1.5 and 6.3.3, the activities of the different protease mutants obtained by over-
expression in E. coli. Moreover, the results of the activity assays were related to the 
role of the mutated position in the newly determined enzyme–substrate complex 
crystal structure (unpublished data, section 2.3.2), which also explained FMDV 
3C
pro
 substrate specificity.  
2.3.1 Activity of 142 mutants 
The activity assays for the different mutants were performed by monitoring the 
hydrolysis of the FRET substrate (1) in the presence of the protease with 
continuous measurements of fluorescence, as indicated in section 6.3.3. All 
enzymatic assays were performed in aqueous phosphate buffer solution (discussed 
in section 2.1.5). As already mentioned, due to its hydrophobic nature the FRET 
substrate has limited solubility and has to be dissolved in DMSO before it can be 
diluted in the reaction buffer (section 2.1.4). Therefore, in order to keep the 
concentration of DMSO below 2%, the maximal working concentration was 
restricted to 90 μM. On the other hand, the corresponding FMDV 3C protease was 
present at a concentration of 0.4 or 0.8 μM. Within the range of concentrations 
investigated the Michaelis-Menten plots obtained for the different mutants did not 
show saturation kinetics, thereby preventing separate elucidation of KM and kcat. 
However, measurements showed that the initial rates for twelve different substrate 
concentrations ranging 0–90 μM, corrected and transformed to the appropriate 
units, depended on the substrate concentration in a linear manner. This indicated 
that the working substrate concentrations were well below KM, thus, allowing the 
determination of kcat/KM (Figure 2.16).  
The Cys variant (Mutant C) was prone to aggregation, most likely because of 
intermolecular disulfide formation (Birtley et al., 2005), which was the original 
reason for this residue being substituted during the crystallisation studies. This 
resulted in some preparations of Mutant C showing differing levels of activity (by 
approximately twofold, data not shown).  
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Figure 2.16 Protease activities of the FMDV 3C
pro
 142 mutant enzymes. 
The different mutants are named after the substitutions at their 142
nd
 residue (Table 2.1). The graph 
shows a plot of the initial rates (v), transformed and corrected from fluorescence readings, for 
different FRET substrate concentrations ([S]). The table shows the comparative specificity constants 
kcat/KM for the different mutant enzymes determined from the linear part of the Michaelis-Menten 
plot. *Some preparations showed differing levels of activity (by approximately twofold) which is 
attributed to the propensity of this enzyme to aggregate. 
 
 
 
Figure 2.17 Relative performance constants of 142 mutants. 
Each letter indicates the amino acid on the 142 position of each mutant. (kcat/KM)rel corresponds to 
the ratio (kcat/KM)mutant/(kcat/KM)C. The error bars indicate the variability between two independent 
FRET assays (each performed in triplicate) from a single enzyme preparation (Figure 2.16).  
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Some striking results were observed from the plot of the performance constant 
values normalised to the wild type activity (Mutant C; Figure 2.17). Serine, which 
is usually considered the amino acid closest to cysteine, was in this case the worst 
of all substitutions studied (reducing enzyme activity to about 1%). This was 
probably due to the introduction of a polar side chain in a mainly hydrophobic 
environment, as shown in the enzyme–substrate co-crystal structure (section 2.3.3). 
When C142 was substituted by amino acids such as Ala, Val or Thr, which are 
more apolar than Ser, much higher levels of proteolytic activity were observed (41 
to 60% of the wild type activity). But most interestingly, the highest level of 
activity was observed with the most hydrophobic substitution; the C142L mutant 
enzyme exhibited levels of activity that were greater than those observed for the 
wild type FMDV 3C
pro
. This trend strongly suggested that an apolar residue at 
position 142 is required for optimal activity. The C142L substitution introduced a 
residue found at the equivalent position in PV and HRV 3C proteases, and was the 
substitution used for the FMDV 3C
pro
 crystal structure presented later in this 
chapter (section 2.3.3). However, although the presence of Leu at this position not 
only rendered a viable protease but increased FMDV 3C
pro
 hydrolytic activity, 
cysteine is strictly conserved at the 142
nd
 position among the different strains of 
FMD virus (appendix 7.5; Sweeney et al., 2007).  
On the other hand, a previous study comparing substrate specificity for Mutant 
C, Mutant S and Mutant A with an array of substrates, these three mutant enzymes 
displayed no significant differences in substrate specificity (Knox, 2006). This 
together with the fact that Mutant A displayed higher protease activity than Mutant 
S and, in contrast with Mutant C, had shown excellent long-term stability, Mutant 
A was the FMDV 3C
pro
 mutant of choice for protease inhibition studies (chapter 4). 
2.3.2 Structure of the FMDV 3Cpro–substrate complex  
Introducing permutations in an enzyme–substrate system and assessing how 
the changes affect its activity, information can be obtained to provide an idea of the 
structural requirements for catalysis. However, this information is most relevant 
when specific structural information is available. As illustrated in chapter 1, 
analysis of the structure of a protease is the first step to elucidating general aspects 
of peptide binding or hydrolysis mechanisms. However, more subtle features can 
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sometimes only be understood by the study of the structure of the enzyme 
complexed with cognate substrates or inhibitors. Even if a crystal structure is a 
―static image‖ of the system in a very specific set of conditions, it is the closest 
picture available of what might occur at the catalytic site of the enzyme. Structure 
determination of enzyme complexes is a fundamental step for inhibitor design and 
is a routine element of modern drug discovery. Therefore, as another step towards 
understanding our target enzyme, extensive work toward the co-crystallisation of 
the enzyme, with both FMDV 3C
pro 
inhibitors and substrates, was undertaken. The 
recently elucidated enzyme–substrate co-crystal structure is presented below. 
 The substrate  
In order to attempt the crystallisation of a substrate–enzyme complex, a series 
of different peptide substrates (compounds 6–14, Table 6.3) were synthesised by 
SPPS. All of them were acetylated on their N-termini but differed in length, 
sequence and the nature of the C-termini (having either a carboxylic acid or an 
amide moiety). The substrate recognition site had been shown to span at least P4–
P4′ (Birtley et al., 2005), thus, the different substrates synthesised covered different 
lengths within the P6–P5′, region always containing the P4–P4′ residues. The 
peptidic sequences were designed to investigate the structural features that account 
for FMDV 3C
pro 
selectivity and in particular the P1–P1′ specificity that allows 
FMDV 3C
pro
 to hydrolyse substrates with both the Q–L and E–G pair (section 
1.4.4). The first set of substrates (6–11) contained the Q–L pair and was based on 
the VP1/2A junction sequence (IAPAKQ↓LLNFD). The second set included a 
modified version of compound 9 with E instead of Q at P1, resulting in substrate 
(12), and substrates containing the E–G pair: compounds 13 (LPSKE↓GIFP) and 
14 (PVVKE↓GPYE), spanned P5–P4′ residues from the VP2/VP3 and 3B2/3B3 
junction sequences respectively (section 1.4.4, Figure 1.13).  
 The enzyme  
Mutants suitable for activity assays are not necessarily adequate for crystal 
structure determination and some mutations might be required to specifically assist 
crystallisation. To render the enzyme closer to its native form, a different bacterial 
expression construct was used for the expression and purification of crystal mutant 
proteases. Instead of the 6 ×  His-3B123-3C-6 ×  His translated product (Figure 
2 FMDV 3C 
pro 
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2.10) this construct expressed the protease with an N-terminal polyhistidine tag 
(6 ×  His-3C), which was removed by thrombin cleavage, allowing the expression 
of the original 1–213 residues of the 3Cpro (section 2.2.1). On the other hand, in 
order to avoid hydrolysis during the crystallisation process, as done previously for 
other FMDV 3C
pro
 mutants used for structure determination, the enzyme was 
rendered inactive by changing the active site cysteine into alanine (C163A). 
Finally, given the activity results obtained for the different C142 mutants (section 
2.3.1), the C142 residue was substituted to Leu instead of Ser to generate a protease 
with higher affinity for the substrate and consequently increase the chances to 
create a complex sufficiently stable for crystallisation. This resulted in a new 
inactive mutant (Mutant iL), with C163A, C95K and C142L substitutions, 
generated by P. Zunszain.  
 The enzyme–substrate complex  
Crystallisation experiments were also performed by P. Zunszain. Substrates 
(6–14) were incubated with inactive FMDV 3Cpro at 18 °C and at a peptide–
enzyme ratio of 5:1. From all the combinations tested, only the incubation of the 
Mutant iL with the P5–P5′ substrate (9, Ac-APAKQ↓LLNFD-NH2) resulted in 
viable crystals for structure determination (section 6.1.6). However, since then 
crystals with substrate 12 (Ac-APAKE↓LLNFD-NH2) were obtained in S. Curry 
lab (personal communication) and a future co-crystal structure with a P1-E 
substrate bound to the active site of the protease cannot be ruled out.  
The X-ray structure obtained with Mutant iL and substrate 9 (Figure 2.18), 
refined to 2.5 Å resolution, showed that from the bound P5-P5′ peptide only the P-
side was significantly embedded in the protease. This structure explained the low 
contribution of the P′-side on the enzyme-specificity and confirmed some of the 
assumptions raised when comparing the structure without the bound peptide 
(Figure 2.9, PDB ID 2J92) with structures of other 3C proteases (Sweeney et al., 
2007). Moreover, the importance of the β-ribbon and the 142nd residue in 
hydrolysis, observed in the activity assays of the C142-mutants, became evident 
with this new structure through direct substrate–enzyme interactions, confirming 
their relevance in substrate binding.  
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Figure 2.18 Enzyme–substrate co-crystal structure. 
X-ray crystal structure at 2.5 Å of A1061 FMDV 3C
pro
 Mutant iL (grey) complexed with the P5–P5′ 
VP1/2A substrate 9 (green). A) Front view of the whole structure. Whereas the P′-side is primarily 
solvent exposed, the P-side is well embedded between the β-ribbon and the β-barrels. The eye 
shows the perspective of the magnification of the main substrate–enzyme interactions: B). The term 
Catalytic triad groups the catalytic residues (pink); some of the enzyme residues from the S1′, S1, 
S2 and S4 pockets interacting with the side chains of the substrate residues are highlighted and 
labelled; the substrate residues P4–P1′ are labelled in bold. 
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2.3.3 Discussion 
Whereas an enzyme–substrate co-crystal structure has also been elucidated for 
a 3C-like protease (nuclear inclusion protease from tobacco etch virus, PDB ID 
1LVB; Phan et al., 2002), the Mutant iL–substrate 9 structure (Figure 2.18) 
represents the first picornaviral 3C
pro–peptide co-crystal structure. However, co-
crystal structures of other picornaviral 3C proteases with modified peptides 
covalently attached to their active sites exist for HRV 3C
pro
 (PDB ID 1CQQ; 
Matthews et al., 1999) and HAV 3C
pro
 (PDB ID 2H6M; Yin et al., 2006).  
The structural details revealed in the enzyme–substrate complex of FMDV 
3C
pro
 followed a mode of peptide recognition that was identified in the inhibitor–
enzyme co-crystal structures of HRV and HAV 3C proteases. The observation of 
these structures helped explaining substrate selectivity (section 1.4.4) and 
highlighted the importance of the β-ribbon and the role of the 142 residue 
confirming the conclusions drawn from the activities of the 142-mutants (Curry 
et al., 2007a; Curry et al., 2007b). 
 The binding pockets 
The specificity pockets of this enzyme are generally quite shallow. Even so, 
looking into the core of the structure starting from the catalytic triad we can easily 
identify the P4-to-P1′ residues (PAKQL) of the substrate and their corresponding 
binding pockets (Figure 2.18, B). 
From the residues that contribute to S1, S2 and S4 pocket formation, Table 2.2 
highlights those residues from FMDV 3C
pro
 that interact with the substrate through 
their side chain, by hydrogen bonding, salt bridge or hydrophobic contacts, in 
relation with the equivalent residues in the structures of HRV, PV and HAV 3C 
proteases. A full list of the interactions identified in the Mutant iL–substrate 9 
co-crystal structure and the corresponding distances can be found in appendix 7.4. 
P1′ residue. The S1′ subsite was found to be nonexistent in many picornaviral 
3C proteases, which explains the P1′ specificity resulting in an almost exclusive 
selectivity for Gly in PV and HRV 3C
 
proteases. In contrast, HAV and FMDV 3C
 
proteases tolerate larger residues at this position. FMDV 3C
pro
 cleaves a wide range 
of substrates that include Gly, Ser, Thr, Leu, Ile and Cys at P1′ (section 1.4.4; 
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Knox, 2006) but did not hydrolyse the AMC-substrate 2 (section 2.1.4), which 
contained a much larger group at P1′.  
In the co-crystal structure the S1′ subsite is constituted by L47 and C31, which 
establish hydrophobic contacts with P1′-Leu (Figure 2.18). When comparing the 
structures of the free enzyme and the enzyme complexed with the substrate a 
conformational change of Leu47, which would allow accommodating P1′-Leu, was 
observed. The promiscuity of this enzyme can therefore be explained by the 
formation of an S1′ pocket upon substrate binding. 
P1 residue. From the structure it was determined that the Gln side chain CO 
formed hydrogen bonds with H181 (2.58 Å) and T158 (3.68 Å), while the NH2 
contributes H-bonding with the T158 backbone CO (3.22 Å). The highly conserved 
His residue in the S1 pocket of all 3C proteases (Table 2.2) accounts for P1 
selectivity although it does not explain the enzyme preference for Gln over Glu, 
which is even more pronounced in other picornaviral proteases. Although 
crystallisation trials with peptidic substrates containing Glu at this position (12–14, 
Table 6.3) are ongoing and crystals of Mutant iL in the presence of substrate 12 
have been obtained, no crystal structures have been elucidated so far and this 
conundrum remains unsolved. 
 
 
Table 2.2 Enzymatic residues involved in pocket formation. 
The amino acids of FMDV 3C
pro
 that interact with the P-side of the substrate and the corresponding 
residues in other picornaviral 3C proteases: HRV (PDB ID 1CQQ; Matthews et al., 1999), PV (PDB 
ID 1L1N; Mosimann et al., 1997) and HAV (PDB ID 2H6M; Yin et al., 2005). *Cysteine in the 
wild type protease. 
Enzyme  
Residues involved in pocket formation  
P1   P2   P4  
FMDV 3C
pro
 H181     T158 
 
L142*    D146 
 
V140     L142*    Y190 
HRV2 3C
pro
 H161    T142 
 
L127  N130 
 
I125        L127 F170 
PV 3C
pro
 H161     T142 
 
L127     R130 
 
I125        L127 F170 
HAV 3C
pro
 H191     G167 
 
Y143     H145 
 
I198        Y143 V200 
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P2 residue. The lysine at the P2 position was originally thought to be solvent 
exposed (Sweeney et al., 2007); instead, the positive charge of this residue was 
found to form a salt bridge with residue D146 (2.08 Å) in the co-crystal structure. 
This is a key structural factor, which had not been described before, and may 
account for the strong preference of FMDV 3C
pro
 for P2-Lys. On the other hand, 
the long side chain of the P2 residue falls into a hydrophobic clef, between the 
active site histidine (H46) and the 142 residue (leucine in the present structure), 
that also defines the S2 pocket. For most of the residues that also occur at P2 (Thr, 
Gln, Ala, His, Arg, and Pro) the ability to make apolar contacts is conserved. Even 
if this hydrophobic cleft was also observed among the different 3C
pro
 S2 pockets 
none presents an aspartate at the equivalent position (Table 2.2), which might be 
responsible for the subtle differences in their P2 specificities.  
P3 residue. The alanine at the P3 residue did not define a binding pocket as 
such; however, it seemed to have hydrophobic contacts with M143 and made an 
important contribution to the polypeptide binding site (see below). 
P4 residue. The P4 residue had also been shown to be a key element for 
FMDV 3C
pro
 mediated substrate cleavage (Birtley et al., 2005). In the co-crystal 
structure P4-Pro appeared to be embedded in an apolar pocket between the β-
ribbon and β-barrel, with major contributions of L142, V140 and Y190 (Figure 
2.18), explaining how on the natural substrates other small apolar residues can be 
found at P4. With a similar S4 pocket, HRV and PV 3C proteases display a similar 
P4 preference (Cordingley et al., 1990; Weidner and Dunn, 1991).  
 The polypeptide binding site 
The polypeptide binding site was also be identified in the present structure, 
with main contributions from the hydrogen bonds observed in the backbone 
interactions of M143 with P4-P (NH-O=C, 2.67 Å), G184 with P3-A (C=O-HN 
and NH-O=C, 2.95 and 2.91 Å respectively), S182 with P1-Q (C=O-NH, 3.12 Å) 
and P1-Q-C=O with Gly161 and Cys163 NHs (2.83 and 4.24 Å respectively), with 
the latter constituting the so-called carboxyanion hole. The absence of backbone 
interactions for the P2 residue is responsible for breaking the β-sheet structure 
identified as a common feature in protease-substrate binding (section 1.4.1), but 
most importantly for accommodating the P1 residue in the S1 pocket (Figure 2.18).  
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 The β-ribbon 
Only minor changes on the conformation of the β-ribbon in the free enzyme 
were identified upon substrate binding. Nonetheless, the β-ribbon has a clear role in 
substrate recognition. It contributed mainly through the direct interactions with 
residues P2-to-P4, tucking the substrate in against the β-barrel and directing the 
scissile bond towards the catalytic triad. From the co-crystal structure it could be 
established that residues D146, L142 and V140, which belonged to the β-ribbon, 
constituted part of the S2 and S4 binding pockets (Table 2.2; Figure 2.18).  
 The 142 residue 
The 142 residue was found to be important due to its contribution to two of the 
binding pockets involved in the enzyme–substrate interaction, which in FMDV 
3C
pro
, mainly extends P4–P1′. As can be seen from the structure the 142nd residue 
(Leu here but Cys in the wild type and Ser in the first and second FMDV 3C
pro
 
crystal structures) lies underneath the P3 residue, making hydrophobic contacts on 
either side with P2 and P4 side chains. The same residue could be identified in 
other homologous picronaviral 3C
pro
 structures. In HRV (PDB ID 1CQQ; 
Matthews et al., 1999) and in HAV (PDB ID 2H6M; Yin et al., 2006) the role was 
performed by the residues L127 and Y143 respectively (Table 2.2). The highly 
conserved hydrophobic function at this position in all of the homologous structures 
listed in Table 2.2 suggested that it is the relatively apolar character of C142 in 
wild type FMDV 3C
pro
 that most contributes to the interaction with the P2 and P4 
side chains of the peptide substrate. The comparative analysis of FMDV 3C
pro
 
mutants with substitutions at position 142 strongly supported this hypothesis 
(section 2.3.1; Sweeney et al., 2007).  
Consistent with this, an HPLC-based assay had shown that Ala substitutions on 
the P2 and P4 positions of the substrate abrogated peptide cleavage (Birtley et al., 
2005). Moreover, preliminary investigations performed by S. Knox using the 
fluorometric assay presented in section 2.1.5, showed that replacement of P2-Lys 
with Thr in substrate 1 prevented cleavage, whilst P2-Arg was cleaved at a reduced 
rate and replacement of P4-Pro with residues found at P4 in other natural substrate 
sequences (Val, Leu or Ile) blocked cleavage completely (Knox, 2006).  
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2.4 Summary  
In this chapter, the basis for the design and evaluation of potential FMDV 
3C
pro
 inhibitors has been addressed.  
Firstly, the method used for assessing protease activity was presented. 
Together with the synthesis of the fluorogenic substrate and the assay conditions 
used, a comparative study showed how so far, despite its limitations, the FRET 
substrate (1) was the only viable substrate for fluorometric assessment of FMDV 
3C
pro
, since Mutant A was not able to hydrolyse the alternative AMC-peptide (2) 
synthesised.  
Secondly, the method used for the production of FMDV 3C
pro
 was presented. 
The mutations introduced for increasing the solubility of the recombinant protein 
highlighted the importance of the 142
nd
 position on protease activity. Therefore, a 
series of C142 mutants was assessed using the FRET assay. The data obtained from 
this study provided the first functional test of the importance of residues in the β-
ribbon for protease activity.  
Finally, the recently determined enzyme–substrate co-crystal structure has 
been discussed. The structure obtained not only confirmed the importance of the β-
ribbon for substrate binding but also provided the most complete picture yet of the 
enzyme–substrate interactions in FMDV 3Cpro, and provides an invaluable basis for 
structure-based inhibitor design. 
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3 Strategy toward FMDV 3Cpro Inhibitors 
    
 
 
The present chapter presents the rationale for inhibitor design and the general 
direction taken for the optimisation of the first FMDV 3C
pro
 inhibitor conceived. 
Moreover, it describes the two general synthetic routes developed to access a 
variety of potential inhibitors, the techniques used for their characterisation and the 
methods used for the evaluation of their inhibition properties. This will set the basis 
of the tools used in this thesis. The information obtained on the activity of different 
compounds synthesised and how it directed the inhibitor design is illustrated in the 
following chapter (Chapter 4). 
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3.1 Inhibitor Design 
Currently there are two main approaches to inhibitor design: rapid screening of 
libraries of small molecules and, when structural information is available, structure-
based design. In a typical discovery research program these two approaches come 
together and, to identify a potential drug candidate, X-ray crystallography, high 
throughput screening and in silico screening techniques are used routinely (Ajay, 
2002; Kerns and Di, 2002).  
When the target enzyme is a protease the structure based design of inhibitors 
often starts with the modification of a known substrate by attaching a reactive 
moiety (warhead) in the position of the scissile bond (Powers et al., 2002). The 
resulting irreversible inhibitors are subsequently refined by establishing structure-
activity relationships. The optimisation of this type of inhibitor involves the 
investigation of two very distinctive parts: the peptide chain, which is usually 
responsible for the selectivity towards the target enzyme, and the warhead, which 
will define the reactivity of the inhibitor. Generally, a better inhibitor–enzyme fit 
will result in both higher selectivity and inhibition; however, increases in the 
reactivity of the warhead might compromise selectivity.  
 The peptide chain 
Protease specificity can differ greatly within a family or even a clan of 
proteases. Thus, since fulfilling the selectivity requirements for one protease will 
probably dissatisfy another, the use of modified peptides generally provides 
specific inhibitors. Sometimes the modification of a single residue can redirect the 
selectivity of an inhibitor towards enzymes with different specificities (Thongyoo 
et al., 2008). 
Looking at the selectivity of the cysteine proteases we can see that the primary 
specificities of papain, calpain, and cathepsin B are determined by the shape and 
electrostatic character of the S2 pocket, whereas the primary specificity of the 
caspase-1, as is the case for most serine proteases, is determined by S1 (Figure 3.1). 
However, many proteases, including FMDV 3C
pro
, have extended substrate binding 
sites and enzymes like thrombin (Bode et al., 1989), neutrophil elastase (Navia 
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et al., 1989) and some caspases (Schweizer et al., 2003) require tri- or tetra-
peptides for inhibition.  
When using peptidyl inhibitors against their targets in vivo, not only is the 
specificity towards the target of most importance, but other characteristics that 
would compromise their use as drugs have to be accounted for: peptidyl inhibitors 
are susceptible to amide bond cleavage by other proteases, have low oral 
bioavailability and, generally, have poor pharmacological profiles (Adessi and 
Soto, 2002). However, by masking the peptidic nature of this type of inhibitor, 
peptidyl derivatives can ultimately be used for the development of inhibitors with 
―drug-like‖ properties (Leung et al., 2000). One common strategy is the use of 
unnatural amino acids, such as D-amino acids, β-amino acids and L-amino acids 
with modified side chains, which are increasingly readily available (Fluka, 2006; 
Novabiochem, 2006). This approach is usually accompanied by backbone 
modification for the generation of azapeptides or retropeptides and the alteration or 
removal of the peptide bond (Adessi and Soto, 2002; Steffansen et al., 2005). There 
are some examples of peptides that have undergone such transformations and have 
reached the drug market (see section 1.4.5 concerning HIV protease inhibitors). 
 
 
 
Figure 3.1 Cysteine protease binding sites.  
Inhibitory specificity can be achieved by satisfying the requirements for each enzyme. Papain, 
cathepsin B and calpain all have very different S2 specificities whereas caspase-1 has S1 specificity. 
Serine proteases tend to have S1 specificity, and for the P1 residues similar pockets can be found: 
S2-papain is similar to S1-chymotrypsin (with Ser189) and S2-cathepsin B resembles S1-trypsin 
(with Asp189). 
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 The warhead 
There is a wealth of inhibitor warheads known to be effective against a variety 
of cysteine proteases (Powers et al., 2002). The original strategy was to replace the 
carbonyl group of a good substrate with a moiety that would trap the enzymatic 
nucleophile (Ser-OH or Cys-SH) without altering the structural features required 
for enzyme recognition and binding. Figure 3.2 shows the mode of action of 
different types of warheads against cysteine proteases. 
 
Halomethyl 
ketones 
 
Aldehydes 
Cyano 
derivatives 
Diazomethyl 
ketones 
Epoxides 
Michael 
acceptors 
Aza peptides 
 
Figure 3.2 Warheads used in the inhibition of cysteine proteases. 
Reaction schemes for inhibitors with cysteine proteases (Powers et al., 2002). All different 
warheads form irreversible adducts with the enzyme except for peptidyl aldehydes and cyano 
derivatives.  
Many warheads were originally designed to inhibit serine proteases and were 
found to be also effective against cysteine proteases. This is the case for N-tosyl-L-
phenylalanyl-chloromethyl ketone (TPCK) (Schoellmann and Shaw, 1963) and N-
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tosyl-L-lysine-chloromethyl ketone (TLCK) (Shaw et al., 1965), two halomethyl 
ketones, that are among the first protease inhibitors developed. This type of 
warhead generally lacks selectivity due to its inherent reactivity; however, 
fluoromethyl ketones have been shown to be unreactive against bionucleophiles 
and have been used in vivo (Lawrence et al., 2006). In contrast, other well 
characterised warheads rely on the cysteine thiol being a softer nucleophile than the 
serine hydroxyl to achieve cysteine-protease specificity. This group includes 
aldehydes and nitrile derivatives, which form reversible covalent adducts (Dufour 
et al., 1995) and irreversible inhibitors like diazomethyl ketones (Janowski et al., 
2004), epoxides (Albeck and Kliper, 2000) and Michael acceptors such as 
vinylsulfones and α,β-unsaturated esters (Santos and Moreira, 2007). Moreover, the 
activity of the corresponding warheads can be modulated by a back-bone 
modification to generate an aza-peptide (Sexton et al., 2006).  
 Design of FMDV 3Cpro inhibitors 
So far two studies from our lab have shown inhibition of FMDV 3C
pro
 by both 
cysteine and serine protease inhibitors. In the first study a panel of commercially 
available inhibitors was tested against FMDV 3C
pro
 using the FRET assay 
described in chapter 2 (Jaulent et al., 2007). Whereas the enzyme was inhibited by 
thiol specific inhibitors such as iodoacetic acid and zinc chloride, other typical 
cysteine protease inhibitors such as leupeptin, cystatin and E-64 were inactive 
towards the enzyme. On the other hand, several chymotrypsin inhibitors showed 
activity against FMDV 3C
pro
, amongst which TPCK was found to be the most 
potent. In the second study, two modified versions of the natural protease inhibitor 
MCoTI-II, where Lys-P1 had been substituted by Gln, were shown to inhibit 
FMDV 3C
pro
 with a Ki on the micromolar scale (Thongyoo et al., 2008). MCoTI-II 
is a microprotein with a cyclic cystine-knot structure known to reversibly inhibit 
trypsin. These results provide further evidence of the duality of picornaviral 3C 
proteases, which, despite being cysteine proteases, are more closely related to 
chymotrypsin than to the papain-like proteases. Therefore, to find FMDV 3C
pro
 
specific inhibitors attention was focused towards another picornaviral 3C protease, 
HRV 3C
pro
 (section 1.4.5), which represents a noticeable success of structure-based 
inhibitor design. HRV 3C
pro
 inhibitors were developed from the substrate 
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specificity of the protease by modifying the C-terminus of a good substrate with a 
reactive moiety and were optimised through extensive SAR studies (Figure 3.3). 
Similarly, the first FMDV 3C
pro
 inhibitor was conceived as tetrapeptide 
modified on its C-terminus with a Michael acceptor: Ac-PAKQ-MA compound 15 
(Figure 3.3). The use of a double bond with an electron withdrawing group (EWG), 
such as the trans α,β-unsaturated ester (CH=CHCO2Et) seemed the most 
appropriate starting point for our inhibitor design since from all the warheads tested 
against HRV 3C
pro
 the ethyl-(E)-propenoate showed the best results (Dragovich 
et al., 1998a). The choice of the peptide sequence PAKQ comes from the now well 
understood requirements of FMDV 3C
pro
 specificity. As seen in the previous 
chapter, from the preferred FMDV 3C
pro
 substrate sequence (VP1/2A junction) the 
residues P4-Pro, P2-Lys and P1-Gln not only have been identified as the most 
important for hydrolysis but have shown to have important contribution to the 
substrate–enzyme interactions (Curry et al., 2007a; Curry et al., 2007b).  
 
 
Figure 3.3 Picornaviral 3C protease P4–P1′ substrate sequences and derived irreversible inhibitors. 
A) HRV 3C
pro
 substrate and Rurpintrivir which is the result of years of optimisation based on 
establishing structure-activity relationships. B) P4–P1′ FMDV 3Cpro substrate and the first inhibitor 
design. MA: Michael acceptor. 
Ruprintrivir is the result of years of optimisation work on both the warhead 
and peptide moiety. As a result, the peptidic nature of the molecule has been 
masked by removing one peptide bond and modifying the side chains of the natural 
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amino acids, resulting in a small molecule with two aromatic groups. These 
changes would give the molecule some drug like properties in terms of stability and 
cell permeability. In Figure 3.4 the HRV–Ruprintrivir co-crystal structure is 
superimposed to the FMDV3C
pro–peptide structure, with compound 15 substituting 
the substrate. Whereas the general binding mode is essentially conserved, the P1-
P1′ fragment is slightly tilted; probably due to the tighter binding of the ―real‖ 
inhibitor after the formation the a covalent bond with the active site cysteine. On 
the other hand, far from the scissile bond, two other major differences can be 
observed (Figure 3.4). Firstly, the 3-methyl isooxazole at the P4 position of 
Ruprintrivir, in the HRV 3C
pro
 structure (pink), sits perpendicular to P4-Pro in the 
FMDV 3C
pro
 structure (grey), secondly the β-ribbon is slightly bigger in FMDV 
3C
pro
, which presumably would stop P3-Val from fitting. 
 
 
Figure 3.4 Comparison of HRV and FMDV 3C
pro
 active sites in the presence of peptidic inhibitors.  
Structures of HRV 3C
pro–Ruprintrivir (pink, PDB ID 1CQQ) and FMDV3Cpro–compound 15 (grey), 
where the inhibitor has been modelled into the FMDV 3C
pro–substrate structure (Figure 2.18), 
superimposed using Pymol (DeLano, 2002). As opposed to the chain representation highlighting 
specific residues used before, here only the surfaces of the enzymes are shown to give an idea of the 
spatial differences. Major differences can be found around the P4 and P3 positions (region circled in 
black). 
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However, the main difference between compound 15 and the successful HRV 
3C
pro
 inhibitor is the presence of a positive charge at the P2 position. As a general 
rule only lipid-soluble, uncharged molecules with molecular weight lower than 
500 Da will be candidates for crossing the cell membrane by passive diffusion 
(Lipinski et al., 2001; Adessi and Soto, 2002), therefore, the P2-Lys represents a 
real disadvantage in terms of the viability of this type of compound. The 
importance for a FMDV 3C
pro
 inhibitor to cross the cell membrane is not only a 
pharmacological issue but a requirement to encounter its target enzyme, which is to 
be found in the cytosol of infected cells. Membrane permeability is therefore 
essential both in vitro, for preliminary cell-based assays, and in vivo, where the 
sites of initial virus replication have been identified on the epithelial cells of lung, 
pharyngeal, oral and pedal areas (Grubman and Baxt, 2004).  
To maximise the chances of the compounds getting into the cell, most of the 
efforts for the optimisation of FMDV 3C
pro
 inhibitors have been driven to make the 
molecules smaller and more hydrophobic, with the biggest challenge being finding 
a replacement for P2-Lys.  
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3.2 Synthesis of FMDV 3C
pro
 Inhibitors 
In this section the synthetic routes used to access FMDV 3C
pro
 inhibitors will 
be presented together with the techniques used for the characterisation of the final 
compounds. 
3.2.1 Synthetic routes 
In order to access to the first proposed inhibitor (15) and analogous compounds 
two different synthetic routes were originally conceived to introduce the highest 
degree of variability to the final molecule in both the peptide and warhead parts of 
the inhibitor (Figure 3.5). Michael acceptors, such as the ethyl propenoate ester in 
Ruprintrivir, are warheads that essentially consist of a double bond with an electron 
withdrawing group (EWG). From a synthetic point of view a straightforward 
disconnection for the formation of a double bond is the reaction of an aldehyde 
with phosphoranes (Wittig reagents) or phosphonates (Horner-Wadsworth-
Emmons reagents). Moreover, the use of a reagent with an EWG will define the 
stereochemistry of the final compound, since the presence of an EWG stabilises the 
ylide intermediate formed in this type of reaction and tends to provide E (or trans) 
double bonds (Wadsworth and Emmons, 1961; Maryanoff and Reitz, 1989).  
Looking at the target compound (Figure 3.5) two different routes could provide 
the desired molecules: in route A Wittig reaction is directly performed on the full 
peptidyl aldehyde and in route B the Wittig reaction is used to modify a building 
block onto which the peptide is subsequently built. In both instances the peptidic 
part of the inhibitor can be conveniently obtained by SPPS. SPPS relies on the 
selective deprotection of carboxylic and amino groups for the sequential addition of 
the amino acids onto a solid support. The two major advantages are the use of large 
reagent excess, to drive the reaction to completion, and easy isolation intermediate 
products by simply washing the resin. An overview on SPPS can be found in 
section 6.2.2.  
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Figure 3.5 Retro-synthesis of peptidyl Michael acceptors. 
Both routes A and B use SPPS and an aldehyde intermediate which will undergo a Wittig reaction. 
Note that in route B P1 corresponds to Gln with R1 = (CH2)2CONH2. WR(AM): Weinreb amide AM 
resin, RA(AM): Rink amide AM resin, EWG: electron withdrawing group.  
 Route A 
Route A was designed to allow variation of both the peptide chain and the 
warhead, by obtaining a peptidyl aldehyde, which was reacted with an appropriate 
HWE or Wittig reagent. One of the ways to obtain C-terminal peptidyl aldehydes is 
the reductive cleavage from a Weinreb amide AM resin (WR(AM)) (Fehrentz et 
al., 1997). The peptide chain was built on the solid support by SPPS and the 
corresponding peptidyl-aldehyde was directly obtained upon reductive cleavage 
from the resin. Under the cleavage conditions any acid labile protecting groups 
present in the sequence remained in place. Following the reaction of the peptidyl-
aldehyde with a HWE reagent, the final Michael acceptor derivative was obtained 
after side chain deprotection (Figure 3.6). See section 6.2.4, page 186, for further 
details. With the appropriate HWE or Wittig reagents many different EWG could 
potentially be introduced. However, in the presence of protecting groups in the 
peptidyl-aldehyde the EWG should be able to resist the conditions of the final 
deprotection step.  
Fehrentz et al. showed that purification of peptidyl-aldehydes by silica gel or 
reverse phase chromatography induced loss of the optical integrity of the C-α 
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attached to the aldehyde (Fehrentz et al., 1997), this together with the fact that 
according to the analytical RP-HPLC traces obtained from the crude reaction 
mixtures the intermediates were fairly pure (Figure 3.7), only one purification step 
was performed at the end of the synthesis. After a total of 13 steps peptides 
synthesised through this method, were only obtained with an overall yield of 3–6% 
after purification. Since completion of the HWE and deprotection reactions was 
judged quantitative as observed by HPLC, the low yields obtained through this 
synthesis were mainly attributed to the first coupling and the reductive cleavage.  
 
 
 
Figure 3.6 Synthesis of H-PAKQ-MA (21) through route A. 
The product was obtained (21) after 13 steps (see section 6.2.4 for details). Note the use of SPPS to 
obtain the peptidyl intermediate and a Wittig reaction for the synthesis of the double bond.  
The first coupling. The first coupling onto the resin proved difficult, mainly 
due to the reaction of a carboxylic acid with secondary amine. Even after repeating 
the coupling, using the conditions described in the Novabiochem catalogue 
(Novabiochem, 2006), loading quantification by Fmoc test (section 6.2.2, page 
178) showed a yield of 50%. Therefore, prior to normal SPPS to build the 
remaining sequence, the potential remaining free amino functionalities were capped 
with acetic anhydride to reduce secondary products. 
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Figure 3.7 HPLC traces of the crude peptidyl derivatives from the three main steps in route A. 
A) Peptidiyl aldehyde 19 from the reductive cleavage (green), B) fully protected peptidyl-MA 20 
from the HWE reaction (red) and C) fully deprotected peptidyl-MA 21 from the deprotection step 
(blue). Gradient 0–100% MeCN in H2O over 35 min 
The reductive cleavage. The reduction step to access the peptidyl-aldehyde 
from the resin required some optimisation (Table 3.1). Diisobutylaluminium 
hydride (DIBALH) was the first reagent assessed since is commonly used for 
obtaining aldehydes from Weinreb amides and had been previously used on solid 
support (O'Donnell et al., 2000); however, no product was recovered. In contrast, 
the use of lithium alumininum hydride (LiAlH4), which had been reported to 
provide peptidyl aldehydes from peptidyl-Weinreb amides on a solid support 
without epimerisation (Fehrentz et al., 1997; Ganneau et al., 2006), provided the 
desired product. In our hands lower temperatures resulted in better yields and the 
peptidyl aldehyde was recovered by reacting the resin with a solution of LiAlH4 in 
THF at –30 °C for 30 minutes and allowing the suspension to reach 0 °C to be 
quenched with water (section 6.2.4). Even with the optimised conditions yields 
were generally low, this was attributed to the use of LiAlH4, which made peptide 
isolation difficult due to the formation of aluminium hydroxide upon addition of 
water during the reaction quenching. The peptidyl-aldehydes were used without 
further purification 
 
0 5 10 15 20 25 30 35
deprotected peptidyl-MA
protected peptidyl-MA
peptidyl aldehyde
Deprotection reaction 
HWE reaction 
Reductive cleavage 
                                                                          
20 
19 
21 
A 
B 
C 
 112 
 
 
Table 3.1 Trial conditions for the reductive cleavage on Boc-PAK(Boc)Q(Trt)-WR(AM) resin (18). 
*
The yield was calculated from the weight of the crude product recovered after cleavage. 
 Route B 
Route B (Figure 3.8) was conceived as an alternative route to access Michael 
acceptor analogues for the more efficient introduction of variation on the peptide 
moiety of the inhibitors. In this case an Fmoc/tBu protected glutamic acid (22) was 
first modified on its C-terminus to provide the corresponding Michael acceptor. 
This transformation had already been described for the α,β-unsaturated ester (23) 
and the reaction conditions were adapted from the literature procedure (Dragovich 
et al., 1998b). The carboxylic acid was coupled to benzyl mercaptan to form a 
thioester (24) that was reduced with palladium over carbon and a source of 
hydrogen (such as triethylsilane) to afford the corresponding aldehyde intermediate 
(25), which was used without further purification. With an appropriate Wittig 
reagent the aldehyde provided the α,β-unsaturated ester (26).  
Once the building block had been obtained, side chain deprotection allowed 
attachment of the modified glutamic acid (23) to the solid support in order to build 
the rest of the peptide on its N-terminus. Under normal cleavage conditions the use 
of the use of rink amide resin (27) provided the fully deprotected peptidyl Michael-
acceptor (15) with a glutamine on the P1 position instead of the original glutamate.  
Even though this synthetic route is slightly longer than route A the overall 
yield is superior (on average 44% after 15 steps). However, it also has some 
limitations; the P1 position is restricted to residues that would allow attachment to 
the resin through their side chain and the introduction of a different warhead 
requires the synthesis of a new building block. Moreover, in this case any EWG 
Reductive cleavage conditions 
Reducing agent Time Temperature Yield* Reference 
DIBALH 2 h r.t. No product (O'Donnell et al., 2000) 
LiAlH4 30 min 0 °C No product (Fehrentz et al., 1997) 
LiAlH4 30 min –20 to 0 °C 30% (Tong and Hong, 2000) 
LiAlH4 30 min –30 °C 54%  
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introduced with the Wittig reagent of choice should also be resistant to acidic 
cleavage conditions. Nonetheless, this route was very useful to study the peptidic 
part of the inhibitor since different amino acids can be easily introduced after P1 
(chapter 4).  
 
  
 
 
Figure 3.8 Synthesis of Ac-PAKQ-MA (15) through route B. 
The product (15) was obtained after 15 steps (see section 6.2.4 for details). The building block 23 
needs to be synthesised prior to SPPS. Following Fmoc deprotection of the Rink amide AM resin 27 
the modified amino acid 23 is loaded onto the resin through the carboxylic moiety on its side chain. 
The final product 15 contains a Gln instead of a Glu on the P1 position.  
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3.2.2 Characterisation 
SPPS is a very well established synthesis method and the characterisation of 
linear peptidic products by MS and HPLC is generally sufficient. However, the 
peptidyl derivatives prepared during this research were small and their C-termini 
were modified. Therefore, since groups such as the ethyl-E-propenoate are very 
distinctive on NMR, NMR spectroscopy data has been incorporated for the full 
characterisation of the final compounds.  
 High performance liquid chromatography 
The retention time is characteristic for a compound in a given HPLC system 
(solvent system, flow, gradient and column). But most importantly, a HPLC trace 
gives an indication of the purity of a compound, which is a fundamental parameter 
to take into account in the activity assays of the inhibitors synthesised. When 
working with peptidic compounds the most common HPLC system uses a reverse 
phase column (C18), a gradient of an increasing percentage of acetonitrile in water 
and UV detection. Absorption is generally recorded at 220 nm, which corresponds 
to the maximum of absorbance for the peptide bond (Aguilar, 2004).  
Integration and comparison of the peak areas obtained in the analytical trace at 
220 nm allows quantification of the purity of the peptide expressed as a percentage. 
Without taking into account the equilibration and injection peaks that are generally 
observed in a normal HPLC trace (Figure 3.9), when a single peak was recorded on 
the analytical trace or the area of the peak was greater than 98% of the total, the 
purity for the corresponding compound was defined as > 98%.  
 Mass spectrometry 
The most common MS techniques used for the ionisation of peptides are 
matrix assisted laser desorption ionisation (MALDI) and electrospray ionisation 
(ESI). Normally, MALDI was used for the characterisation of intermediates and 
compounds with MW ≥ 1000 Da and high resolution ESI for final products. 
Accurate ESI MS provided an m/z value down to the 4
th
 decimal place, which for 
all the compounds synthesised correlated with the calculated mass for theoretical 
molecular formula of the charged compound [M + H]
+
 within a difference 
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generally well below 5 ppm (± 0.0027 Da) which allowed the confirmation of the 
elemental composition of the ion detected (Biemann, 1990).  
 
 
Figure 3.9 RP-HPLC trace of compound 15 after purification. 
Compound 15 displayed a retention time of 8.3 min and a purity > 98%. Absorbance was monitored 
at 220 nm and a gradient of 0–100% MeCN in H2O over 16 minutes at 1 mL/min was used in a 
reverse phase C18 column. 
 Nuclear magnetic resonance spectroscopy (NMR) 
In contrast with MS, NMR spectroscopy provides structural information of a 
compound and is also a good indicator of the purity of a sample. After the fourier 
transform of the corresponding free induction decay (FID) signal the chemical 
shift, multiplicity, coupling constant and integration of a signal in the 
1
H-NMR 
spectra will very accurately define a proton in its environment. For molecules like 
compound 15 where many protons have a similar environment and fall in the same 
region of the spectra full characterisation can be achieved by using two-
dimensional spectroscopy involving proton-proton correlation (such as COSY) or 
proton-carbon correlation (such as HMBC).  
The coupling constant observed for the olefinic protons of the compounds 
synthesised corresponded in every instance to a trans coupling constant (15.5–
15.7 Hz) as reported for other ethyl-peptidyl-(E)-propenoates (Dragovich et al., 
1998a; Dragovich et al., 1998b), which confirmed the E-stereochemistry of the 
final compounds synthesised with both Wittig and HWE stabilised reagents. Figure 
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3.10 corresponds to an amplification of the 
1
H-NMR spectrum of the double bond 
of the α,β-unsaturated ester. 
 
 
Figure 3.10 Characterisation of α,β-unsaturated esters by proton NMR. 
Amplification of the olefine region of the 
1
H-NMR of compound 15. 
1
H-NMR spectra obtained at 
400 MHz showing the signals corresponding to the double bond protons in compound 15 and the 
coupling constants observed: Jtrans = 15.7 Hz, J1,2 = 5.6 Hz and J1,3 = 1.6 Hz.  
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3.3 Inhibition Assays 
In the core of a cysteine protease, inhibitors containing a Michael acceptor can 
undergo nucleophilic attack from the active-site thiol with the subsequent 
formation of a covalent bond that modifies the active site cysteine (Figure 3.11). 
Thus, Michael acceptor inhibitors follow irreversible inhibition (Powers et al., 
2002). The inactivation of a protease with an active-site irreversible inhibitor 
proceeds via the rapid formation of a non-covalent enzyme–inhibitor complex (E·I) 
to produce an enzyme–inhibitor adduct (E–I) in a slower chemical step. The 
inhibition rate can then be described with Michaelis-Menten kinetics (section 2.1.1) 
where Ki (= k1/k–1) is the dissociation constant for the intermediate complex and k2 
is the first-order rate constant for the formation of the covalent bond E–I (Figure 
3.11).  
 
 
 
 
Figure 3.11 Inactivation of an enzyme with an irreversible inhibitor. 
A) The mechanism of inhibition of cysteine proteases by α,β-unsaturated ester derivatives 
(EWG=COOEt). B) The general representation of irreversible inhibition with the kinetic constants 
for the formation of the reversible and irreversible complexes.  
3.3.1 Active site modification 
To confirm the irreversible nature of the inhibition and the modification of the 
active site two assays were performed using compound 15 and Mutant A. 
 Evidence of the irreversible complex 
The purified recombinant FMDV 3C
pro
 (MWseq 23.032 kDa) was incubated for 
1 h at 37 °C in pH 7.4 assay buffer (section 6.3.1) both with (E + I) and without (E) 
an excess of compound 15 (0.538 kDa). After incubation a buffer exchange was 
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performed on the reaction mixture using a concentrator (Vivaspin 500) with a 
5 kDa cut-off, in order to remove all the excess of inhibitor but also wash away any 
potentially reversibly bound inhibitor (see section 6.3.4 for details). Under these 
conditions only free and irreversibly modified FMDV 3C
pro
 should be detected by 
MS. The resulting solutions were analysed by ES-TOF MS by M. Sutton-Smith 
from the Biopolymer Mass Spectrometry Group at Imperial College London.  
The most abundant m/z peaks obtained from the free enzyme mixture 
corresponded to 23106, 23182 and 23258. The difference between these m/z values 
is exactly of 76, which is an indication of the presence of β-mercaptoethanol 
adducts (Sundqvist et al., 2007), which in this case could come from the presence 
of this reducing agent in the buffer used in the purification of the recombinant 
protein (section 6.1.5). On the other hand, the most abundant m/z peak for the 
enzyme–inhibitor mixture corresponded to 23640. The mass difference between 
peak 23106 and 23640 is 534 which, within the error of the MS determination, 
would correspond to the increase of 538 Da from the addition of one molecule of 
inhibitor. However, when comparing these peaks with the calculated MW 
23106 Da would correspond to [ME + 74]
+
 and 23640 Da to [ME+I + 71]
+
. This mass 
increase could also be attributed to the formation of the corresponding 
β-mercaptoethanol adducts mentioned above; however, the presence of an 
unaccounted mutation cannot be ruled out since the sequencing of Mutant A had 
shown some unknown residues towards its C-terminus (Figure 2.13). Nonetheless, 
this result confirms the formation of the enzyme–inhibitor covalent complex and 
suggests that compound 15 binds to the active site of the protease, since other five 
cysteines exist in Mutant A and the mass increase only accounts for the addition of 
a single molecule. 
 Reactivity toward free thiols 
The reactivity of the Michael acceptor 15 against free thiols was tested by 
comparing the activity of FMDV 3C
pro
 (0.6 μM) upon addition of fluorogenic 
substrate (1) after incubation with different concentrations of compound 15 (10–
0 μM) in the presence or absence of an excess of DTT (5 mM). Loss of inhibition 
by compound 15 was up to 24% when comparing the IC50 values obtained after 
30 minutes of incubation (see below). When the inhibitor was submitted to a short 
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exposure (two–three minutes) to the same excess of DTT the loss of activity was 
only around 1%, suggesting that the inhibitor only significantly reacts with a large 
excess of free thiols (500 ×) after long time exposure. This result disagrees with 
previous findings, which indicated that various peptidyl α,β-unsaturated esters were 
unreactive towards DTT under similar conditions (Dragovich et al., 1998a). Even 
though, as indicated on the previous section, compound 15 seemed to react with the 
catalytic cysteine of FMDV 3C
pro
 non-specific reactivity cannot be ruled out 
in vivo, where the intracellular concentration of free thiols in mammalian cells can 
go up to 12 mM (Sönmez et al., 2003).  
3.3.2 Evaluation of FMDV 3Cpro inhibition 
In order to evaluate the activity of the potential inhibitors, the initial enzyme 
activity (v0), which corresponds to the activity of the free enzyme (without 
inhibitor), is compared to residual enzyme activity (vt), after incubation with the 
inhibitor, by defining the relative rate (vt/v0). In our system enzyme activity was 
monitored using the FRET assay described in section 2.1 (Figure 3.12). If the 
enzyme and substrate concentrations are kept constant by varying the incubation 
time and the inhibitor concentration different kinetic data can be obtained.  
 
 
Figure 3.12 Method for detection of residual enzyme activity using the FRET substrate (1).  
After incubation of the enzyme (E) with an inhibitor (I) for a certain period of time an excess of 
substrate (S) is added to the mixture, and upon hydrolysis separation of the C-terminal and N-
terminal products (P-Ct and P-Nt) results in a recordable increase in fluorescence (sections 2.1.2 and 
2.1.5, Figure 2.3). Incubation and substrate hydrolysis are performed under physiological conditions 
(37 °C and pH = 7.4).  
For all inhibitors in this thesis two different assays were performed as 
described in the following sections. Firstly, a wide range of inhibitor concentrations 
was analysed in order to detect any inhibition and determine the IC50 for the active 
compounds. Secondly, time course experiments were performed to further 
E E  I II E
E  S E
S
P-Ct Nt-P
Incubation  
Substrate 
hydrolysis 
Fluorescence 
 120 
 
characterise those inhibitors that showed some degree of activity. All assays were 
performed with FMDV A1061 3C
pro
 Mutant A at 37 °C under the conditions of the 
FRET assay using pH 7.4 phosphate buffer (section 6.3.5). The final enzyme and 
substrate concentrations used were of 0.6 and 50 µM respectively.  
 The IC50  
The determination of the concentration of inhibitor required to decrease the 
activity of the enzyme by 50% (IC50) is the standard method to initially evaluate the 
activity of a given inhibitor. Since the lower the IC50 the more potent the inhibitor, 
IC50 values can give a crude comparison between different inhibitors and was 
always obtained prior the determination of the inhibition constants. However, the 
incubation time is an important factor when assessing irreversible inhibitors, for 
which a longer incubation time is reflected in a lower IC50 value. Therefore, an IC50 
alone does not allow conclusions to be drawn as to the reversibility of the inhibition 
mechanism.  
For IC50 determination, different inhibitor concentrations were incubated with 
the enzyme for 30 minutes at 37 °C, after which time the residual enzyme activity 
was measured upon addition of the FRET substrate (1) (Figure 3.12). In order to 
obtain IC50 curves the relative rate is plotted against inhibitor concentration using a 
logarithmic scale. Figure 3.13 shows a representative example of an IC50 curve 
obtained where the inhibitor concentration used has been adjusted from a previous 
assessment of a wide range of inhibitor concentrations (starting with [I] ≥ 103[E]).  
Compound 15 was used as an internal control for the inhibition assays; in 
every new set of experiments the IC50 of compound 15 was determined and the 
variation of the values obtained was never bigger than the standard error from the 
determination. The value quoted for the IC50 of compound 15 corresponds to the 
main for five independent experiments (0.68 ± 0.06 μM). This indicated that 
Mutant A (unlike Mutant C) was very robust under the purification, storage and 
assay conditions. 
 
 
 
3 Strategy toward FMDV 3C 
pro
 Inhibitors 
121 
 
 
 
 
Figure 3.13 Representative IC50 curve (compound 15).  
Readings were obtained after 30 minutes of incubation with the enzyme upon the addition of the 
FRET substrate (1) at the final concentrations of 0.6 µM and 50 µM respectively. The error bars 
show the standard deviation from the main value from triplicates. The IC50 of this compound is 0.68 
± 0.08 µM as determined with GraFit computer package (Leatherbarrow, 2003).  
 The incubation method  
The incubation method was first developed by  Kitz and Wilson (1962) and in 
contrast with the IC50 experiments was designed to monitor the activity of the 
inhibitor with time. The enzyme was mixed with an excess of inhibitor and allowed 
to incubate (at 37 °C). At various time intervals (t) the residual enzyme activity (vt) 
was measured by adding an assay solution containing a large excess of the cognate 
substrate (in our case FRET substrate 1) into the inhibition mixture (Figure 3.12). 
Two parameters were varied in these experiments: the incubation time and the 
inhibitor concentration. The longest incubation time used was thirty minutes and 
readings were taken at intervals of five minutes (starting at time zero). Readings 
were also obtained for the free enzyme kept under the same conditions. For the 
inhibitors assayed, longer incubation times resulted in smaller residual enzyme 
activities (small vt), which confirmed the irreversible nature of the inhibition. The 
curves defined by plotting the relative rate (vt/v0) obtained at different incubation 
times followed a single exponential decay. The range of inhibitor concentrations 
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assessed was limited to values that would allow exponential curves to be well 
defined within the time of the experiments. Figure 3.14 is a representative example 
of the type of curves obtained.  
Irreversible inhibition follows second order kinetics and the variation of both 
enzyme and inhibitor concentration with time is defined by Equation 3.1, which 
can be expressed in terms of the relative rate (Equation 3.2). When the inhibitor 
concentration is at least ten fold in excess of the enzyme concentration the system 
follows pseudo-first order kinetics. Under these circumstances it can be assumed 
that [I] >> [E]0 and Equation 3.2 can be transformed into Equation 3.3, where kobs 
corresponds to k2nd[I]0 and can be directly obtained for a given inhibitor 
concentration from the exponential decay plots of the relative rate (vt/v0) with time.  
 
 
Under pseudo first order conditions kobs is also the pseudo-first-order rate 
constant for inactivation and relates to the kinetic constants according to Equation 
3.4 (Kitz and Wilson, 1962). If Ki > [I] it can be established that kobs/[I] = k2/Ki, 
which is equivalent to kcat/KM in substrate hydrolysis characterisation (section 
2.1.1). Since the initial inhibitor concentration is known, k2/Ki corresponds to the 
slope of the straight line defined by the plot of kobs vs [I].  
All inhibition curves were determined for at least 5 different concentration 
values and in triplicate. The main values were fitted to the single exponential decay 
equation (Equation 3.3) with GraFit (Leatherbarrow, 2003) in order to obtain the 
value of kobs for every inhibitor concentration. Subsequent kobs/[I] values (M
–1
 s
–1
) 
ln 
 𝐸 0( 𝐼 0 − 𝑥)
 𝐼 0( 𝐸 0 − 𝑥)
 = 𝑘2𝑛𝑑 𝑡 ( 𝐼 0 −  𝐸 0) Equation 3.1 
ln 
 𝐼 0 −  𝐸 0 +  𝐸 0  × 𝑣𝑡 𝑣0 
 𝐼 0 × 𝑣𝑡 𝑣0 
 = 𝑘2𝑛𝑑 𝑡 ( 𝐼 0 −  𝐸 0) Equation 3.2 
ln  
𝑣𝑡  
𝑣0
 = −𝑘2𝑛𝑑 𝑡  𝐼 0 = −𝑘𝑜𝑏𝑠 𝑡 𝑘𝑜𝑏𝑠 =  
𝑘2[𝐼] 
( 𝐼 + 𝐾𝑖)
 
Equation 3.3 Equation 3.4 
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were determined by linear fit (also in GraFit). The error associated to these values 
corresponds to the standard deviation of the linear fit with respects to the standard 
error values from kobs.  
For the best inhibitors pseudo-first-order conditions could not be widely 
applied since high inhibitor concentrations resulted in inhibition that was too fast to 
allow a proper definition of the inhibition curves under the assay conditions. The 
progress curve method developed by Tian and Tsou (1982), which monitors the 
substrate hydrolysis upon adding enzyme to a mixture of substrate and inhibitor, 
had been considered for these inhibitors. However, the requirement to know the KM 
value of the substrate in the definition of the inhibition constant observed meant 
that this method could not be used for the FRET substrate (1) (section 2.1.5). 
Therefore, for inhibitors such as compound 15, the kobs/[I] value was determined 
from a single concentration value ([I]  ≥ 10[E]0) from triplicates.  
 
 
 
Figure 3.14 Representative time course curves obtained by the incubation method (compound 15).  
Readings were taken every five minutes of incubation with the enzyme upon the addition of the 
FRET substrate (1) at final concentrations of 0.6 µM and 50 µM respectively. With the rest of the 
values falling under 10[E]0, only curve 6.25 fills the pseudo-first order criteria with a kobs/[I] = 
376 M
–1
 s
–1
.  
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3.4 Summary 
In this chapter the synthesis and characterisation of peptidyl Michael acceptors 
has been presented. The two different synthetic routes developed were successful to 
provide the target compounds assessed in chapter 4 but in general terms variations 
on the peptide were more easily introduced through route B and route A would be 
more suitable for the introduction of different EWG in the warhead of the 
molecule. On the other hand, the characterisation of the final compounds was 
achieved with the use of normal peptide characterisation techniques such as HPLC 
and MS but the structure of the final molecules was also confirmed by NMR.  
The formation of a covalent complex between FMDV 3C
pro
 and compound 15 
has been demonstrated by MS confirming the irreversible nature of the inhibition 
by α,β-unsaturated esters and, even if the reactivity of the warhead against free 
thiols could not be ruled out, the modification of the active site. In addition, the 
FRET substrate presented in chapter 2 has shown to be suitable for inhibition 
assays used for the assessment of the potential inhibitors. Whereas the IC50 was 
used as a first indication of the inhibition activity of the compounds synthesised, 
with lower values indicating higher inhibition, the incubation method was used for 
the determination of second-order constants (k2/Ki expressed as kobs/[I]), with 
higher values reflecting more potent inhibitors. However, as it will be seen in the 
following chapter, the trends showed by the IC50 values were generally maintained 
by the kobs/[I] values.  
This chapter has illustrated the synthesis and characterisation of the first 
substrate-based FMDV 3C
pro
 inhibitor (compound 15). Even if compound 15 
showed an IC50 in the low micromolar range (0.7 μM), very close to the enzyme 
concentration used in the assay conditions (0.6 μM), its inhibition constant 
(376 M
-1
 s
-1
) falls in the slow range for this type of inhibitors. For example, from 
all the inhibitors containing an α,β-unsaturated ester tested against HRV 3Cpro 
(Dragovich et al., 1998b) constants as high as 280,000 M
–1
 s
–1
 can be found. 
Nonetheless, the reactivity of this warhead against FMDV 3C
pro
 has allowed 
exploring the peptidic moiety of the inhibitor and the methods developed in this 
chapter were used to prepare and characterise a range of different FMDV 3C
pro
 
inhibitors (chapter 4). 
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4 Peptide Chain Structure Activity 
Relationships     
 
 
In this chapter, investigations into the peptidic moiety of the inhibitor are 
presented. With the ultimate aim being to produce an inhibitor that would reach its 
target in the cytosol of the cell, the peptide design was focused on enhancing the 
hydrophobicity of the initial FMDV 3C
pro
 inhibitor (compound 15). Taking 
compound 15 as a reference and maintaining the α,β-unsaturated ester (ethyl-(E)-
propenoate) as the warhead, modifications were introduced in the peptide. The 
minimal peptide length required for inhibition, the introduction of aromatic groups 
in the molecule and the substitution and masking of the positive charge at the P2 
position were studied.  
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4.1 The Peptide Size 
This section is concerned with the study of the effect of the P3, P4 and P5 
positions on antiprotease activity. In order to assist the discussion, Figure 4.1 
illustrates some of the important enzyme–substrate interactions likely to be affected 
by truncation or other modification of the peptide.  
 
 
 
   
Figure 4.1 Amplification of the S4 and S3 subsites in the enzyme–substrate co-crystal structure. 
The P3 and P4 interactions identified between Mutant iL and substrate 9 are represented by dotted 
lines and are red for the hydrogen bonds, blue for the hydrophobic contacts and green for the 
potential interaction with neighbouring Asn186 (5 Å). *Ala in Mutant A and Cys in the wild type 
and Mutant C. Structure rendered with Pymol (DeLano, 2002). 
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4.1.1 Size scan 
Firstly, the minimal peptide length required for inhibition was evaluated. As it 
is well-established that FMDV 3C
pro
 displays an extended substrate specificity 
(section 1.4.4), it was expected that a single amino acid would not be sufficient to 
inhibit the protease, thus all compounds contained at least the P1 (Gln) and P2 
(Lys) residues. To look at providing an extended peptide recognition motif, the first 
set of inhibitors synthesised spanned to the P5 position. Moreover, all compounds 
were acetylated on their N-terminus to have a better mimicry of the peptide bond 
than a free amine. Together with compound 15, which incorporates the P1–P4 
tetrapeptide, the pentapeptide 29, the tripeptide 30 and the dipeptide 31 in Table 4.1 
were obtained through synthetic route A (section 3.2). 
 
 
Table 4.1 Structure, molecular weight and antiprotease activity of compounds 29, 30, 31 and 15. 
These compounds were assessed for inhibitory activity against FMDV 3C
pro
 Mutant A (0.6 µM) 
using FRET substrate 1 (50 µM) for a total incubation time of 30 minutes (IC50) with samples taken 
at intervals of 5 minutes (kobs/[I]). *Obtained from triplicates for a single inhibitor concentration 
value.
 †
Obtained from triplicates for three different inhibitor concentration values. 
 
R
N
H
H
N
O
NH2O
O
O
NH2
Compound R 
MW      
(Da) 
IC50 
(µM) 
kobs/[I] 
(M
–1
 s
–1
)
 
29 Ac-Ala-Pro-Ala- 609 0.64 ± 0.08 280 ± 15
†
 
15 Ac-Pro-Ala- 539 0.68 ± 0.06 376* 
30 Ac-Ala- 441 16.7 ± 0.8 ND 
31 Ac- 370 > 600 ND 
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From the four compounds assessed, tetrapeptide 15 showed the highest 
inhibitory activity, indicating that at least four residues were required to maintain a 
good level of inhibition. Maintaining all P1–P4 residues, compound 15 should 
interact with all the binding pockets (S1–S4) indentified in the substrate–enzyme 
crystal structure described in section 2.3 (Figure 4.1). However, these interactions 
would be increasingly lost with the shortening of the peptide.  
It was found that shorter versions of the inhibitor resulted in a significant loss 
of inhibitory activity. The absence of proline had a dramatic effect on the IC50 
value for the N-acetylated tripeptide 30 (16.7 μM), resulting in a compound about 
24-fold less potent than the tetrapeptide (15) and for which the time course 
experiment was not performed as the activity was considered to be too low. This 
loss of activity could only be attributed to the loss of hydrophobic interactions with 
S4, which includes residues from the β-ribbon (V140 and L142) and the β-barrel 
(Y190). The absence of a P4 residue is likely to influence the positioning of the P2 
and P1 residues and consequently the orientation of the active site thiol to the 
Michael acceptor.  
Perhaps more significant was the drop in activity observed for compound 31. 
The dipeptide showed only a slight degree of inhibition, with a 70% reduction in 
protease activity at the highest concentration evaluated (1.2 mM). Although the 
IC50 value could not be determined accurately, it was estimated to be between 600 
and 700 µM, which represents a loss in antiprotease activity of about 850-fold 
compared to the tetrapeptide 15 and 35-fold to the tripeptide 30. This result 
highlights the importance of the contributions of the P3 residue to the polypeptide 
binding site. In the dipeptide 31, even if the N-terminal acetyl group was likely to 
maintain the hydrogen bond between Gly184-NH and P3-CO, in the absence of P3 
the P3-NH and P4-CO backbone interactions with Gly184-CO and Met143-NH 
would be lost (Figure 4.1). Since no S3 pocket was identified for P3-alanine the 
side chain of P3 was believed to have poor contribution to substrate binding 
(Birtley et al., 2005). However, this result could also indicate that the role of the 
side chain of this residue is more significant than initially envisaged and the 
contribution of the hydrophobic interaction with Met143, indentified in the co-
crystal structure (Figure 4.1 and Figure 3.4), should not be dismissed.  
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The extended version of the inhibitor (compound 29) with an alanine in the P5 
position gave the same IC50 as the tetrapeptide 15 along with a slightly lower 
kobs/[I] value. According to the structural information, the N-terminal acetyl of 
substrate 9 is disordered, which is the reason for not being depicted in Figure 4.1. A 
disfabourable interaction of this group with the neighbouring asparagine (N186) 
could explain the slightly decreased inhibitory activity of compound 29. However, 
a 26% loss in inhibition indicated that the P5 residue, which is solvent exposed in 
the co-crystal structure (Figure 4.1), had a relatively little contribution in affecting 
antiprotease activity.  
4.1.2 The N-terminus of the peptide 
As seen in the previous section, the presence of the P4 position was crucial to 
retain a reasonable inhibitory activity for this type of compound. Conversely, the 
addition of an extra amino acid at P5 was found to have only little effect on 
antiprotease activity. This is consistent with the observation that residues with very 
different structures (Ala, Pro, Arg and Leu) are found among the naturally 
occurring cleavage sequences of FMDV 3C
pro
 at P5, suggesting that the N-terminus 
of the tetrapeptide could accept other groups; it is also possible that judicious 
substitution here could potentially increase the inhibitory activity of the final 
compound. To further analyse this result, five more compounds spanning P1–P4 
and differing at their N-termini were synthesised and assessed against FMDV 3C
pro
 
(Table 4.2). Compound 21 was obtained through synthetic route A, but compounds 
32–35 were synthesised via route B, which allowed easy derivatisation of the N-
terminus of the molecule. Compounds 32, 33 and 34 were generated by capping the 
tetrapeptide with tosyl, benzyl and benzoyl respectively and 35 by capping the 
tripeptide with benzoyl. 
P5-Tos, Bn and Bz 
Prior to the co-crystal structure determination little was known about the S5 
subsite in FMDV 3C
pro 
and, in terms of inhibitor design, two factors led to the 
choice of the groups introduced to the N-terminus of the tetrapeptide. Firstly, since 
the addition would increase the molecular weight of the final molecule, aromatic 
groups were introduced to improve membrane permeability. Secondly, to 
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investigate the effect of any potential backbone interactions the number of 
hydrogen bond acceptors was varied. The set of compounds synthesised contained 
a phenyl group attached to the N-terminus in three different ways (Figure 4.2): with 
the p-toluenesulphonyl group (Tos, 32), the chances of hydrogen bonding were 
increased by addition of an extra oxygen; with the benzyl group (Bn, 33) any 
hydrogen bonding acceptor was eliminated and with the benzoyl group (Bz, 34) the 
original carbonyl was maintained at the N-terminus. 
 
 
Table 4.2 Structure, molecular weight and antiprotease activities of compounds 15, 21 and 32–35. 
These compounds were assessed for inhibitory activity against Mutant A (0.6 µM) using FRET 
substrate 1 (50 µM) for a total incubation time of 30 minutes (IC50) with samples taken at intervals 
of 5 minutes (kobs/[I]). *Obtained from triplicates for a single inhibitor concentration value.
 
 
Compounds 32 and 33 presented identical antiprotease activities, with kobs/[I] 
values about 3-fold lower than 15. In contrast, the structurally related compound 
34, exhibited an inhibitory activity 13% greater than 15. In the co-crystal structure 
no backbone interactions were identified for the N-CO bond at this position (Figure 
4.1) and the P5 position appeared to be mostly solvent exposed. Therefore, given 
the very different nature of the N-terminal bond on the three compounds (Figure 
R
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N
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O
NH2O
O
O
NH2
Compound R 
MW      
(Da) 
IC50 
(µM) 
kobs/[I] 
(M
–1
 s
–1
)
 
15 Ac-Pro- 539 0.68 ± 0.06 376* 
32 Tos-Pro- 650 1.6 ± 0.1 111 ± 3 
33 Bn-Pro- 586 1.5 ± 0.1 117 ± 3 
34 Bz-Pro- 600 0.43 ± 0.03 428* 
21 H-Pro- 497 4.6 ± 0.3 77 ± 2 
35 Bz- 503 2.3 ± 0.3 109 ± 5 
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4.2), variations in the relative position of the phenyl group with respect tp the 
enzyme should account for the differences in antiprotease activity.  
In compound 33 the benzyl group has free rotation around the N–C bond and 
the slower binding that is observed could be attributed to the increase in 
conformational flexibility. Instead, the benzoyl group in 34 would maintain the 
properties of the prolyl bond (peptidic bond in N-substituted proline) and rotation 
around the amide bond would be restricted. In the co-crystal structure the prolyl 
bond exhibited a trans conformation (Figure 4.1), which is predominantly observed 
in N-substituted prolines. However, the population of the cis isomer has been 
shown to be influenced by the N-terminal substitution, ranging from 5 to 35% in 
different unstructured peptides (Fischer, 2000). Therefore, the presence of the 
phenyl group could favour the trans isomer accounting for the increased reactivity 
of this compound with respect to 15. Finally, the conformation of N-(p-
toluensulfonyl) amino acids has been shown to be very well defined for acyclic 
amino acids, where both the sulphur and nitrogen in the sulfonamide bond present 
tetrahedral geometries (Aguilar-Castro et al., 2004). Therefore, the loss in 
antiprotease activity in compound 32 is likely to be attributed to the loss of the 
peptide bond. 
 
Tos-Pro- Bz-Pro- Bn-Pro- 
 
32 
 
33 
 
34 
 
 
Figure 4.2 Chemical structures of the N-terminal groups attached onto the tetrapeptidyl α,β-
unsaturated ester: p-toluensulfonyl (32), benzyl (33) and benzoyl (34). 
 
P4-Pro 
Even if antiprotease activity was moderately improved with compound 34, in 
order to keep the size of the peptide to a minimum, maintaining the P1 to P4 
positions, compound 21, which has a free N-terminus, was tested. This inhibitor 
showed the most significant loss of inhibitory activity of the set of compounds in 
Table 4.2. The free secondary amine from the N-terminal proline (pKa ~ 11) would 
N
NH
O
O
N
NH
O
N
NH
O
S
O O
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be protonated under the assay conditions (pH 7.4). The presence of a positive 
charge on P4 would require desolvation of the N-terminus to bind to the 
hydrophobic S4 subsite, accounting for the detrimental inhibitory activity of this 
compound.  
P4-Bz 
Compound 35 was designed to remove the positive charge from the P4 
position whilst keeping the molecular weight of the final molecule close to the 
500 Da barrier. Moreover, the benzoyl group was chosen to fulfil the hydrophobic 
requirements of the S4 pocket. The activity of 35 markedly improved with respect 
to 21, but was only found to be in the range of compounds 32 and 33, still far from 
the activity of the parent compound 15 (Table 4.2). A six-membered aromatic ring, 
planar and slightly bigger than the twist-shaped proline, might require a different 
binding mode within the S4 pocket, as is the case for Ruprintrivir in the co-crystal 
structure with HRV 3C
pro
 (Figure 3.4), which would explain its decreased activity. 
Nonetheless, this result indicates that a certain degree of flexibility can be 
attributed to the S4 pocket.  
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4.2 The P2 Position 
As discussed in section 3.1 a major concern for the viability of the FMDV 
3C
pro
 peptidyl Michael acceptor that was initially designed was the presence of a 
positive charge at P2. In this section the requirement for a cationic residue at P2 
was studied through the evaluation of inhibitors with different P2-residues (Table 
4.3). Figure 4.3 illustrates the main interactions observed within the S2 pocket of 
the substrate–enzyme co-crystal structure to assist the discussion.  
 
 
  
Figure 4.3 Amplification of the S2 subsite in the enzyme–substrate co-crystal structure. 
The P2 interactions identified between Mutant iL and substrate 9 are represented by dotted lines and 
are red for the salt bridges and blue for the hydrophobic contacts. *Ala in Mutant A and Cys in the 
wild type and Mutant C. Structure rendered with Pymol (DeLano, 2002). 
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4.2.1 The nature of P2 
Although in the preferred FMDV 3C
pro
 substrate (VP1/2A polyprotein 
junction) P2 corresponded to lysine, among the natural cleavage sequences other 
residues (Thr, Gln, His and Arg) were present in this position (section 1.4.4, Figure 
1.13). A previous study on FMDV 3C
pro
 substrate specificity had shown how 
substrates containing other positively charged residues (Orn and Arg) were 
hydrolysed by the protease whereas the presence of neutral side chains at P2 (Thr 
and Nle) abrogated hydrolysis (Knox, 2006). In an attempt to find an alternative to 
lysine for the P2 position, these results were investigated further and other P2 
substitutions were introduced to the parent compound through synthetic route B 
(Table 4.3). 
  
 
Table 4.3 Structure, molecular weight and antiprotease activities of compounds 15 and 36–43. 
These compounds were assessed against Mutant A (0.6 µM) using FRET substrate 1 (50 µM) for a 
total incubation time of 30 minutes (IC50) with samples taken at intervals of 5 minutes (kobs/[I]). 
*Obtained from triplicates for a single inhibitor concentration value.
 †
No inhibition detected for the 
highest inhibitor concentration assessed (500 μM). ‡Obtained from triplicates for three different 
inhibitor concentration values.  
N
H
N
O
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H
O R
H
N
O
NH2O
O
O
O
Compound P2 R MW 
IC50 
(µM) 
kobs /[I] 
(M
–1
 s
–1
)
 
15 Lys -(CH2)4-NH2 539 0.68 ± 0.06 376* 
36 Gly -H 467 2833 ± 445 ND 
37 Glu -(CH2)2-CO2H 539 NI
†
 ND 
38 Lys(Ac) -(CH2)4-NH-Ac 580 126 ± 12 5.5 ± 0.2 
39 Gln -(CH2)2-CONH2 538 52.5 ± 0.2 8.5 ± 0.7 
40 His -CH2-(2-Imd) 547 9.8 ± 0.3 25 ± 1 
41 Arg -(CH2)3-Gnd 566 0.84 ± 0.03 265 ± 4
‡
 
42 Orn -(CH2)3-NH2 525 2.7 ± 0.1 93 ± 10 
43 Dab -(CH2)2-NH2 511 21.3 ± 0.8 22 ± 2 
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P2-Gly 
In compound 36 the P2 side chain was removed by substituting lysine with 
glycine. This compound, which only reduced the protease activity by about 20% at 
the highest concentration assessed (4 mM), displayed the most dramatic decrease in 
inhibitory activity recorded. This result highlights the importance of the P2 side 
chain. Due to the absence of hydrogen bond interactions between the backbone of 
the P2 position and the enzyme, the side chain of this residue is required to position 
this part of the molecule and so orient P1 correctly. Therefore, with a glycine on P2 
the lack of activity of compound 36 is attributed to the loss of binding affinity in 
the absence of side chain interactions and the consequential flexibility introduced at 
a key position for the adequate orientation of the warhead. 
P2-Glu 
Before the determination of the co-crystal structure it was proposed that, upon 
binding, the end of the P2 lysine would be solvent-exposed, allowing a charged 
residue in this position (Sweeney et al., 2007). Compound 37 was designed to test 
this hypothesis. In this inhibitor the P2 lysine was substituted by glutamic acid, 
which under the assay conditions would be deprotonated; therefore, if the S2 
pocket was solvent exposed, the negative charge should be tolerated. However, no 
inhibitory activity was identified for the highest inhibitor concentration assessed 
(Table 4.3) indicating that some structural element within the S2 pocket should be 
responsible for discrimination between a positive and a negative charge. When the 
co-crystal structure was elucidated, the P2–S2 interactions observed clearly 
supported this result (Figure 4.3). As originally predicted, the S2 pocket comprised 
two hydrophobic residues (Leu142, Ala in Mutant A, and His46), but instead of 
being solvent-exposed, the amine in lysine established an electrostatic interaction 
with aspartate 144 and 146 (Figure 4.3 and section 2.3.3). Therefore, the lack of 
antiprotease activity of compound 37 is attributed to the presence of the two 
anionic residues in the S2 pocket.  
P2-Lys(Ac) and Gln 
Compounds 38 and 39 were designed to remove the positive charge from P2 
maintaining the hydrogen bonding properties for this position. The N-acetylated 
lysine derivative 38, a direct modification of the parent compound 15, would be 
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neutral at pH 7.4 whilst retaining a hydrogen donor group and gaining a hydrogen 
acceptor group at P2. Similarly, the glutamine derivative 39, which is found among 
the polyprotein 3C
pro 
cleavage sites on P2, would also be neutral under the assay 
conditions and offered the possibility to establish hydrogen bonding interactions 
through the amide group.  
The inhibitory activity was partially recovered with the introduction of these 
neutral polar side chains. Compound 39 was slightly favoured with respect to 38, 
probably due to the steric effects of the acetyl group within the S2 pocket. 
However, with a decrease in the kobs/[I] values of 68-fold (for 38) and 44-fold (for 
39) with respect to 15, both compounds proved to be poor FMDV 3C
pro
 inhibitors. 
This result indicated that hydrogen bonding alone is not sufficient to retain the 
inhibitory activity of the parent compound 15.  
P2-His 
In compound 40 lysine was substituted by a histidine, a residue also found at 
P2 among the naturally occurring FMDV 3C
pro
 substrate sequences (section 1.4.4). 
Compound 40 exhibited a decrease in inhibitory activity of about 15-fold with 
respect to 15. Since the imidazole group in histidine has a pKa of about 6, this 
residue would be mostly deprotonated at physiological pH (7.4) and the reduced 
antiprotease activity could be attributed to the small population of cationic 
molecules (~ 5%). However, the kobs/[I] value displayed by this compound was 
markedly higher than that from compounds 38 and 39, indicating that the aromatic 
group was tolerated at this position, probably through hydrophobic interactions 
established with His46 and Ala142 (Leu142 in the crystal structure, Figure 4.3).  
P2-Arg, Orn and Dab 
In compound 41 the positive charge was restored at the P2 position with 
arginine, which displays the highest pKa of all naturally occurring amino acids 
(~ 12.5) and would be protonated under the assay conditions. This analogue 
displayed a kobs/[I] value of 265 M
–1 
s
–1
 (Table 4.3), only 1.4-fold lower than the 
lysine derivative (15). The difference in activity could be attributed to the 
delocalisation of the positive charge over the guanidino group, rendering the 
electrostatic interactions within the S2 substite somewhat weaker. Nonetheless, 
even though the structure of arginine differs greatly from the primary amine of 
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lysine, the planar guanidino group seemed to deliver the positive charge almost as 
well as lysine. This result indicated that to restore the level of inhibitory activity to 
the same order of magnitude as the parent compound the presence of the positive 
charge was required. However, the acceptance of a structurally different side chain 
implied a degree of flexibility for this position, probably due to the presence of the 
two aspartate residues (D144 and D146) from the β-ribbon that constituted the S2 
subsite (Figure 4.3). 
Therefore, to evaluate the length of P2 residue required for inhibition, the 
relative position of the positive charge within the S2 pocket was varied. For this 
purpose, instead of the four carbon long primary amine of lysine (15) two unnatural 
amino acids with truncated primary amines on their side chains were introduced at 
this position, resulting in compound 42 with P2-ornithine (three carbons long) and 
compound 43 with P2-diaminobutiric acid (two carbons long). When assessed 
against FMDV 3C
pro
 both derivatives showed reduced inhibitory activity with 
respect to 15, confirming that the positioning of the positive charge within the S2 
pocket was also crucial in maintaining inhibition. The analogue with the shortest 
primary amine (43) showed the lowest level of inhibition (22 M
–1
 s
–1
), and the 
ornithine analogue (42), with an inhibition constant of 93 M
–1
 s
–1
, was revealed as 
third best amino acid at the P2 position (Table 4.3).  
4.2.2 Masking the positive charge 
As seen in the previous section, substitution of the P2-lysine by neutral 
residues resulted in reduced inhibitory potency of the peptidyl Michael acceptors. 
On the other hand, only inhibitors with P2-residues bearing long side chains and a 
positive charge at the end, such as lysine and arginine, retained a reasonable 
antiprotease activity. Moreover, the two aspartate residues at the 144 and 146 
positions of the 3C
pro
 sequence are strictly conserved among all FMDV strains 
(appendix 7.5); hence, maintaining the positive charge at the P2 position could be 
crucial to ensure activity of the inhibitor against different viral strains. Therefore, a 
―pro-drug‖ approach was considered at this stage in order to keep and mask the 
positive charge at P2.  
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 The pro-drug approach 
This approach consists of the temporary derivatisation of a functional group in 
order to improve some of its undesired properties. In order to serve its purpose, 
such transformation should be biorevesible, with the active compound recovered 
after chemical or enzymatic transformation. The pro-drug approach has been 
widely applied to small organic compounds and peptides (Bundgaard, 1992b; a; 
Adessi and Soto, 2002; Rautio et al., 2008; Simplício et al., 2008). Many efforts 
have focused on active compounds that are charged at physiological pH and 
numerous strategies have been developed to temporally mask the charge in order to 
enhance membrane penetration. Generally, carboxylic acids or amines present in a 
molecule can be converted into the corresponding esters, carbamates, amides, 
Mannich bases, imines or oximes. Moreover, together with masking the charge, 
such modifications can be used for the introduction of hydrophobic substituents 
that will serve to enhance the lipophilicity of the compound and add to its 
membrane permeability. However, the applicability of this approach is limited by 
the molecular size of the moieties introduced, especially when modifying big 
molecules, such as peptides; choosing a derivatisation that significantly increases 
the molecular weight of the initial compound might have the opposite effect and 
hamper passive diffusion. 
When considering the FMDV 3C
pro
 inhibitors designed, which were generally 
slightly larger than 500 Da, any modification should add as little as possible to their 
molecular weight and should be cleaved within the cell. The observation that the 
analogue with arginine at the P2 position (41) maintained a good level of inhibition 
led us to consider N-hydroxylation of the guanidinium group. This modification 
could serve the purpose of masking the positive charge as is probably the smallest 
derivation used as a pro-drug, being cleaved by reductases present in the cell 
(Ettmayer et al., 2004).  
 Hydroxyamidines 
Hydroxyamidines have been used as pro-drugs in the development of amidine 
containing compounds such as Ximelgatran (Clement and Lopian, 2003), a 
thrombin inhibitor, and Sibrafiban (Weller et al., 1996), an antagonist of the 
glycoprotein IIb-IIIa complex receptor (GP IIb-IIIa) (Figure 4.4). In both cases, the 
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active compounds contained benzamidines, which mimic the guanidine functional 
group of arginine and are protonated at physiological pH. N-Hydroxylation was 
shown to reduce the basicity of such compounds by about 6 pKa units (from 11.5 to 
5.2 in the case of Ximelgatran; Gustafsson et al., 2001), which rendered them 
neutral at physiological pH and enhanced their membrane permeability.  
 
Figure 4.4 Structures of Ximelgatran and Sibrafiban. 
Both compounds have been used as double pro-drugs with the N-hydroxybenzamidine and ester 
moieties concealing a benzamidine and a carboxylic acid respectively, which are both liberated 
in vivo by enzymatic cleavage (Ettmayer et al., 2004).  
 Subsequent liberation of the active compound by reductases is well 
documented and has been observed in vitro upon treatment of amidoximes with 
microsomal and mitochondrial preparations, from different organs and different 
species, as well as reconstructed enzymatic systems (containing NADH, 
cytochrome P450, cytochrome b5 and NADH cytochrome b5 reductase) (Clement, 
2002). Even if amidines, guanidines and amidinohydrazones can be oxidised to the 
corresponding N-hydroxylated derivatives by nitric oxide synthases (NOSs) and 
undergo subsequent generation of nitric oxide (Jousserandot et al., 1998), the 
retroreduction of amidoxime derivatives had been shown to predominate in vivo for 
Ximelgatran (Clement and Lopian, 2003). Figure 4.5 shows the potential metabolic 
pathways that N-hydroxyamidines can undergo in vivo.  
The ubiquity of P450 systems (McLean et al., 2005) could potentially extend 
the applicability of this approach to other drugs. In the case of FMDV 3C
pro
 
inhibitors this would be of particular interest since P450 enzymes are present in the 
mucosa of the lung and gastrointestinal tract, which are among the tissues targeted 
by FMDV (Grubman and Baxt, 2004). Moreover, microsomal preparations of lung 
and intestinal tissues of pig have already been shown to reduce this type of 
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compound (Clement, 2002). Even if immediate interest in the pro-drug approach 
came from the requirement of masking the positive charge at P2 of FMDV 3C
pro
 
inhibitors in order to enhance membrane penetration of these compounds in an 
antiviral cell-based assay, the in vivo applicability of this kind of modification 
should be also kept in mind at every stage of inhibitor development. Therefore, a 
new set of FMDV 3C
pro
 inhibitors, corresponding to peptidyl α,β-unsaturated esters 
with the N-hydroxylated guanidine function at the P2 position and their 
dehydroxylated analogues, were synthesised and assessed for anti-FMDV 3C
pro
 
activity. 
       
                  
Figure 4.5 Possible metabolic pathways of amidine derivatives in vivo. 
N-Hydroxylation of benzamidines, guanidines and amidohydrazones and the subsequent NO 
formation are catalysed by NOS, whereas the reduction of the N-hydroxylated compounds is 
attributed to P450 systems. 
 Synthesis  
The synthesis of guanidine derivatives can be achieved from the corresponding 
primary amines. The versatility of the synthetic routes chosen suggested that they 
could be directly applied to inhibitors with a primary amine at the P2 position. 
Despite the complexity of these inhibitors, the presence of no other nucleophile in 
the molecule (glutamine does not generally act as nucleophile) indicated their 
potential suitability as primary amine starting materials. Given the effect of the 
length of the P2 side chain on the activity of the corresponding primary amine 
inhibitors it was considered necessary to study the effect that length would have on 
the corresponding guanidine derivatives. Therefore, using the synthetic routes 
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described below, guanidine derivatives of different lengths (homoarginine, arginine 
and norarginine) and their N-hydroxylated versions were synthesised from the P2-
primary amine inhibitors (15, 42 and 43, obtained previously through synthetic 
route B) providing the compounds in Table 4.4 (page 145).  
Guanidine derivatives 
Maybe the simplest method for the preparation of guanidines is the reaction of 
a primary amine with a thiourea in the presence of an activating agent (Katritzky 
and Rogovoy, 2005). Copper (II) sulphate, mercury (II) chloride, EDCI, DIC and 
Mukaiyama‘s reagent are the main reagents used to assist desulfurisation. 
Mukaiyama‘s reagent (44), first described for the formation of carbodiimides 
(Shibanuma et al., 1977), has been used with the commercially available N,N′-
bis(tert-butoxycarbonyl)thiourea (45) in the presence of a both primary and 
secondary amines for the synthesis of the corresponding guanidines (Figure 4.6; 
Yong et al., 1997).  
 
 
 
Figure 4.6 Guanidinylation of amines with the Mukaiyama‘s reagent. 
The activation of N,N′-bis(tert-butoxycarbonyl)thiourea (45) with the Mukaiyama‘s reagent 44 leads 
to the formation of the carbodiimide intermediate 46. In the presence of an amine, in this case a 
primary amine (R-NH2), the carbodiimide will react to form a guanidine derivative. 
This was the route chosen for the modification of the primary amines present 
in the peptidyl α,β-unsaturated esters (Figure 4.7). After obtaining the fully 
protected guanidine derivative 47 under the conditions described (Yong et al., 
1997), treatment with an acidic deprotection mixture (TFA:TIS:H2O) afforded the 
final compound 48 (full details can be found in section 6.2.4, page 199). 
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Figure 4.7 Reaction scheme for the formation of the homoarginine derivative (48).  
In the first step the primary amine 15 was reacted with N,N′-bis(tert-butoxycarbonyl)thiourea in the 
presence of Mukaiyama‘s reagent 44 and triethylamine to form the fully protected guanidine 
derivative 47. In a second step the protecting groups were removed under strong acidic conditions in 
the presence of a carbocation scavenger (TFA:TIS:H2O).  
N-Hydroxylated guanidine derivatives 
Recently, a one-pot synthesis of N-hydroxyguanidines has been described for a 
wide range of primary amine substrates, from Boc-diprotected L-ornithine to the 
more hindered tert-butylamine (Martin et al., 2006). This synthesis required the 
preparation of Cbz-protected isothiocyanate 50, which was achieved from 
potassium isothiocyanate and benzyl chloroformate in the presence of crown ether 
using the conditions optimised by Martin et al. (section 6.2.4, page 201). 
Subsequently, the primary amine, in this case compound 15, was treated with 50. 
Upon consumption of the starting material (as judged by HPLC) the thiourea 
intermediate 51 was activated in situ with EDCI in the presence of triethylamine 
and THP O-protected hydroxylamine for the formation of the fully protected 
N-hydroxyguanidine derivative 52, presumably via a carbodiimide, as described for 
Mukaiyama‘s reagent (Martin et al., 2006).  
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Finally, the fully deprotected N-hydroxyhomoarginine (49) was obtained upon 
treatment with TFA–thioanisole deprotection mixture and was purified by RP-
HPLC.  
 
 
Figure 4.8 Reaction scheme for the synthesis of the N-hydroxylated homoarginine derivative (49). 
The synthesis is achieved through three steps from the lysine derivative 15: the formation of a 
thiourea intermediate, the formation of the guanidine derivative and the final deprotection. 
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 Antiprotease activity 
The compounds synthesised were assessed against FMDV 3C
pro
 and the results 
for the guanidine and N-hydroxylated guanidine derivatives are summarised in 
Table 4.4. This table also includes the activities of the compounds with P2 lysine 
(15), arginine (41) and ornithine (42) for comparison. 
 
  
Table 4.4 Structure, molecular weight and antiprotease activities of compounds 15, 41 and 44–52. 
These compounds were assessed against FMDV 3C
pro
 Mutant A (0.6 µM) using FRET substrate 1 
(50 µM) for a total incubation time of 30 minutes (IC50) with samples taken at intervals of 5 minutes 
(kobs/[I]). *Obtained from triplicates for a single inhibitor concentration value.
 †
Obtained from 
triplicates for three different inhibitor concentration values.  
 
R2
H
N
O
N
H
O
H
N
NH2O
O
O
R1
Compound P2 R1 R2 
MW  
(Da) 
IC50 
(µM) 
kobs /I 
(M
–1
 s
–1
)
 
15 Lys -(CH2)2-NH2 Ac-Pro- 539 0.68 ± 0.06 376* 
41 Arg -CH2-Gnd Ac-Pro- 566 0.84 ± 0.03 265 ± 4
†
 
42 Orn -CH2-NH2 Ac-Pro- 525 2.7 ± 0.1 93 ± 10 
53 nArg -Gnd Ac-Pro- 553 3.8 ± 0.1 75 ± 5 
48 hArg -(CH2)2-Gnd Ac-Pro- 581 1.2 ± 0.2 149 ± 10
†
 
54 Arg(OH) -CH2-Gnd(OH) Ac-Pro- 583 2.4 ± 0.2 97 ± 5 
55 nArg(OH) -Gnd(OH) Ac-Pro- 569 8.4 ± 0.4 36 ± 2 
49 hArg(OH) -(CH2)2-Gnd(OH) Ac-Pro- 597 2.7 ± 0.3 126 ± 8 
56 Arg(OH) -Gnd(OH) Bz- 547 3.3 ± 0.2 61 ± 7 
57 Orn -CH2-NH2
 
Bz- 489 3.5 ± 0.3 39 ± 2 
58 Arg -CH2-Gnd Bz - 530 1.22 ± 0.06 178 ± 3
†
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P2-nArg and hArg 
Compounds 53 and 48 were designed to investigate whether the partial loss in 
inhibitory activity of 41 with respect to 15 could be recovered by modifying the 
length of the guanidine derivative (Figure 4.9). However, even if the changes in 
activity observed for the different guanidine derivatives were quite small, both 
compounds 53 and 48 showed reduced antiprotease activity with respect to 41 
(Table 4.4).  
 
hArg Arg Lys nArg Orn 
 
  
 
 
Figure 4.9 Representation of the P2 residues hArg, Arg, Lys, nArg and Orn. 
The main difference among these amino acids is in the structure of the group bearing the positive 
charge. Whereas on the primary amines (lysine and ornithine) the positive charge is localised on the 
amine function, on the guanidine derivatives (homoarginine, arginine and norarginine) the positive 
charge is delocalised.  
The norarginine derivative 53, with a side chain one methylene shorter than 
arginine, followed the tendency observed with the shortening of the primary amine 
side chain. This substitution rendered compound 53 approximately 3.5-fold less 
active than the arginine homologue 41, a difference comparable to the 4-fold 
decrease observed for the ornithine derivative 42 compared to compound 15 
(section 4.2.1, Table 4.3). Although norarginine contained an amino group at the 
equivalent position of the primary amine in lysine (the δ position relative to the Cα) 
(Figure 4.9), this residue seemed to behave, within the S2 subsite, closer to Orn, 
probably due to the delocalisation of the charge over the guanidine group. This 
result confirmed, as indicated in section 4.2.1, that the activity of these compounds 
relies on the electrostatic interaction observed between P2 and the S2 pocket 
(Figure 4.3) rather than the hydrogen bonding properties of the P2 residue.  
In contrast, the homoarginine derivative 48 contained a side chain longer than 
both arginine and lysine (Figure 4.9). This compound, which displayed an IC50 in 
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the low micro molar range and a kobs/[I] value only 1.8-fold smaller than 41, was 
shown to be more active than the inhibitors with truncated P2 side chains (42 and 
53). This result provided further evidence of the flexibility of the S2 pocket. 
Providing the electrostatic interaction was maintained, the S2 pocket could 
accommodate a residue larger than the naturally occurring amino acids at P2 
without significant detriment of inhibitory activity.  
P2-Arg(OH), nArg(OH) and hArg(OH) 
The N-hydroxyguanindine derivatives 49, 54 and 55 were found to be active 
against FMDV 3C
pro
. Even though their activity was lower than the corresponding 
non-hydroxylated analogues, the presence of the hydroxyl group did not stop these 
inhibitors from inhibiting the protease. In marked contrast to the loss in activity of 
the N-acetylated lysine derivative 38 (section 4.2.1, Table 4.3), the IC50 values for 
these compounds were found to lie in the low micromolar range (Table 4.4) and the 
N-hydroxyarginine derivative 54, the N-hydroxynorarginine derivative 55 and the 
N-hydroxyhomoargine derivative 49 retained 33%, 48% and 84% of the activity of 
their non-hydroxylated analogues respectively.  
The fact that N-hydroxyguanidine derivatives displayed antiprotease activity 
indicated that their P2 residues were likely to be mostly protonated under the assay 
conditions (pH 7.4). The pKa values of N-hydroxylated guanidine derivatives were 
shown to be quite dependant on the substitution; varying between 6.9 and 8.3 
(Lefevre-Groboillot et al., 2001). However, the values reported for the side chain of 
N-hydroxyarginine (pKa ~ 8.1) had been based on the free N-hydroxyguanidine 
value (Fukuto, 1996; Crane, 2000). Considering a pKa of 8.1 for the 
N-hydroxylated guanidine derivatives 49, 54 and 55 at physiological pH (7.4), 
16.6% of the molecules would be deprotonated, whereas for the corresponding 
arginine and lysine analogues the neutral species would be present at just 0.0008% 
and 0.08% respectively. Thus, even if most of the N-hydroxylated molecules would 
be protonated, the presence of a much higher population of neutral molecules 
compared with the arginine and lysine derivatives should increase the chance of 
these compounds entering the cell. Moreover, the fact that N-hydroxylated 
compounds were also active against FMDV 3C
pro
 would render them not fully 
dependent on the enzymatic processing of the OH group.  
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Whereas the population of charged molecules can be assumed comparable for 
the different guanidine derivatives, the steric effects of the hydroxyl might 
influence the activity of each of the compounds differently. The analogue with the 
longest side chain (49) displayed the smallest change in antiprotease activity. This 
indicates that the decrease was mostly due to the change in the population of 
positively-charged molecules and that the hydroxyl group is too far from the core 
of the S2 pocket to have a great impact on the binding properties of the molecule. 
Conversely, the influence of the hydroxyl group could be more important for the 
derivatives with shorter side chains at P2 (compounds 54 and 55), perhaps 
accounting for the greater difference in activity of these compounds with respects 
their non-hydroxylated analogues.  
P4-Bn and P2-Arg, Arg(OH) and Orn 
The two main modifications designed to improve membrane permeability of 
the FMDV 3C
pro
 inhibitors by enhancing the hydrophobicity of the final molecule 
were combined in compound 56. This analogue consisted of a tripeptidyl inhibitor 
with both a benzoyl group at the N-terminus and an N-hydroxyarginine at P2; and 
was synthesised through the synthetic route described above from its ornithine 
derivative precursor 57, which had previously been obtained through synthetic 
route B (section 3.2.1). The corresponding arginine analogue 58 was also prepared 
via synthetic route B in order to compare its activity with the N-hydroxylated 
derivative (56).  
Following the trend previously observed, the N-hydroxyarginine derivative 57, 
retained 34% of the activity of the arginine analogue 58, a decrease in inhibitory 
activity very close to the 77% decrease detected for the equivalent tetrapeptide 
analogues 41 and 54 (Table 4.4). On the other hand, as seen in section 4.1.2, it was 
also confirmed that the benzoyl derivatives were slower inhibitors than the 
respective tetrapeptidyl analogues. However, the change to the P4 position seemed 
to affect the compounds with diverse P2 residues differently. When looking at the 
P2 substitutions the trend in the activity of the tetrapeptidyl inhibitors (Lys > Arg > 
Orn) was different from that one observed for the N-benzoylated tripeptide 
derivatives (Arg > Lys > Orn). This was a surprising result as changes at P4 were 
expected to affect all compounds in a similar way, but even if the substitution 
lowered the activity of them all, the lysine derivative seemed to be the most 
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sensitive to the change. It is difficult to explain this effect, which contradicts the 
additive effect of SAR (Free and Wilson, 1964). Nonetheless, non-additive effects 
have often been observed (McClure et al., 2006). It is possible that the presence of 
two aspartic acids in the S2 subsite might render the compound with P2 arginine, 
the charge being delocalised over the guanidino group, less sensitive to changes in 
other parts of the molecule and, in comparison, a better defined interaction might 
suffer more from such alterations. 
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4.3 Antiviral Cell-Based Assays  
The activity of an inhibitor against isolated FMDV 3C
pro
 does not give 
information as to whether an inhibitor can stop viral replication and, for instance, 
an inhibitor with poorer antiprotease activity could display better antiviral activity 
if it had improved membrane permeability. A cell-based assay with live virus, 
where the level of infection can be quantified in the presence or absence of a 
potential inhibitor, would provide this information. Therefore, compounds that had 
shown activity against FMDV 3C
pro
 were tested for the identification of any 
potential antiviral properties by monitoring the level of FMD viral infection in cell-
based assays. The experiments were performed by the teams of T. Jackson at the 
Institute of Animal Health (IAH) in Pirbright, UK, and G. Belsham at the National 
Veterinary Institute (NVI) in Lindholm, Denmark. There are different ways to 
monitor the level of viral infection, and two different methods were used: the 
quantification of infected cells using an enzyme-linked immunospot (ELISPOT) 
assay and the quantification of viral RNA using a quantitative real time polymerase 
chain reaction (qRT-PCR) assay.  
4.3.1 ELISPOT assay 
In the experiments run at the IAH the level of viral infection was quantified by 
using an ELISPOT assay (Berryman et al., 2005). Cells were incubated for 1 h with 
FMDV. After washing, the cells were incubated in culture medium for 4 h before 
being fixed and permeabilised. Infected cells were then detected by recognition of 
viral protein 3A by the corresponding monoclonal antibody (MAb). Subsequent 
treatment with a biotinylated secondary antibody, streptavidin-conjugated alkaline 
phosphatase and the corresponding chromogenic substrate turned cells containing 
3A protein dark blue. Infected cells were then be visualised and counted using an 
ELISPOT plate reader. For the inhibition assays the cells were incubated in the 
presence of inhibitor (at 200 μM) for 30 min prior to FMDV infection.  
The parent compound 15 and compounds 21 (P4-Pro, free Nt), 29 (P5-AcAla), 
33–35 (P5-Tos, Bn and Bz) and 38–41 (P2-K(Ac), Gln, His and Arg) were assessed 
with this method. No antiviral activity was detected for any of the compounds 
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tested under the assay conditions, where only one inhibitor concentration was used 
(200 µM). Figure 4.10 shows a representative example of the results obtained with 
this assay. In this case the ELISPOT readings showed the level of infected cells for 
the control and the cells treated with the FMDV 3C
pro
 inhibitor 15 at 200 μM, 
which can be clearly appreciated from the pictures of the cells after the 
corresponding chromogenic treatment. 
 
Figure 4.10 Representative result for the ELISPOT antiviral assays.  
Pictures from SW480-αvβ6 cells after a chromogenic treatment for FMDV 3A protein. A) Cells that 
have not been infected with FMDV. B) Cells infected with FMDV in the absence of inhibitor. C) 
Cells treated with compound 15 at 200 μM for 30 minutes prior FMDV infection. Equivalent levels 
of FMDV 3A protein can be clearly observed in B) and C). 
4.3.2 qRT-PCR assay 
In the assay performed at the NVI, qRT-PCR analysis was used according to 
the established method (Belsham and Normann, 2008), in order to determine the 
amount of viral RNA in cells infected with FMDV. The parent FMDV 3C
pro
 
inhibitor 15 and compounds 35 (P4-Bz), 48 (P2-hArg), 49 (P2-hArg(OH)), 53–55 
(P2-nArg, Arg(OH) and nArg(OH)) and 56–58 (P4-Bz and P2-Arg(OH), Orn and 
Arg) were evaluated with this assay. Cells were infected with virus in the presence 
or absence of inhibitor (at 100 μM) and incubated overnight at 37 °C. The cells 
A) No FMDV infection B) No inhibitor C) Compound 15 (200 μM) 
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were then frozen at –70 °C, the viral RNA was then extracted from the cell harvest 
and used to produce the complementary DNA (cDNA) with reverse transcriptase. 
cDNA was subsequently amplified by PCR and the newly formed DNA was 
continuously monitored by fluorescence. During the early exponential phase of the 
PCR, when all reagents are in excess and the products do not compete for primer 
binding, each cycle doubles the amount of DNA. Then, comparative readings can 
be expressed in the number of PCR cycles required for a sample to reach a 
fluorescence threshold; namely threshold cycle or Ct. If a high level of RNA is 
present in the original sample then the fluorescence generated during the PCR 
rapidly exceeds the threshold value (i.e. a low Ct). In this case, all reactions were 
performed using 50 cycles and the results are presented, with the appropriate 
controls, as a value (N = 35) minus the Ct observed, the lower the 35 – Ct value the 
higher the inhibition (Figure 4.11). With a difference of 9 cycles between its Ct 
with respect to the Ct of the untreated sample, cells treated with guanidine (an 
inhibitor of picornaviral RNA synthesis) displayed about 500-fold less viral RNA. 
However, as it can be appreciated from the chart (Figure 4.11), with variations on 
the Ct values within one cycle, no significant difference between the high levels of 
FMDV RNA could be observed with or without the FMDV 3C
pro
 inhibitors.  
 
 
Figure 4.11 Results for the qRT-PCR antiviral assays. 
FMD viral RNA level (in 35–Ct) from cells treated for FMDV infection in the presence of FMDV 
3C
pro
 inhibitors 15, 35, 48, 49 and 53–58 at a final concentration of 100 µM. *Gua = guanidine∙HCl, 
which is a picornaviral RNA replication inhibitor, was used as positive control at a final 
concentration of 5 mM. 
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4.4 Summary 
In this chapter the requirements of the peptidic part of the α,β-unsaturated 
esters for antiprotease activity were analysed and substitutions were directed 
towards the minimisation of the hydrophilic character of the final compounds.  
Firstly, compounds spanning the P1–P4 positions were indentified as inhibitors 
with the minimal peptidic length for inhibition. From the introduction of aromatic 
groups on the N-terminus of the tetrapeptide only one compound (34) offered a 
moderate increase in antiprotease activity. On the other hand, the substitution of 
P4-proline by a benzoyl group resulted in a compound (35) with a molecular 
weight of 503 Da that, without significantly breaking the 500 Da rule, did not 
dramatically compromise antiprotease activity. In contrast with the tetrapeptides 
with substituents on the N-terminus, tripeptidyl α,β-unsaturated esters with small 
cyclic groups on its N-terminus would keep the molecular weight low and reduce 
the number of natural peptidic bonds, increasing the lipophilicity of the final 
molecule.  
Secondly, substitutions on the P2 residue were performed in order to study the 
role of a charged residue at this position. Not only was the cationic charge found to 
be a major determinant in the activity of ethyl-3-[peptidyl]-(E)-propenoate 
inhibitors but the length of the P2 residue side-chain differentially influenced the 
antiprotease activity of these compounds and only derivatives with P2-lysine or P2-
arginine were found to maintain inhibitory potency. These findings, together with 
the absolute conservation of the 144 and 146 Asp residues among FMD viral 
strains, lead to the consideration of masking the positive charge by lowering the 
pKa of the P2 position and N-hydroxylated guanidine derivatives were synthesised. 
These compounds retained antiprotease activity indicating that, despite the decrease 
on the pKa of the molecule, they would be mostly protonated at pH 7.4. 
Finally, the findings were amalgamated in compound 58. The antiprotease 
activity of this compound confirmed that a good level of inhibition was retained by 
substituting P4-Pro with the benzoyl group. In addition, this compound offered the 
possibility of N-hydroxylation reducing the pKa of the P2 residue in compound 56, 
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which, with a molecular weight of 530 Da, would be one of the analogues 
potentially most cell permeable. 
These results have defined the requirements for FMDV 3C
pro
 inhibition 
in vitro. However, any favourable effect of the modifications introduced to the 
parent compound to enhance membrane permeability could not be observed with 
the antiviral assays performed. The results from both the ELISPOT and qRT-PCR 
assays indicated that either the FMDV 3C
pro
 inhibitors assessed could not reach the 
cytosol or if they did, they were too slow to show any antiviral activity under the 
assay conditions, which is probably not surprising for compounds with antiprotease 
activities ranging 6–400 M–1 s–1. 
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5.1 Conclusions 
The main objective of this thesis was the discovery of novel FMDV 3C
pro 
inhibitors. The synthesis and evaluation of potential inhibitors required the 
preparation of active recombinant protease, the development of the synthetic routes 
to access a number of potential FMDV 3C
pro
 inhibitors and the inhibition assays to 
assess their antiprotease activities. These tools, together with a recently determined 
enzyme–substrate co-crystal structure, allowed the characterisation of valuable 
structure-activity relationships for FMDV 3C
pro 
inhibition. This was achieved 
through the study of the activity of different FMDV 3C
pro 
mutants and the 
determination of the antiprotease activity for an extensive group of compounds.  
5.1.1 FMDV 3Cpro activity 
Protease activity assays had already provided valuable information on the 
peptidic requirements for hydrolysis (Birtley et al., 2005), but in this thesis an 
insight into the structural requirements of the enzyme has been presented through 
the activity of different recombinant FMDV 3C
 
proteases (Sweeney et al., 2007). 
The mutations introduced for the production of soluble recombinant FMDV 3C
pro
 
highlighted the importance of the 142
nd
 residue on protease activity. This residue 
was situated in a region of the protease that had appeared disordered in different 
crystal forms of the protease but formed a β-ribbon that folded over the substrate 
binding cleft in the latest FMDV 3C
pro
 structure published (Sweeney et al., 2007). 
This indicated a certain degree of flexibility for this loop and strongly suggested 
that it would play a role in FMDV 3C
pro
 peptide recognition.  
It was shown how the 142–146 loop plays a key role in protease activity by 
monitoring the activity of different recombinant FMDV 3C
pro
 mutants, which 
differed at the 142
nd
 residue (originally a cysteine in all FMD viral strains). 
Substitutions by polar amino acids significantly reduced enzyme activity with 
respect to the wild type (100-fold loss for Mutant S) whereas more hydrophobic 
substitutions maintained or even slightly increased the proteolytic activity of the 
wild type Mutant C. The co-crystal structure indicated that changes in protease 
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activity could be attributed to direct enzyme–substrate interactions. Not only did 
the 142
nd
 residue establish hydrophobic contacts with the P2 and P4 residues of the 
substrate as predicted (Sweeney et al., 2007), but other residues from the β-ribbon 
have been shown to be essential constituents of the S2 and S4 substrate binding 
pockets (section 2.3).  
These findings placed FMDV 3C
pro
 close to its viral relatives, HRV, HAV and 
PV 3C proteases, which share a common substrate biding pattern and contain an 
apolar residue at the 142
nd
 position, but also highlighted some of the particularities 
of this enzyme. Maybe the most distinctive trait is the electrostatic interaction 
established between Asp146 and P2, which had not been observed in the other 
inhibitor–3Cpro co-crystal structures. However, insights into the more relaxed P1 
specificity of FMDV 3C
pro
, which accepts both Glu and Gln at this position, cannot 
be explained by the present crystal structures, which display an S1 pocket 
equivalent to the other 3C proteases (Curry et al., 2007b). In this direction, 
extensive crystallisation trials of FMDV 3C
pro
 with a peptide containing E-G at the 
P1-P1′ junction are ogoing.  
5.1.2 FMDV 3Cpro inhibition 
The initial inhibitor design, based on previous work on HRV 3C
pro
 inhibition 
(Patick, 2006), provided FMDV 3C
pro
 irreversible inhibitors. The parent compound 
consisted of a small peptide (using the P-side of the polyprotein junction preferred 
by FMDV 3C
pro
) modified on its C-terminus with an α,β-unsaturated ester. This 
inhibitor presented a major drawback: the presence of a charged residue at the P2 
position, which would reduce the membrane penetration of this type of compound 
and thus the chances to meet its target protease in the cytosol of infected cells. 
Therefore, efforts were directed towards reducing the hydrophilicity of the peptidyl 
derivatives.  
 Structure activity relationships for inhibition 
Three main aspects of the peptidic part of the inhibitor were investigated: the 
minimal peptide size, the requirement of a cationic P2 residue and the use of a pro-
drug approach to mask the positive charge at the P2 position. 
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Michael acceptors spanning the P1–P4 positions were identified as the 
compounds with the minimal peptide length required for inhibition. Compounds 
lacking P4 and P3 residues displayed detrimental inhibition activities. This 
confirmed the importance of the P4–S4 hydrophobic contacts and the P3–G184 
backbone interactions in the correct positioning of the warhead moiety. The 
introduction of different groups at the P5 position also affected inhibitory activity 
and in one instance produced a compound with a moderately increased inhibitory 
potency. However, the most remarkable result was obtained by substituting P4-Pro 
by an aromatic group, which resulted in a compound that retained a large part of 
the inhibitory activity and, by eliminating the N-terminal amine, had a reduced size 
and enhanced hydrophobicity.  
The inhibitory activity of peptidyl α,β-unsaturated esters was abolished by the 
presence of a negative charge at P2, which provided direct evidence of the 
importance of the electrostatic interaction within the S2 pocket for inhibition. The 
absence of a P2 side chain and the introduction of residues with hydrogen bonding 
properties moderately improved inhibition; but only positively charged residues 
were found to retain significant inhibitory potency. The presence of two aspartate 
residues within the S2 pocket (D144 and D146) would account for the enzyme 
accommodating a range of positively charged residues with different structures. 
However, optimal inhibitor potency was restricted to compounds containing P2-
Lys and P2-Arg. 
The absolute requirement for a cationic P2 residue for inhibition and the strict 
conservation of D144 and D146 residues in the FMDV 3C
pro
 sequences reported 
(appendix 7.5) led us to consider a pro-drug approach to temporarily mask the 
positive charge. N-Hydroxylated guanidine derivatives were designed to lower the 
pKa at this position and deliver the deprotected active compound into the cytosol. 
Surprisingly, N-hydroxylated derivatives displayed an antiprotease activity close to 
the corresponding guanidine analogues, which indicated that despite their lower 
pKa these compounds were mostly protonated under the assay conditions. 
Nonetheless, the population of neutral molecules should still be superior to that 
from analogues with Lys or Arg at the P2 position.  
When the FMDV 3C
pro
 inhibitors were assessed against FMDV using 
ELISPOT and qRT-PCR cell-based assays, none of the compounds synthesised 
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displayed antiviral activity. This indicated that under the assay conditions the 
cytosolic concentration of the inhibitors was not sufficient to inhibit the 3C 
protease fast enough to stop viral replication. The lack of antiviral properties of this 
first generation of FMDV 3C
pro
 inhibitors might be due to the low membrane 
permeation properties inherent in peptides, and particularly charged molecules, but 
most likely due to their weak inhibitory activity (with the most active compounds 
showing kobs/[I] between 400 and 100 M
–1
 s
–1
).  
Nonetheless, the investigation of the peptidic moiety of the initial inhibitor 
(15) has provided a deep insight of the requirements for inhibition. This study 
generated compound 56, which represents a new lead to provide a second 
generation of FMDV 3C
pro
 inhibitors with potential enhanced membrane 
permeability (Figure 5.1). 
 
     
  
Figure 5.1 First generation of FMDV 3C
pro
 inhibitors. 
From the parent compound (15) to a potential new lead for compounds with enhanced membrane 
permeability (56). 56 contains a benzoyl group at the P4 position and N-hydroxyarginine at P2, 
which when dehydroxylated retains 47% of the antiprotease activity of 15.  
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5.2 Perspectives 
The small variations on the inhibition properties of the compounds obtained by 
modifying the peptidic moiety of the parent compound strongly suggest that the 
study of the warhead moiety of the inhibitor should be prioritised at this stage. The 
use of the α,β-unsaturated ester as a warhead was the most logical starting point for 
the design of FMDV 3C
pro
 inhibitors. However, it provided compounds with 
moderate antiprotease activities that lacked antiviral activities in vivo. Moreover, 
this warhead was shown to be slightly reactive toward free thiols and contains a 
group susceptible to hydrolysis.  
There is a wealth of warheads that could potentially be introduced (section 3.1) 
but making the right choice is a difficult task since antiprotease activity should be 
increased without compromising selectivity. Therefore, rather than using warheads 
with increased reactivity, it is possible that interactions with the S1′ subsite (section 
2.3.3) could be exploited. The synthetic routes developed (section 3.2) could serve 
this purpose. The introduction of several Wittig or HWE reagents has allowed 
varying the ester moiety on the Michael acceptor with E-stereochemistry. A 
derivative with a Weinreb amide as the EWG (59) displayed a much reduced 
FMDV 3C
pro
 inhibition (IC50 = 25 ± 3 µM, kobs/[I] = 12 ± 1 M
–1
 s
–1
) compared to 
the parent compound 15 (IC50 = 0.68 ± 0.06 µM, kobs/[I] = 376 M
–1
 s
–1
), and the 
characterisation of other α,β-unsaturated esters and Michael acceptors such as vinyl 
sulfones is ongoing in the Leatherbarrow research group. The introduction of 
Michael acceptors with Z-stereochemistry, which showed moderate activity against 
HRV 3C
pro
, might result in good FMDV 3C
pro
 inhibitors and should also be 
investigated. Conversely, warheads that have already been shown to be toxic or to 
be inactivated by non-enzymatic thiols should be avoided. Many of these examples 
can be found in the literature, but in our hands bromomethyl and chloromethyl 
ketones that inhibited FMDV 3C
pro
 in vitro (Long, 2006) displayed high levels of 
toxicity in cell-based assays (Jackson, 2006).  
Even though the peptidic requirements for FMDV 3C
pro
 inhibition have been 
largely defined in this thesis, the lessons learned have opened potential new routes 
to improve the parent compound and depeptidise the molecule. Given the tolerance 
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for the benzoyl group at P4, substitutions with small aromatic groups could 
potentially regain antiprotease activity by, for example, offering an alternative 
binding mode within the S4 pocket such as the one presented by the N-terminal 
3-methyl isooxazole in Ruprintrivir (section 3.1). Since the aromatic group of 
histidine was tolerated at P2, the introduction of arginine mimics, such as 
benzylamidines, could lead to active compounds with lower pKas than the 
corresponding guanidine and N-hydroxyguanidine analogues (Gustafsson et al., 
2001). Isosteric replacements of glutamine have been studied to overcome 
intramolecular cyclisation of peptidyl aldehydes with P1 glutamine (Webber et al., 
1998) and have been introduced in Ruprintrivir and TG-0205221, inhibitors of 
HRV 3C
pro
 and SARS-CoV 3C-like
pro
 respectively (section 1.4.5, Figure 1.15). 
Therefore, such substitutions could potentially work against FMDV 3C
pro
, which 
has a similar S1 pocket and P1 specificity. Finally, given the absence of backbone 
interactions for the P2 residue, two peptidic bonds could be removed or replaced 
(Steffansen et al., 2005). This would reduce the number of potential proteolytic 
cleavages, the molecular weight of the final molecule and the number of hydrogen 
donor and acceptor groups, all of which tend to enhance membrane permeability 
(Lipinski et al., 2001).  
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6  Materials and Methods    
  
 
 
This chapter is divided in three main areas and describes in detail the optimised 
conditions used for the experimental work carried out: the expression and 
purification of recombinant FMDV 3C
pro
; the synthesis and characterisation of all 
peptides and peptidyl derivatives including 3C
pro
 substrates and inhibitors; and the 
FMDV 3C
pro
 activity assays and inhibition assays for the evaluation of potential 
inhibitors.  
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6.1 Preparation of Recombinant FMDV 3C
pro
  
6.1.1 FMDV A1061 3C
pro
 mutants 
 All FMDV 3C
pro
 active mutants used in activity assays and inhibition assays 
were obtained from the construct described in section 2.2.1. Mutations at residue 
142 (Table 6.1) were introduced with a QuikChange mutagenesis kit (Stratagene) 
and the corresponding mutant 3C
pro 
proteins were expressed and purified (to 
homogeneity greater than 95%) by T. Sweeney (Sweeney et al., 2007). The over-
expression and purification of Mutant A (to apparent homogeneity) used in the 
inhibition assays (section 3.3 and chapter 4) was performed by the author. Inactive 
mutants used in crystallisation experiments have been included in Table 6.1 for 
clarity. However, Mutant iS and Mutant iL were obtained by T. Sweeney and P. 
Zunszain respectively using a slightly different construct and method that will not 
be described here (Sweeney et al., 2007).  
 
Table 6.1 Recombinant FMDV 3C
pro
 mutants and their application. 
Active FMDV 3C
pro
 mutants were used for activity and inhibition assays and inactive mutants for 
crystallisation and structure determination. The mutations present in each mutant are specified. 
*Active mutants contain three further mutations that constitute a C-terminal His tag whereas inactive 
mutants bear the wild type C-terminus (section 2.2.1, Figure 2.10).  
Name Mutations* Application 
Mutant C C95K Activity assay 
Mutant S C95K, C142S Activity assay 
Mutant V C95K, C142V Activity assay 
Mutant T C95K,C142T Activity assay 
Mutant A C95K,C142A Activity + Inhibition assays 
Mutant L C95K,C142L Activity assay 
Mutant iS K51Q, C95K, C142S, C163A Crystallisation 
Mutant iL C95K,C142L, C163A Crystallisation 
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6.1.2 General protocols 
 dH2O  
dH2O refers to distilled water filtered through a Milli-Q
®
 Gradient Ultrapure 
Water System (Millipore) with a resistivity of 18.2 MΩ cm. dH2O was used to 
prepare all growing media, antibiotic, IPTG and buffer solutions.  
 Preparation of antibiotics 
Kanamycin (Melford labs), was dissolved in dH2O to a final concentration of 
50 mg/mL (a 1000 × stock solution). It was then filter-sterilised using a syringe 
mountable 0.2 μm membrane filter (Sartorius). 1 mL aliquots were dispensed into 
sterilised 1.5 mL microfuge tubes and stored at –20 °C. Alcohol-soluble 
chloramphenicol (Sigma-Aldrich) was dissolved to a final concentration of 
34 mg/mL (a 1000 × stock solution) using propan-2-ol and stored at –20 °C foil-
wrapped. 
 Preparation of bacterial growth media 
Sterilised growth media, LB broth (20 g/L) and LB agar (35 g/L) (both from 
Sigma-Aldrich), were prepared according to manufacturer‘s instructions by 
dissolving the required amount of LB in dH2O and autoclaving the resultant 
solutions at 121 °C for 20 minutes. Work was then carried out under flame 
sterilised atmosphere. Bottles of sterilised LB broth were allowed to cool at room 
temperature and antibiotics were added at the appropriate concentrations (see 
below) immediately prior to use. Molten LB agar was cooled to ~ 50 °C, prior to 
the addition of the appropriate antibiotics (see below) and was poured into sterile 
disposable petri dishes (10–15 mL/dish). Once set, they were used immediately or 
sealed in air-tight bags and stored at 4 °C. 
 Transformation of E. coli 
Transformation of E. coli was carried out under flame sterilised atmosphere. 
Two different cell lines were used in the transformation of competent E. coli: 
XL-10 (Stratagene) for DNA amplification and BL21(DE3)pLysS (Stratagene) for 
the over-expression of active protein. The commercial suspensions of competent 
cells were thawed on ice for a period of 30 minutes. Then, 50 μL of cells were 
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placed in a chilled 1.5 mL microfuge tube pre-loaded with 1 μL of plasmid DNA 
(about 100 ng), and incubated on ice for 30 minutes. A heat-shock was performed, 
for the DNA to be taken up by the competent cells, by placing the reaction mixture 
in a water bath at 42 °C for 45 seconds and immediately back on ice for 5 minutes. 
0.5 mL of warmed LB broth (37 °C) was subsequently added and the resulting 
culture was incubated at 37 °C for 1 hour with shaking (200 RPM). Cells were 
pelleted at 14,000 × g for 1 minute using a micro centrifuge (Eppendorf) and the 
pellet was resuspended in LB broth (100 μL). The cells were then spread on LB 
agar plates with kanamycin (50 µg/mL) for the XL-10 cells and kanamycin + 
chloramphenicol (50 µg/mL and 34 µg/mL respectively) for the BL21(DE3)pLysS 
cells. Plates where then incubated for 16 hours at 37 °C and the colonies obtained 
were stored at 4 °C for subsequent use.  
 Determination of concentration by UV-vis absorption 
Optical density (OD) for monitoring culture growth and final DNA and protein 
concentrations were determined from the UV absorption of the corresponding 
solutions at the appropriate wave length (600 nm for OD, 260 for DNA and 280 for 
protein) using a Beckman DU
® 
530 UV spectrophotometer. The readings were 
obtained by triplicate and were kept within the linear range (0.1–1 absorption units) 
by diluting the original sample appropriately.  
6.1.3 DNA amplification 
 DNA extraction and purification 
DNA was amplified by transformation of competent XL-10 cells with the 
pET-28b plasmid encoding for FMDV A1061 3C
pro
. Five different single colonies 
were picked to inoculate 5 mL of LB broth containing kanamycin (50 µg/mL) for 
vector selection; cultures were grown with shaking at 200 RPM and at 37 °C. After 
approximately 16 hours of incubation the saturated cultures were centrifuged at 
3,800 × g in a JS-4.2 rotor (Beckman). The plasmid DNA was then purified from 
the cell pellets using the QIAprep mini preparation kit (Qiagen) following the 
manufacturer‘s instructions (Qiagen, 2006). DNA was eluted in sterile dH2O.  
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Final DNA concentration, typically 70–100 µg/mL, was determined by reading 
the absorbance at 260 nm, which is equal to 1 for a 50 µg/mL solution of double 
stranded DNA (ε260 = 0.020 mL μg
–1
 cm
–1
) in a 1 cm quartz cuvette. The purity of 
the genetic material obtained was evaluated by measuring the A260/A280 ratio 
(Manchester, 1995), and was always found to be greater than 1.7.  
 DNA restriction enzyme analysis 
The results of DNA cloning and general transformation reactions were checked 
by restriction enzyme analysis of purified plasmid DNA. Restriction enzymes were 
purchased from New England Biolabs (NEB). Typically 10% of the DNA extracted 
from a 5 mL 18 h culture was restricted with the appropriate enzyme according to 
the manufacturer‘s instructions. For Mutant A, 1 μL of EcoRV (10 units) was added 
to approximately 1 μg of purified DNA in a final volume of 50 μL of commercial 
buffer (100 mM NaCl, 50 mM Tris-HCl, 10 mM MgCl2, 1 mM DTT, pH 7.9) in the 
presence of bovine serum albumin (BSA) at 100 μg/mL and incubated at 37 °C for 
1 hour. Samples were then mixed with an appropriate volume of 6 × agarose gel 
loading buffer (10 mM Tris-HCl pH 8.0, 40% sucrose, 1 mM EDTA and enough 
bromophenol blue to turn the solution blue, typically 2–3 mg) and analysed by 1% 
(w/v) agarose gel electrophoresis.  
 DNA analysis by agarose gel electrophoresis 
Agarose (Cambrex Bio Science) was mixed with TAE buffer (40 mM Tris 
base, 2.5 mM EDTA and 5.7% (v/v) of glacial acetic acid) at a final concentration 
of 1% (w/v) and the mixture was homogenised by heating in a microwave oven. 
Ethidium bromide (Sigma-Aldrich) was added before casting to a final 
concentration of 0.5 μg/mL, the molten gel was allowed to cool to ~ 60 °C and was 
pourred into the cassettes (GIBCO mini-gels). When the gel was set, DNA samples, 
along with appropriate markers, 0.5 μg of 10 kbp ladder from NEB, were loaded 
into the wells and ran at 9 volts/cm for approximately 40 minutes in TAE buffer. 
Bands were visualised by ethidium bromide staining of DNA using an UV light box 
(Fluo Link) on medium power with the image recorded using a Polaroid camera. 
An example of the output from the gel is shown in Figure 2.12. 
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 DNA sequencing 
All DNA sequencing reactions were performed by OSWEL Research 
(University of Southampton) from a sample of purified DNA (~ 500 ng) in dH2O.  
6.1.4 FMDV 3Cpro over-expression in E. coli 
 Preparation of IPTG  
2.4 g of IPTG (Sigma-Aldrich) were dissolved in dH2O to a final concentration 
of 1 M (a 1000 × stock solution). The solution was then filter-sterilised using a 
syringe mountable 0.2 μm membrane filter (Sartorius) and stored at –20 °C. 
 Preparation of buffers for protein over-expression 
All chemicals were purchased from Sigma-Aldrich and dissolved in dH2O. The 
buffers are referred to with the name in italic and their composition is shown 
between brackets. Buffer A (50 mM HEPES pH 7.0, 400 mM NaCl, 1 mM 
β-mercaptoethanol and 0.01% sodium azide in dH2O); sonication buffer (buffer A + 
0.1% Triton
®
 X-100); E5 (buffer A + 5 mM imidazole); E100 (buffer A + 100 mM 
imidazole); E250 (buffer A + 250 mM imidazole); SDS-PAGE loading buffer (a 
2 × stock solution made by mixing 3 mL dH2O, 2 mL of glycerol, 0.5 mL of 
β-mercaptoethanol, 2 mL of 10% w/v SDS, 5 mL of 12.5 mM Tris-HCl pH 6.8 and 
2 mg bromophenol blue).  
 Analysis of proteins by SDS-PAGE 
Protein over-expression in E. coli and its subsequent purification was 
monitored by SDS-PAGE (using a Hoefer apparatus). 12% (v/v) acrylamide gels 
(Pierce Biotechnology) were used for analysing purified 3C protease. Following the 
loading of samples into the wells (typically 8 µL), with the appropriate molecular 
weight marker (BenchMark
TM
 10–220 kDa Protein Ladder, Invitrogen), SDS-
PAGE was performed at 200 volts for 45 minutes. Discrete protein bands were 
visualised by staining in an aqueous solution containing 25% (v/v) propan-2-ol, 
10% (v/v) acetic acid and 0.1% (w/v) Coomassie blue stain followed by destaining 
in an aqueous solution containing 45% ethanol and 10% acetic acid.  
 170 
 
 Small-scale protein over-expression  
In order to make sure the colony chosen for a large-scale preparation had a 
high level of expression, five starter cultures (typically 3 mL of LB broth, plus 
antibiotic) were inoculated with a single transformed colony selected from the 
BL21(DE3)pLysS agar plate. The cultures were incubated at 37 °C with shaking at 
200 RPM and cell growth was monitored by UV absorption (600 nm) until an OD 
of 0.6 was reached. IPTG was added (1 mM) to induce protein expression and 
cultures were further incubated at 37 °C. After 2 and 3 hours of incubation the level 
of expression was monitored by SDS-PAGE analysis. A 200 μL sample of each cell 
culture was pelleted by centrifugation in a micro centrifuge (Eppendorf) for 
2 minutes at 16,000 × g, the supernatant was removed to waste and 2 × SDS gel 
loading buffer added to the pellets. After analysis of the gel the colony showing the 
most intense band of FMDV 3C
pro
 (at around 23 kDa), was used for the large-scale 
protein expression. 
 Large-scale expression of FMDV 3Cpro 
The chosen transformed single colony was used to inoculate an overnight 
culture (200 mL of LB-broth with kanamycin and chloramphenicol at a final 
concentration of 50 and 34 μg/μL respectively). A 1/50 dilution of this overnight 
culture was used to inoculate 4 litres of LB broth (5 × 800 mL) and the culture was 
incubated at 37 °C with shaking at 200 RPM and cell growth was monitored by UV 
absorption (600 nm) until an OD of 0.6 was reached. IPTG was added to a final 
concentration of 1 mM to induce protein expression and cultures were incubated at 
37 °C for further 4 hours under the same conditions, which gave an optimal yield of 
3C
pro
, typically 8 mg per litre of LB broth. The cells were harvested by 
centrifugation in a JS-4.2 rotor (Beckman) at 5,000 × g for 15 minutes at 4 °C. The 
supernatant was discarded and the pellets stored at –80 °C. All contaminated 
material was disinfected with 1% Virkon (ANTEC International) for at least 16 h 
and washed thoroughly. 
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6.1.5 FMDV 3Cpro purification  
 Immobilised metal affinity chromatography (IMAC) 
The FMDV 3C
pro
 over-expressed from the pET-28b vector containing 
C-terminal 6 ×  His tag (Figure 2.10) was purified using TALON® IMAC resin 
(Clontech). FMDV 3C
pro
 protein purification was initiated by thawing and 
incubating bacterial cell pellets on ice for 30 minutes with 20 mL of sonication 
buffer (see page 169) for every litre of culture harvested (the presence of the 
bacterially-expressed lysozyme from the BL21(DE3)pLysS cells aided cell lysis). 
The pellet was mobilised by gentle hand agitation and by using an automatic 
pipette. The resuspended pellet was transferred into 50 mL centrifuge tubes 
(Falcon
®
, Becton, Dickinson & Co.) for sonication. Each tube was sequentially 
sonicated 3 times for 20 seconds at maximum power on ice. The sonicate (with a 
typical volume of approximately 100 mL from a 4 L LB broth culture) was then 
centrifuged in pre-chilled centrifuge tubes (Nalgene) at 23,000 × g using a F0850 
rotor (Beckman) for 20 minutes at 4 °C in order to separate insoluble material from 
the supernatant. At this point protamine sulphate (Sigma-Aldrich) was added to a 
final concentration of 1 μg/mL in order to precipitate the nucleic acids. The tubes 
were then rotated by hand and re-centrifuged for a final 20 minute spin. The 
sonicate, containing all soluble proteins, was adjusted to pH 7.0 (when necessary) 
using saturated sodium hydroxide. 
TALON
®
 resin for IMAC was prepared by pipetting an appropriate volume 
into a 50 mL Falcon tube (approximately 1 mL of resin bed volume was used per 
15 mg of 6 × His-tagged protein, typically 2.0 mL of TALON® was used per 4 litre 
LB broth culture). The TALON
®
 resin was washed twice with dH2O (to remove 
residual ethanol) and once with buffer A to equilibrate the resin. These steps were 
performed by spinning at 3,000 × g in the JS-4.2 rotor (Beckman) for 1 minute and 
decanting the buffer (leaving the TALON
®
 resin at the bottom). Supernatant was 
added to the resin and the mixture was allowed to rotate gently (1 RPM) at 4 °C for 
1 hour. 
The TALON
®
 resin was pelleted as before in order for the unbound material to 
be removed by decanting. The resin was washed by resuspending in buffer A, 
followed by gentle hand rotation and re-centrifugation in the JS-4.2 rotor 
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(Beckman). This procedure was repeated six times. The resin was further washed 
with 10 mL of E5 buffer and bound proteins were eluted with two 10 mL volumes 
of E100 buffer and 2 final washes with 10 mL of E250 buffer. The eluted materials 
were collected into 10 mL disposable tubes and kept at 4 °C until after SDS-PAGE 
analysis. Fractions containing 3C
pro
 were added together and were dialysed to 
remove the imidazole. The dialysis membrane (3 kDa cut-off, from Medicell 
International) was boiled in a solution of 2% (w/v) sodium carbonate and 1 mM 
EDTA in dH2O for 20 minutes, cooled at room temperature, washed thoroughly 
with dH2O and equilibrated with buffer A for 30 minutes prior to use. The protease 
was transferred to the membrane and left stirring for 18 h at 4 °C in 4 L of 
pre-chilled buffer A. The dialysed FMDV 3C
pro
 was concentrated in a 5,000 MW 
cut-off centrifugal concentrator (Vivaspin 20, Viva Science) to a final volume of 
0.5 mL with a final concentration no higher than 30 mg/mL (to avoid protein 
aggregation and precipitation). 
 Size exclusion chromatography 
The 3C protease was further purified using a Hi Load 16/60 Superdex 75 
(Amersham Biosciences) column (60 cm × 16 mm) in an ÄKTA fast protein liquid 
chromatographer (Amersham Biosciences), a typical chromatogram is shown in 
chapter 2 (Figure 2.6). All solutions used were filtered through 0.2 µm cellulose 
acetate membrane filters (Sartorius) prior to addition into the column. The column 
was washed of its 20% ethanol, 0.01% sodium azide preservative solution by 
equilibrating with 2 column volumes of dH2O with 0.01% sodium azide followed 
by 2 column volumes of buffer A. 
The concentrated enzyme was then centrifuged in a Spin-X column 
containing 0.22 µm cellulose acetate filters (Costar) for 2 minutes at 16,000 × g 
with a micro centrifuge (Eppendorf) to remove insoluble material or aggregates. 
0.5 mL of concentrated protein was loaded per run into a pre-chilled 1 mL syringe, 
mounted with a needle and injected into a 0.5 mL Superloop (Amersham 
Pharmacia) pre-equilibrated with buffer A. The purification proceeded at a flow 
rate of 0.75 mL/min and was monitored by UV detection (at 280 nm) with 1 mL 
fractions of the peak elution being collected. The purification was evaluated using 
SDS-PAGE analysis (Figure 2.15). 
6 Materials and Methods 
173 
 
Following gel filtration the fractions collected around the main peak on the UV 
trace, generally after elution of 60–75 mL of buffer A, corresponded to the active 
mutant. Fractions containing a single band on SDS-PAGE were pooled together and 
glycerol was added to a final concentration of 10%. The protein was concentrated 
in a 5,000 MW cut-off centrifugal concentrator (Vivaspin 6, Viva Science) and the 
final concentration was measured by UV absorption (see below) to afford 
approximately 4 mL of protein at 8 mg/mL. The protein was stored at –80 °C in 
100 µL aliquots for convenient single use in the activity assays.  
 FMDV 3Cpro concentration 
The method for determination of protein concentration was based on the 
absorbance of the protein at 280 nm. The extinction coefficient (ε280 nm = 
9200 M
-1 
cm
-1
) was obtained by introducing the primary sequence of the protease 
on PROTPARAM (Gasteiger et al., 2003) and an absorption of 0.413 corresponded 
to 0.1% of protein (1 mg/mL).  
6.1.6 Substrate–FMDV 3Cpro crystallisation 
Mutant iL suitable for crystallisation was obtained by P. Zunszain with a 
method similar to the one described in the previous sections. The purified enzyme 
was concentrated to 17 mg/mL in pH 7.0 HEPES buffer (50 mM) containing NaCl 
(200 mM), EDTA (1 mM) and β-mercaptoethanol (1 mM). Extensive crystallisation 
trials were also performed by P. Zunszain, in the presence of substrates (6–14, 
Table 6.3) at a 5:1 molar ratio (peptide to protein), at 4 °C and 18 °C with 
commercial screening kits in robotic sitting-drop vapor diffusion experiments 
(Sweeney et al., 2007). In these experiments, 100 nL of protein–peptide solution 
was mixed with 100 nL from the 100 μL reservoir solution (of variable 
composition). Optimisation of crystallisation conditions was performed manually 
with 2 μL drops over a 200 μL reservoir solution. Crystals were obtained at 41–
44% PEG 400, 0.1–0.25 M Li2SO4, pH 8 and 18 °C and were frozen in 
cryprotectant for X-ray diffraction data collection. The structure was refined at 
2.5 Å resolution to an Rfree of 26.7%. 
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6.2 Synthesis of Peptides and Peptidyl Derivatives  
6.2.1 Chemicals and general methods 
All L-amino acids, coupling reagents and resins were purchased from 
Novabiochem (EMD chemicals, Merck KGaA) except for resin 5 which was 
purchased from Cambridge BioSciences. Peptide synthesis grade DMF was from 
Rathburn Chemicals and HPLC-grade acetonitrile from Fisher Scientific or Sigma-
Aldrich. All other chemicals and solvents were purchased from Sigma-Aldrich. 
Ultra pure water with a resistivity of 18.2 MΩ cm was obtained using an Elix® 
Water Purification System, followed by a Milli-Q
®
 Gradient Ultrapure Water 
System, both from Millipore. Optical rotation was measured on a polarimeter from 
Optical Activity Ltd. with a cell path of 10 cm, against a blank of the solvent used 
for the measurement. Uncorrected melting points were measured in a Gallen Kamp 
melting point apparatus (Sanyo). 
The N-α-Fmoc protected L-amino acid derivatives used, with their 
corresponding side chain protecting groups shown in brackets, were the following: 
Ala, Arg(Pmc), Asn(Trt), Asp(tBu), Cys(Trt), Dab(Boc), Glu(tBu), Gln(Trt), Gly, 
His(Trt), Ile, Leu, Lys(Boc), Orn(Boc), Phe, Pro, Ser(tBu), Thr(tBu) and Val.  
A simplified naming system employing amino acid abbreviations (appendix 
7.1) from the N-terminus to the C-terminus of the peptide is used to name peptityl 
intermediates and final products. Side-chain modifications (i.e. protecting groups) 
are positioned between brackets next to the corresponding amino acid, and both N-
terminal and C-terminal modifications are marked at the beginning and the end of 
the peptidic sequence respectively. Common and/or IUPAC nomenclature of all 
chemicals and groups can be found in the list of abbreviations (page 15).  
6.2.2 General methods for SPPS 
 Solid support 
The choice of solid support determined the nature of the group attached to the 
resin after cleavage (Table 6.2). Under the appropriate cleavage conditions 
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carboxylic acids were obtained from Wang resin (3), amides from Rink amide resin 
(5 or 27) and aldehydes from Weinreb resin (16).  
If available, resins were purchased with the first amino acid already coupled 
onto the linker (pre-loaded resins) since the coupling of the first amino acid onto 
the solid support can present difficulties due to potential hindrance of the reactive 
moiety of the linker or proximity of the polymeric mesh. Another factor that can 
influence the synthesis is the concentration of amino acid loading, also known as 
the resin substitution, as highly substituted resins may affect reduced yields due to 
inter-peptide aggregation during synthesis. 
 
Table 6.2 Resins used in automated and manual peptide synthesis. 
The corresponding substitution, cleavage conditions and the product obtained after cleavage 
according to the nature of the group attached directly onto the resin.  
 Peptide chain elongation 
Automated synthesis was performed using an Advanced ChemTech Apex 396 
multiple peptide synthesiser (Advanced ChemTech Europe). Both in automated and 
manual SPPS the peptide was grown on the corresponding solid support following a 
standard Fmoc/tBu strategy (Fields and Noble, 1990) with DMF as solvent (Figure 
6.1). In a typical automated peptide synthesis 25 μmol of resin per well were used. 
The resin was swelled in DMF for at least 1 hour prior to the first synthesis cycle to 
maximise linker separation and preclude interactions between growing peptide 
Resin 
Substitution 
(mmol/g) 
Cleavage Product 
Fmoc-Lys(Boc)-Wang (3a) 0.60 
concentrated 
TFA 
Carboxylic acid 
Fmoc-Glu(Rink amide AM)-AMC (5) 0.25 
concentrated 
TFA 
Amide 
Fmoc-Phe-Wang (3b) 1.00 
concentrated 
TFA 
Carboxylic acid 
Fmoc-Asp(tBu)-Wang (3c) 0.55 
concentrated 
TFA 
Carboxylic acid 
Fmoc-Rink amide AM (27) 0.62 
concentrated 
TFA 
Amide 
Fmoc-Weinreb AM (16) 0.77 LiAlH4 Aldehyde 
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chains. A typical cycle involved two steps: the deprotection of the N-terminal Fmoc 
group of the resin or the last amino acid attached to the resin and the coupling of the 
following aminoacid (Figure 6.2). This alternation allowed the sequential growth of 
the peptide chain. 
 
 
Figure 6.1 Fmoc/tBu protection scheme on an acid labile resin used in SPPS. 
Orthogonal protection was achieved by using piperidine labile N-terminal protecting group (Fmoc) 
and TFA labile side chain protecting groups. Generally, tBu was used for the protection of 
carboxylic acids. Other acid labile side chain protecting groups used were Boc (for the protection of 
amines), Trt (for the protection of amides, thiols or amines) and Pmc for the protection of the 
guanidino group in Arginine.  
 
 
Figure 6.2 Typical peptide chain elongation cycle alternating deprotection and coupling steps. 
Every cycle was iniciated by removal of the Fmoc protecting group directly attached onto the resin 
(at the beginning of the synthesis) or onto the N-terminus of the last residue (n) of the growing 
peptide chain (i). This allowed coupling of the following amino acid (n+1) on the newly freed 
N-terminus (ii). The growing peptide chain is represented by the wavy line. At the beginning of the 
cycle Rn+1 is renamed Rn. This cycle was repeated until the last amino acid of the desired sequence is 
coupled. 
N-terminal deprotection. Fmoc N-terminal deprotection was achieved by 
shaking the resin (3 × 5 min) in an excess of 20% piperidine/DMF (v/v), generally 
1 mL/well in the automated synthesis and 1 mL per 100 mg of resin in manual 
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synthesis (Figure 6.4). The resin was then washed repeatedly (5 × 1 min) by 
shaking in DMF (1 mL). 
Amino acid activation and coupling. Coupling of the next amino acid was 
mediated by activation in situ using a 5-fold excess with respect to the resin. 
250 μL of amino acid (0.5 M in DMF, 0.125 mmol), 250 μL of HOBt–HBTU as the 
coupling reagents (1:1, 0.5 M in DMF, 0.125 mmol) and 500 μL of DIPEA as the 
base (0.5 M in DMF, 0.625 mmol) were sequentially added to the resin 
(0.025 mmol) and the suspension was mixed for 45 min. Thorough DMF washings 
were then conducted (1 mL, 5 × 1 min). Sporadically, particular peptide sequences 
contained residues which proved difficult to couple, in these cases repetition of the 
coupling steps (―double coupling‖) was required to overcome the problem.  
 
  
Figure 6.3 Activation of the carboxylic moiety of an amino acid with benzotriazole derivatives. 
Typically HOBt and HBTU or their azo derivatives HOAt and HATU were the coupling reagents of 
choice and DIPEA the base used. For the coupling step (Figure 6.2) the activation of the amino acid 
was performed in situ.  
 Kaiser test 
The Kaiser test (Kaiser et al., 1970) was performed ―on resin‖ during manual 
peptide synthesis exclusively, and was used mainly as a qualitative indicator of the 
success of the coupling step. The test was performed for the product of the coupling 
reaction and two reference samples, the fully deprotected resin prior to coupling 
and a fully protected resin. The resin was dryed dried in vacuo over silica gel prior 
use. Approximately 1 mg of dry resin was weighed out and 75 μL of a phenol 
solution in ethanol (80% v/v), 75 μL of a ninhydrin solution in ethanol (0.2 M) and 
100 μL of a KCN solution in pyridine were added to the peptidyl-resin. The 
resulting suspension was heated at 110 ºC for 10 minutes. A yellow solution 
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indicated a negative test, whereas was a purple coloured solution indicated the 
presence of primary amines. When the result was positive or dubious the coupling 
step was repeated. 
 Fmoc test 
The substitution of the manually loaded resin was quantified by monitoring the 
amount of Fmoc groups present on the resin after coupling of the first amino acid. 
This test was first developed by Sheppard et al. (Atherton and Sheppard, 1989). 
The Fmoc deprotection reaction was followed spectrophotometrically by 
monitoring the absorbance of the piperidine–dibenzylfulvene adduct, which absorbs 
in the 290–320 nm region with ε290nm= 5,800 M
–1
 cm
–1
, ε301nm= 7,800 M
–1
 cm
–1
 
(Newcomb et al., 1998; Figure 6.4). Typically, 1 mg of extra-dry resin (or peptidyl-
resin), weighed accurately (to 0.01 mg), was incubated with a solution of 1 mL of 
30% piperidine in DMF for 10 minutes. The solution was then filtered to remove 
the beads and the filtrate measured for its absorbance at 290 nm against a blank of a 
solution of 30% piperidine in DMF. 
 
 
 
Figure 6.4 Fmoc deprotection. 
N-terminal deprotection of the Fmoc protecting group of a growing peptide chain was performed 
with 20% piperidine in DMF and, for the Fmoc test, with 30% piperidine in DMF. The formation of 
the piperidine-dibenzylfulvene adduct, which absorbs in the 290–320 nm region (with ε290nm = 
5,800 M
–1
 cm
–1
 and ε301nm = 7,800 M
–1
 cm
–1
), allows quantification of the number of Fmoc groups 
present on a given amount of resin. 
 Capping 
Capping was performed when the N-terminus of the full peptide was required 
in acetylated form but also when in manual peptide synthesis the result of a Kaiser 
test still indicated residual free amines after a coupling had been already repeated. 
Typically, a solution of DIPEA (10%) and Ac2O (20%) in DMF was added to the 
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pre-swelled resin (1 mL for each well or 100 mg of resin). The resulting suspension 
was mixed for 30 minutes followed by washing with DMF, DCM and MeOH (3 × 
1 mL each). Finally the resin was dried in vacuo over silica gel. 
 Peptide recovery 
Generally, target peptides were recovered by simultaneous amino acid side 
chain deprotection and cleavage from the solid support. The acid labile nature of 
the peptide-resin linkage and side-chain protecting groups (Figure 6.1) makes this 
concerted reaction possible for peptides built on Wang and Rink amide resins, and 
the fully deprotected crude peptidic material can be separated from the insoluble 
solid support by filtration. However, when Weinreb resin was used side-chain 
deprotection was achieved in solution (under the same conditions) after reductive 
cleavage.  
During strongly acidic mediated deprotection (TFA, 85–95% v/v) there is a 
large concentration of cationic protecting groups within the mixture (Guy and 
Fields, 1997). So as to circumvent reattachment and side reactions, the deprotection 
mixture also contained a cocktail of cation scavengers (Novabiochem, 2006). The 
standard scavengers used were EDT, known to scavenge extremely well, especially 
tBu cations (Novabiochem, 2006), and TIS which is particularly successful in 
capturing highly stabilised cations such as Trt (Pearson et al., 1989). When present, 
Arg-Pmc, required the presence of phenol and thioanisole, which are reported to 
accelerate deprotection, capture the cation and protect against O-sulfonation of Ser 
and Thr residues (Jaeger et al., 1993). 
Peptidyl Wang and Rink Amide AM Resins. The deprotection mixture 
containing TFA–H2O–TIS (95:2.5:2.5) was used, unless otherwise stated, for 
simultaneous cleavage and side-chain deprotection. In a typical reaction, 1 mL of 
deprotection mixture (per well) was added to the dry peptidyl-resin and left to shake 
at room temperature for up to 4 hours. The solution was then filtered off and a 
further rapid wash of the resin was conducted with a small volume of the 
deprotection mixture. The filtrates were precipitated and washed with cold TBME 
(10 mL), centrifuged at 5,000 RPM for 5 minutes at 4 °C (BR4i centrifuge, Jouan), 
and the supernatant discarded. This procedure was repeated 3 times by re-
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suspending the pellet in TBME (10 mL). The crude peptide was then dried in vacuo 
over silica gel and obtained as a white solid.  
 RP-HPLC systems 
RP-HPLC systems were used for analysis and purification of crude peptides or 
peptidyl-derivatives and for assessment of product purity. For both HPLC systems, 
detection of the peptides was performed by UV absorption at 223 nm for amide 
bond absorption together with 335 nm for EDANS absorption when required. All 
mobile phases for HPLC, H2O and MeCN, contained 0.1% TFA (v/v) and were 
filtered and degassed with helium prior to application to the columns.  
Analytical RP-HPLC. Analytical traces of crude and purified peptides were 
obtained on a Gilson HPLC system (Anachem Ltd.) with a Gilson 322 pump, a  
Gilson 234 autoinjector and a Gilson 151 UV/vis detector. The system was fitted 
with an ACE 5 µm C18 column (250 × 4.6 mm) and an ACE 5 µm C18 guard 
cartridge system (12 × 7 mm) both from Hichrom Ltd. A typical analytical trace 
was obtained by using one drop of MeCN to dissolve a minimal amount of dry 
peptide in 200 μL water (containing 0.1% TFA) and eluting it using a suitable 
solvent method. Unless specified the typical analytical trace was obtained with a 
gradient of 2–100% of MeCN in H2O over 16 min at 1 mL/min. The purity of a 
peptide was determined from the peak integration of the analytical trace by 
comparison with a blank trace, and without taking into account the equilibration 
and injection peaks. For peaks integrating more than 98% the purity is stated as > 
98%.  
Preparative RP-HPLC. Purification of the crude peptides was performed on a 
Gilson semi-preparative RP-HPLC system (Anachem Ltd.) equipped with three 
Gilson 306 pumps and a Gilson 151 UV/vis detector. The system was fitted with an 
ACE 5 µm C18 column (250 × 21.2 mm) and an ACE 5 µm C18 guard cartridge 
system (12 ×  14 mm) both from Hichrom Ltd. For purification, non-water soluble 
peptides were first dissolved in MeCN (0.1% TFA) and then water (0.1% TFA) was 
added to a final concentration of 2% of MeCN, alternatively peptides which 
required DMSO-mediated solvation, the solution was diluted at least 5-fold in water 
(containing 0.1% TFA). The peptides were loaded manually and were eluted at 
12 mL/min with a gradient of 2–98% MeCN in H2O over 40 minutes. However, the 
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gradient was adjusted when necessary to the analytical trace of the crude. Fractions 
were collected upon absorbance increase according to the UV trace. 20 μL of the 
collected fractions corresponding to the main peaks were diluted in 100 μL of water 
and 100 μL of the final mixture were analysed with the analytical RP-HPLC 
system. Fractions that were judged homogenous were pooled together and diluted 
4-fold in water. Peptides were obtained as fluffy powders or glassy solids after a 
final lyophilisation step on a Christ Alpha 2-4 freeze dryer (Osterode am Harz) and 
were stored at –20 °C. 
 Mass spectrometry  
The final and intermediate compounds were identified by nominal MS (NMS) 
by FAB-MS or MALDI-TOF-MS and compounds with MW < 1000 Da where 
characterised by high resolution MS (HRMS) by ESI-TOF-MS. 
FAB-MS. The spectra were obtained by J. Barton on a Micromass AutoSpec 
Premier spectrometer at the mass spectrometry service of the Department of 
Chemistry at Imperial College London (UK). A minimal amount of peptide was 
mixed with a matrix of 3-nitro benzyl alcohol and ionised by bombardment with a 
beam of caesium ions at an energy of 20–25 keV. 
MALDI-TOF-MS. A solution of peptide (1 µL), taken directly from a purified 
fraction or obtained by dissolving a minimal amount of peptide in MeCN or a 
mixture of MeCN–H2O, was mixed with 1 μL of a matrix solution of α-cyano-4-
hydroxycinnanic acid (10 mg, Sigma-Aldrich) in MeCN (495 µL), EtOH (495 µL) 
and 0.1% TFA in water (10 µL). 1 μL of the mixture was spotted on a MALDI 
target plate (Waters). The sample was ionised by directing pulsed laser energy in 
the UV range (337 nm) at the target to desorb sample molecules from the matrix. 
The spectra were recorded on a Micromass MALDI micro MX spectrometer from 
the mass spectrometry service in the Department of Chemistry or the Centre for 
Molecular Microbiology and Infection (CMMI), both at Imperial College London 
(UK), and processed using MassLynx Global software.  
ESI-TOF-MS. The spectra were obtained by J. Barton on a Micromass LCT 
spectrometer at the mass spectrometry service of the Department of Chemistry at 
Imperial College London (UK). 10 μL of a very dilute solution of product in a 
suitable solvent (1 ng/μL) is injected into the mobile phase (H2O/MeCN) and an 
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ionised spray of charged droplets is created by the application of a high voltage 
(typically 1–3 kV) to a capillary containing a stream of the mobile phase. The 
process is assisted by use of a heated co-axial nebuliser gas, such as nitrogen. 
Accuracy for the elemental composition correlation was calculated from the 
difference between the calculated mass and the mass measured by accurate ESI-
TOF-MS and expressed in ppm and was generally lower than 5 ppm, and often 
below 3 ppm (Equation 6.1). 
 
 
𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦  𝑝𝑝𝑚 =
 𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑 − 𝑐𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑 𝑚𝑎𝑠𝑠 × 106
𝑐𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑 𝑚𝑎𝑠𝑠
 
Equation 6.1 
 
 NMR spectroscopy 
1
H and 
13
C NMR spectra were recorded in 5 mm tubes on Bruker AV 
spectrometers at 300, 400 or 500 MHz and 75, 100 or 125 MHz respectively. 2D 
1
H 
and 
1
H–13C correlation NMR experiments were carried out where appropriate to aid 
assignment of spectra. Chemical shifts (δ) are reported in ppm and coupling 
constants (J) are given in Hertz. The residual solvent peak was used as the internal 
reference: CHCl3 (δH = 7.24 ppm or δC = 77.2 ppm), CH3OH (δH = 3.31 ppm or δC 
= 49.2 ppm) and DMSO (δH = 2.50 ppm or δC = 39.5 ppm).  
6.2.3 FMDV 3Cpro substrates 
 FRET substrate 
Fmoc-L-Asp(EDANS)-OH (4). Compound 4 was prepared according to the 
previously stablished method (Taliani 
et al., 1996). Fmoc-L-Asp-OtBu (2.55 g, 
6.2 mmol) was dissolved in DMF (45 mL) 
containing HOBt (0.95 g, 6.2 mmol), DIC 
(0.78 g, 6.2 mmol) and stirred for 
15 minutes at room temperature. Addition of DIPEA (2.1 mL g, 12.4 mmol) and the 
sodium salt of EDANS (1.79 g, 6.2 mmol) resulted in the formation of a white 
suspension, which was stirred for 15 hours at room temperature. The suspension 
was then filtered and the solvent removed in vacuo. The crude oily product was 
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purified by silica gel flash column chromatography (DCM–MeOH, 9:1) yielding an 
off-white solid (Rf = 0.25, 20% MeOH). The resulting solid was dissolved in TFA–
DCM, 1:1 (30 mL) and stirred at room temperature for 2 hours. Subsequently the 
solvent was removed, the oily product re-dissolved in TFA (7 mL), and poured into 
MeOH (18 mL) with continuous stirring, the product precipitated and was filtered 
and dried in vacuo to afford an off-white solid (2.64 g, 64%).
 δH/ppm (400 MHz, 
DMSO-d6) 2.54 (1H, m, Dβ), 2.67 (1H, m, Dβ), 3.30 (2H, m, -NH-CH2-CH2-NH-), 
3.52 (2H, m, -NH-CH2-CH2-NH-), 4.22 (1H, m, Fmoc-9), 4.27 (2H, m, Fmoc-
CH2), 4.42 (1H, m, Dα), 6.76 (1H, m, EDANS-2), 7.25–7.40 (6H, m, Fmoc-2, 7, 3 
and 6 and EDANS-3 and 7), 7.61 (1H, d, J = 8.2, NH-Dα), 7.69 (2H, d, J = 7.4, 
Fmoc-1 and 8), 7.88 (2H, d, J = 7.1, Fmoc-4 and 5), 7.97 (1H, d, J = 6.8, EDANS-
H), 8.08 (1H, d, J = 7.2, EDANS-H), 8.20 (1H, m, NH), 8.36 (1H, d, J = 8.2, 
EDANS-4); m/z, NMS (FAB) 604 ([M + H]
+
), HRMS (ESI) 604.1780 
(C31H30N3O8S, [M + H]
+
, requires 604.1754).
 
DABCYL-APAKQLLD(EDANS)FDLLK-OH (1). The FRET substrate was 
obtained from pre-loaded Wang resin (3a) by automated SPPS. The chain 
elongation was paused after the addition of the first four residues (Leu, Leu, Asp 
and Phe) to couple Fmoc-L-Asp(EDANS)-OH (4) manually. After Fmoc 
deprotection (page 176) of the pentapeptidyl-Wang-resin (0.025 mmol), DMF 
(400 μL) was added to the resin followed by 100 μL of Fmoc-L-Asp(EDANS)-OH 
(0.5 M in DMF, 0.05 mmol), 100 μL of HOAt–HATU (1:1, 0.5 M in DMF, 
0.05 mmol) and 200 μL of DIPEA (0.5 M in DMF, 0.1 mmol). The suspension was 
shaken for 1 hour before washing with DMF (5 × 1 mL × 1 min). Automated chain 
elongation was resumed. After completion and deprotection of the last Fmoc group 
DABCYL was also manually coupled on the N-terminus of the full polypeptide 
under the standard HOBt/HBTU conditions (page 177). 250 μL DABCYL (0.5 M in 
DMF, 0.125 mmol), 250 μL HOBt/HBTU (0.5 M in DMF, 0.125 mmol), and 
500 μL DIPEA (0.5 M, 0.25 mmol) were added and the suspension was mixed for 
45 min. Cleavage and side chain deprotection were achieved with TFA–TIS–H2O 
(95:2.5:2.5) in one step and HPLC purification was monitored at λ = 335 nm for 
absorption of EDANS-containing peptides as described methods (page 180). The 
FRET substrate (1) was obtained as a fluffy red solid (24.8 mg/well, 51% yield). Rt 
 184 
 
= 13.1 min (2–100 MeCN in H2O over 16 min), purity > 98%; m/z, NMS (ES) 1971 
([M + H]
+
).  
 AMC substrate  
Ac-APAKQ-AMC (2). The AMC substrate was prepared by SPPS under 
standard conditions from a preloaded Rink amide resin (5), and 
was obtained as an off white solid (11.3 mg/well, 55% yield). 
Rt = 8.9 min (2–100% MeCN in H2O over 16 min), purity 
> 98%; δH/ppm (400 MHz, CD3OD) 1.34 (3H, d, J = 7.0, Aβ), 1.42 (3H, d, J = 7.2, 
Aβ), 1.52 (2H, m, Kγ), 1.69 (2H, m, Kδ), 1.80 (1H, m, Kβ), 1.90 (1H, m, Kβ) 1.92–
2.12 (4H, m, Qβ, Pγ and Pβ), 1.96 (3H, s, Ac), 2.13–2.31 (3H, m, Qβ and Pγ), 2.40 
(2H, t, J = 3.8, Qγ), 2.47 (3H, d, J = 1.1, AMC-Me), 2.94 (2H, t, J = 7.6, Kε), 3.65 
(1H, m, Pδ), 3.82 (1H, m, Pδ), 4.29 (1H, q, J = 7.2, Aα), 4.32 (1H, m, Kα), 4.41 
(1H, m, Qα), 4.46 (1H, m, Pα), 4.56 (1H, q, J = 7.0, Aα), 6.25 (1H, s, AMC-3), 7.51 
(1H, dd, J = 8.7 and 2.0, AMC-6), 7.73 (1H, d, J = 8.7, AMC-5), 7.89 (1H, d, J = 
2.0, AMC-8); m/z, NMS (MALDI) 714 ([M + H]
+
), HRMS (ESI) found 713.3600 
(C34H49N8O9, [M + H]
+
, requires 713.3623). 
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 P6-P5′ Substrates  
 The different substrates spanning P6–P5′ residues of the 3Cpro substrates from 
the VP1/2A, VP2/VP3 and 3B2/3B3 polyprotein junctions (section 1.4.4) were 
obtained through automated peptide synthesis as described in section 6.2.2. All of 
the peptides in Table 6.3 were capped with an acetyl group at the N-terminus and 
either carboxylic acid or amide functionality was obtained on the C-terminus under 
the cleavage conditions using the appropriate resin. The peptides were purified by 
RP-HPLC and characterised by MALDI-TOF MS.  
Table 6.3 Peptides synthesised for enzyme–substrate co-crystallisation. 
*
MALDI-TOF-MS. 
†
Retention time in minutes for a gradient of 0–100% MeCN in H2O over 
25 minutes. 
‡
Gradient of 2–98% MeCN in H2O over 16 minutes. 
Substrate Resin m/z
*
 Rt
†
/min Purity Yield 
Ac-IAPAKQLLNF-OH (6) 3b 1157 ([M + H]
+
) 14.9 97% 52% 
Ac-IAPAKQLLNF-NH2 (7) 27 1156 ([M + H]
+
) 14.7 96% 69% 
Ac-APAKQLLNFD-OH (8) 3c 1159 ([M + H]
+
) 13.8 > 98% 48% 
Ac-APAKQLLNFD-NH2 (9) 27 1158 ([M + H]
+
) 13.5 > 98% 59% 
Ac-PAKQLLNF-OH (10) 3b 973 ([M + H]
+
) 14.6 96% 46% 
Ac-PAKQLLNF-NH2 (11) 27 972 ([M + H]
+
) 14.2 95% 68% 
Ac-APAKELLNFD-NH2 (12) 27 1159 ([M + H]
+
) 14.4 > 98% 60% 
Ac-LPSKEGIFP-NH2 (13) 27 1029 ([M + H]
+
) 10.0
‡
 > 98% 35% 
Ac-PVVKEGPYE-NH2 (14) 27 1059 ([M + H]
+
) 8.6* > 98% 64% 
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6.2.4 FMDV 3Cpro inhibitors 
 General procedures from Route A 
Peptidyl Weinreb(AM)-resin. Synthesis on Weinreb resin (16) was performed 
manually. The resin (400 mg, 0.35 mmol) was swelled in DMF (4 mL) and after 
standard Fmoc deprotection, the first amino acid was coupled to the resin according 
to the protocol of the manufacturer (Novabiochem, 2006): Fmoc-L-Gln(Trt)-OH 
(1.07 g, 1.76 mmol) was pre-activated for 10 minutes with DIPCDI (276 µL, 1.76 
mmol) and HOAt (240 mg, 1.76 mmol) in 1 mL of DMF for 100 mg of resin. The 
suspension was shaken for 1 hour before washing with DMF, DCM and MeOH 
(3 × 1 mL each). This first coupling was repeated. The yield of the coupling (50%) 
was quantified with the Fmoc test (page 178) and the resin was capped prior to 
growing the remaining sequence. The rest of the peptide was grown following 
standard SPPS. The success of each coupling was monitored by the Kaiser test 
(page 177) with the coupling being repeated when necessary. 
Peptidyl aldehyde. For the reductive cleavage the optimised conditions were 
adapted from (Tong and Hong, 2000) (section 3.2.1, page 109), the extra-dry 
peptidyl Weinreb AM resin (100 mg, 0.044 mmol) was swelled with anhydrous 
THF (1 mL) under agitation for 1 h under atmosphere of nitrogen. The suspension 
was placed in a MeCN–dry-ice bath and the temperature maintained at –50 °C. 1 M 
LiAlH4 in THF (0.22 mL, 0.22 mmol) was added drop wise to the suspension with 
a syringe. The reaction mixture was allowed to reach –30 °C and kept at this 
temperature under agitation for 30 min. An aqueous solution of KHSO4 (1 M, 
1 mL) was added to the mixture, which was then allowed to reach room 
temperature. The resin was filtered off and washed with DCM and saturated 
aqueous KHSO4. Following partition, the organic layer was dried over MgSO4 and 
the solvent was removed under vacuum. The side-chain protected peptidyl-
aldehydes in Table 6.4 were obtained as off white solids and were used without 
further purification. The presence of the peptidyl aldehyde in the crude mixture was 
confirmed by FAB-MS, 
1
H-NMR and HPLC (Table 6.4).  
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Table 6.4 Peptidyl aldehydes obtained through synthetic route A. 
*
FAB-MS, for all samples the main peak (100%) corresponded to 243 ([Trt]
+
). 
†
Proton NMR 
(300 MHz) in CDCl3 chemical shifts (δH) in ppm.
 ‡
Retention time in minutes for a gradient of 0–
100% MeCN in H2O over 30 minutes. 
Fully protected ethyl-peptidyl-(E)-propenoate. Conditions were adapted from 
(Dragovich et al., 1998a). 1.0 M sodium bis(trimethylsilyl) amide in THF (55 µL, 
0.055 mmol) was added to a solution of triethyl phosphonoacetate (10 µL, 
0.053 mmol) in THF (0.5 mL) in an acetone–dry-ice bath and the temperature 
maintained at –78 °C, and the resulting solution was stirred for 20 min at that 
temperature. The corresponding peptidyl-aldehyde (0.044 mmol) in THF (1 mL) 
was added via syringe, the reaction mixture was stirred at –78 °C until completion 
(as judged by HPLC, generally after 1 h) and it was then warmed to 0 °C for 
10 min, and partitioned between 0.5 M HCl (2 mL) and EtOAc–Hx (1:1, 
3 × 2 mL). The combined organic layers were dried over MgSO4, filtered and the 
solvents were removed under vacuum. The corresponding crude ethyl-3-[peptidyl]-
(E)-propenoates were obtained as off-white solids and used without further 
purification. The presence of the α,β-unsaturated ester was confirmed by FAB-MS, 
1
H-NMR and HPLC (Table 6.5). 
 
 
Peptidyl-aldehyde m/z
* δH/ppm
 
CHO
†
 Rt
‡
/min
 
Boc-PAK(Boc)Q(Trt)-H (19) 869 ([M]
+
) 9.46 20.2 
Ac-APAK(Boc)Q(Trt)-H (60) 923 ([M + K]
+
) 9.47 19.6 
Ac-PAK(Boc)Q(Trt)-H (61) 834 ([M + Na]
+
) 9.46 19.7 
Ac-AK(Boc)Q(Trt)-H (62) 737 ([M + Na]
+
) 9.42 18.9 
Ac-K(Boc)Q(Trt)-H (63) 666 ([M + Na]
+
) 9.41 19.5 
 188 
 
Table 6.5 Ethyl-3-peptidyl-(E)-propenoates obtained through synthetic route A. 
*
FAB-MS, for all samples the main peak (100%) corresponded to 243 ([Trt]
+
).
 †
Proton NMR 
(300 MHz) in CDCl3 chemical shifts (δH) in ppm and coupling constants (J) in Hz.
 ‡
Retention time 
in minutes for a gradient of 0–100% MeCN in H2O over 30 minutes.  
Deprotected ethyl-3-peptidyl-(E)-propenoates. Side chain deprotection was 
achieved by adding the deprotection mixture (0.5 mL, TFA–TIS–H2O, 95:2.5:2.5) 
to the corresponding fully protected α,β-usaturated ester (0.044 mmol). Completion 
of the deprotection was judged by HPLC and was generally achieved after 2 h of 
mixing. Addition of cold TBME resulted in no precipitation for this type of 
compound and the solvent was evaporated. The crude was purified by RP-HLPC 
(page 180) and the fractions judged homogenous were pooled together and 
lyophilised to provide the corresponding deprotected ethyl-3-[peptidyl]-(E)-
propenoate. 
Ethyl-3-[Ac-APAKQ]-(E)-propenoate (29). TFA salt obtained as a pale yellow 
gluey solid (3% yield from resin 16). Rt = 11.3 min (2–98% MeCN in H2O over 
25 min), purity 97%; δH/ppm (300 MHz, CD3OD) 1.26 (3H, t, J = 7.1, Et-2), 1.34 
(3H, d, J = 7.0, Aβ), 1.40 (3H, d, J = 7.2, Aβ), 1.30–1.42 (2H, m, Kγ), 1.61 (m, 2H, 
Kδ), 1.97 (3H, s, Ac), 1.72–2.16 (7H, m, Kβ, Qβ, Pγ and Pβ), 2.27 (2H, m, Qγ), 
2.43 (1H, m, Pβ), 2.77 (2H, m, Kε), 3.65–3.90 (2H, m, Pδ), 4.17 (2H, q, J = 7.1, Et-
1), 4.22–4.33 (2H, m, Aα and Kα), 4.38 (1H, m, Pα), 4.45–4.62 (2H, m, Qα and 
Ethyl-3-[peptidyl]-(E)-
propenoate 
m/z
*
 
δH/ppm, m (J/Hz) 
Qα-CH=† 
δH/ppm, m (J/Hz) 
=CH-CO2
†
 
Rt
‡
/min 
[Boc-PAK(Boc)Q(Trt)] (20) 
962  
([M + Na]
+
) 
6.86, dd 
(4.7 and 15.5) 
5.91, d 
(15.6) 
25.6 
[Ac-APAK(Boc)Q(Trt)] (64) 
975  
([M + Na]
+
) 
6.85, dd 
(4.8 and 15.5) 
5.90, d 
(15.5) 
21.2 
[Ac-PAK(Boc)Q(Trt)] (65) 
904  
([M + Na]
+
) 
6.86, dd 
(4.9 and 15.5) 
5.90, d 
(15.7) 
22.3 
[Ac-AK(Boc)Q(Trt)] (66) 
806  
([M + Na]
+
) 
6.84, dd 
(4.9 and 15.6) 
5.90, d 
(15.7) 
21.7 
[Ac-K(Boc)Q(Trt)] (67) 
735  
([M + Na]
+
) 
6.82, dd 
(4.8 and 15.6) 
5.89, d 
(15.5) 
22.3 
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Aα), 5.94 (1H, d, J = 15.7, =CHCO2Et), 6.87 (1H, dd, J = 15.7 and 5.4, Qα-CH=); 
m/z, NMS (FAB) 610 ([M + H]
+
), HRMS (ESI) found 610.3552 (C28H48N7O8, [M + 
H]
+
, requires 610.3564). 
Ethyl-3-[Ac-PAKQ]-(E)-propenoate (15). TFA salt obtained as a very pale 
yellow glassy solid (6% yield from resin 16). Rt = 10.4 min (2–98% MeCN in H2O 
over 25 min), purity > 98%; δH/ppm (400 MHz, CD3OD) 1.27 (3H, t, J = 7.1, Et-2), 
1.40 (3H, d, J = 7.2, Aβ), 1.48 (2H, m, Kγ), 1.69 (2H, m, Kδ), 1.75–1.94 (4H, m, Pγ 
and Kβ), 1.95–2.07 (3H, m, Qβ and Pβ), 2.12 (3H, s, Ac), 2.21–2.35 (3H, m, Qγ 
and Pβ), 2.93 (2H, m, Kε), 3.55–3.75 (2H, m, Pδ), 4.17 (2H, q, J = 7.0, Et-1), 4.27 
(1H, m, Aα), 4.29 (1H, m, Kα), 4.34 (1H, m, Pα), 4.52 (1H, m, Qα), 5.92 (1H, dd, 
J = 15.7 and 1.6, =CHCO2Et), 6.87 (1H, dd, J = 15.7 and 5.4, Qα-CH=); m/z, NMS 
(FAB) 539 ([M + H]
+
), HRMS (ESI) found 539.3167 (C25H43N6O7, [M + H]
+
, 
requires 539.3193). 
Ethyl-3-[H-PAKQ]-(E)-propenoate (21). TFA salt obtained as a pale yellow 
oil (6% yield from resin 16). Rt = 10.5 min (2–98% MeCN in H2O over 25 min), 
purity > 98%; δH/ppm (400 MHz, CD3OD) 1.27 (3H, t, J = 7.2, Et-2), 1.39 (3H, d, J 
= 6.5, Aβ), 1.46 (2H, m, Kγ), 1.67 (2H, m, Kδ), 1.73–1.95 (6H, m, Kβ, Qβ, Pγ and 
Pβ), 1.98 (1H, m, Qβ), 2.18 (1H, m, Pβ), 2.29 (2H, m, Qγ), 2.90 (2H, m, Kε), 3.04 
(2H, m, Pδ), 3.79 (1H, m, Pα), 4.18 (2H, q, J = 7.2, Et-1), 4.25–4.36 (2H, m, Kα 
and Aα), 4.52 (1H, m, Qα), 5.90 (1H, d, J = 15.7, =CHCO2Et), 6.86 (1H, dd, J = 
15.7 and 5.6, Qα-CH=); m/z, NMS (FAB) 497 ([M + H]+), HRMS (ESI) found 
497.3090 (C23H41N6O6, [M + H]
+
, requires 497.3088). 
Ethyl-3-[Ac-AKQ]-(E)-propenoate (30). TFA salt obtained as a pale yellow 
gluey solid (8% yield from resin 16). Rt = 11.0 min (2–98% MeCN in H2O over 
25 min), purity > 98%; δH/ppm (400 MHz, CD3OD) 1.27 (3H, t, J = 7.2, Et-2), 1.36 
(3H, d, J = 7.2, Aβ), 1.46 (2H, m, Kγ), 1.64 (2H, m, Kδ), 1.75 (2H, m, Kβ), 1.85 
(2H, m, Qβ), 1.99 (3H, s, Ac), 2.29 (2H, t, J = 7.6, Qγ), 2.83 (2H, m, Kε), 4.18 (2H, 
q, J = 7.2, Et-1), 4.26 (1H, q, J = 7.2, Aα), 4.30 (1H, m, Kα), 4.52 (1H, m, Qα), 
5.91 (1H, d, J = 15.6, =CHCO2Et), 6.86 (1H, dd, J = 15.6 and 5.4, Qα-CH=); m/z, 
NMS (FAB) 442 ([M + H]
+
), HRMS (ESI) found 442.2663 (C20H36N5O6, [M + H]
+
, 
requires 442.2666). 
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Ethyl-3-[Ac-KQ]-(E)-propenoate (31). TFA salt obtained as a pale yellow 
gluey solid (7% yield from resin 16). Rt = 10.7 min (2–98% MeCN in H2O over 
25 min), purity 98%; δH/ppm (300 MHz, CD3OD) 1.27 (3H, t, J = 7.1, Et-2), 1.44 
(2H, m, Kγ), 1.64 (2H, m, Kδ), 1.69–1.83 (2H, m, Kβ), 1.80–1.98 (2H, m, Qβ), 
2.02 (3H, s, Ac), 2.31 (2H, m, Qγ), 2.84 (2H, m, Kε), 4.18 (q, J = 7.1, 2H, Et-1), 
4.26 (m, 1H, Kα), 4.53 (m, 1H, Qα), 5.90 (d, J = 15.7, 1H, =CHCO2Et), 6.86 (dd, J 
= 15.7 and 5.6, 1H, Qα-CH=); m/z, NMS (FAB) 371 ([M + H]+), HRMS (ESI) 
found 371.2280 (C17H31N4O5, [M + H]
+
 requires 371.2294). 
 Preparation of the building block for route B. 
Fmoc-L-Glu(tBu)-SBn (24). DMAP (0.141 g, 1.15 mmol) and DCC (2.5 g, 
12.1 mmol) were added sequentially to a 
solution of Fmoc-L-Glu(tBu)-OH (5 g, 
11.5 mmol) and benzyl mercaptan (2.73 mL, 
23 mmol) in THF (65 mL) at room temperature. 
The cloudy reaction mixture was stirred at room 
temperature for 18 h and then was filtered. After concentrating the filtrate it was 
partitioned between EtOAc (70 mL) and 1.0 M HCl (40 mL). The organic layer was 
dried over Na2SO4 and concentrated. Subsequent addition of Et2O (15 mL) resulted 
in a white precipitate that was collected by vacuum filtration and washed with 
petroleum ether. Compound 24 was obtained as a white solid and was used without 
further purification (4 g, 72% yield). Rf = 0.67 (EtOAc–Hx, 2:1); mp 114–116 °C; 
δH/ppm (400 MHz, CDCl3) 1.43 (9H, s, tBu), 1.93 (1H, m, Eβ), 2.17 (1H, m, Eβ), 
2.32 (2H, m, Eγ), 4.08 (1H, d, J = 13.6, Bn-CH2), 4.13 (1H, d, J = 13.6, Bn-CH2), 
4.21 (1H, t, J = 7.0, Fmoc-9), 4.33 (1H, dd, J = 7.2 and 10.5, Fmoc-CH2), 4.43 (1H, 
m, Eα), 4.52 (1H, dd, J = 6.9 and 10.5, Fmoc-CH2), 5.65 (1H, d, J = 8.4, NH), 
7.22–7.31 (7H, m, Bn, Fmoc-2 and 7), 7.37 (2H, app td, J = 2.0 and 7.4, Fmoc-3 
and 6), 7.59 (2H, app dd, J = 5.0 and 7.0, Fmoc-1 and 8), 7.74 (2H, d, J = 7.5, 
Fmoc-4 and 5); m/z, NMS (ESI) 554 ([M + Na]
+
), HRMS (ESI) found 554.1992 
(C27H33NO10Na, [M + Na]
+
, requires 554.2002). 
Fmoc-L-Glu(tBu)-H (25). Triethylsilane (4.5 mL, 28.2 mmol) was slowly 
added to a suspension of 24 (3 g, 5.6 mmol) and Pd/C (10%, 1.5 g) in acetone 
(130 mL) at room temperature previously degassed with N2. The reaction mixture 
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was stirred for 15 min, and was then filtered through Celite. The filtrate was 
concentrated to afford 2.3 g of crude 25 which was used without further 
purification. Rf = 0.57 (EtOAc–Hx, 2:1); δH/ppm (400 MHz, CDCl3) 1.45 (9H, s, 
tBu), 1.87 (1H, m, Eβ), 2.22 (1H, m, Eβ), 2.33 (2H, m, Eγ), 4.18 (1H, t, J = 6.8, 
Fmoc-9), 4.27 (1H, m, Eα), 4.41 (2H, d, J = 7.0, Fmoc-CH2), 5.86 (1H, d, J = 7.6, 
NH), 7.29 (2H, app t, J = 7.4, Fmoc-2 and 7), 7.38 (2H, app t, J = 7.4, Fmoc-3 and 
6), 7.59 (2H, d, J = 7.1, Fmoc-1 and 8), 7.74 (d, J = 7.1, 2H, Fmoc-4 and 5), 9.54 
(1H, s, CHO); m/z, NMS (ESI) 432 ([M + Na]
+
). 
Ethyl-3-[Fmoc-L-Glu(tBu)]-(E)-propenoate (26). (Carbethoxymethylene)-
triphenyl phosphorane (3.08 g, 8.4 mmol) was added to a solution of crude 25 
(2.3 g, 5.6 mmol) in THF (25 mL) at room temperature. The resulting mixture was 
stirred for 24 h and then concentrated under reduced pressure. The residue was 
purified by silica gel flash column chromatography (15% EtOAc in Hx) to afford 
26 as a white solid (1.87 g, 70% yield from 24). Rf = 0.68 (EtOAc–Hx, 2:1); mp 
46–48 °C; [α]24
𝐷
 –10.5° (c 1.1, CHCl3); δH/ppm (400 MHz, CDCl3) 1.25 (3H, t, J = 
7.1, Et-2), 1.43 (9H, s, tBu), 1.64–2.00 (2H, m, Eβ), 2.11–2.34 (2H, m, Eγ), 4.12–
4.23 (3H, m, Fmoc-9 and Et-1), 4.27–4.46 (3H, m, Eα and Fmoc-CH2), 5.56 (1H, d, 
J = 8.4, NH), 5.93 (1H, d, J = 15.6, =CHCO2Et), 6.84 (1H, dd, J =15.7 and 5.6, Eα-
CH=), 7.26 (2H, app t, J = 7.4, Fmoc-2 and 7), 7.35 (2H, app t, J = 7.4, Fmoc-3 and 
6), 7.56 (2H, d, J = 7.3, Fmoc-1 and 8), 7.71 (2H, d, J = 7.5, Fmoc-4 and 5); m/z, 
NMS (ESI) 480 ([M + H]
+
), HRMS (ESI) found 480.2400 (C28H34NO6, [M + H]
+
, 
requires 480.2386). 
Ethyl-3-[Fmoc-L-Glu]-(E)-propenoate (23). TFA (2 mL) was added to a 
solution of 26 (0.6 g, 1.25 mmol) in DCM (8 mL) at room temperature. The 
reaction mixture was stirred for 2 h, and then the volatiles were removed under 
reduced pressure. The residue was triturated with a 1:1 mixture of Et2O and 
hexanes (3 mL), and the resulting solid was collected by filtration and washed 
thoroughly with cold Et2O–Hx to afford 23 as a white solid (0.5 g, 92% yield). Rf = 
0.16 (EtOAc–Hx 2:1); mp 152–154 °C; δH/ppm (400 MHz, CD3OD) 1.28 (3H, t, J 
= 7.1, Et-2), 1.76 (1H, m, Eβ), 1.92 (1H, m, Eβ), 2.35 (2H, t, J = 7.4, Eγ), 4.14–4.24 
(3H, m, Et-1 and Fmoc-9), 4.27 (1H, m, Eα), 4.41 (2H, d, J = 6.8, Fmoc-CH2), 5.88 
(1H, d, J = 15.7, =CHCO2Et), 6.84 (1H, dd, J = 15.7 and 5.6, Eα-CH=), 7.31 (2H, 
app t, J = 7.4, Fmoc-2 and 7), 7.38 (2H, app t, J = 7.3, Fmoc-3 and 6), 7.65 (2H, 
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app dd, J = 3.1 and 5.4, Fmoc-1 and 8), 7.79 (2H, d, J = 7.5, Fmoc-4 and 5);
 δC/ppm 
(100 MHz, CD3OD) 14.3 (Et-2), 30.3 (Eβ), 31.4 (Eγ), 48.7 (Fmoc-9), 52.9 (Eα), 
61.8 (Et-1), 67.8 (Fmoc-CH2), 121.1 (Fmoc-4 and 5), 122.1 (=CHCO2Et), 126.3 
(Fmoc-1 and 8), 128.3 (Fmoc-2 and 7), 128.9 (Fmoc-3 and 6), 142.8 (Fmoc-4b and 
5b), 145.4 (Fmoc-1b and 8b), 149.4 (Eα-CH=), 158.4 (OCON), 168.0 (CO2Et), 
176.6 (CO2H); m/z, NMS (ESI) 424 ([M + H]
+
), HRMS (ESI) found 424.1743 
(C24H26NO6, [M + H]
+
, requires 424.1760). 
Ethyl-3-[Fmoc-L-Glu(RA(AM)resin)]-(E)-propenoate (28). 
Following swelling in DMF (5 mL) and Fmoc deprotection of Rink amide AM 
resin (27) (0.5 g, 0.62 mmol/g, 0.31 mmol), compound 23 (0.254 g, 0.62 mmol), 
HOAt (84 mg, 0.62 mmol), HATU (0.236 g, 0.62 mmol) and DIPEA (0.22 mL, 
1.24 mmol) in DMF were added to the resin at room temperature with a final 
volume of 5 mL. The suspension was mixed for 2 h and the resin was washed with 
DMF, DCM and MeOH (3 ×  5 mL each) and the resin was dried at reduced 
pressure. According to the Fmoc-test the yield of the coupling was of 84%. A 
capping (page 178) was performed to ensure a final loading of 0.52 mmol/g. 
N-Methoxy-N-methyl-3-[Fmoc-L-Glu(tBu)]-(E)-promenamide (68). Sodium 
bis-(trimethylsilyl) amide (0.6 mL, 1.0 M in THF, 0.6 mmol) was added to a 
solution of diethyl (N-methoxy-N-methylcarbamoyl methyl)-phosphonate (130 µL, 
0.6 mmol) in THF (0.5 mL) in an acetone-dry ice bath at –78 °C, and the resultant 
solution was stirred for 20 min at that temperature. A solution of the aldehyde 25 
(200 mg, 0.5 mmol) in THF (2 mL) was added with a syringe, the reaction mixture 
was stirred at –78 °C for 2 h, it was then warmed to 0 °C for 10 min, and 
partitioned between 0.5 M HCl (3 mL) and EtOAc–Hx (1:1, 3 ×  3 mL). The 
combined organic layers were dried over MgSO4, filtered and the solvents were 
removed under vacuum. The residue was purified by flash column chromatography 
(EtOAc–Hx, 2:1) to afford 26 as a pale yellow oil (173 mg, 70% yield). Rf = 0.18 
(EtOAc–Hx, 2:1); δH/ppm (400 MHz, CDCl3) 1.42 (9H, s, tBu), 1.88 (2H, m, Eβ), 
(2H, dd, J = 7.04 and 5.8, Eγ), 3.21 (3H, s, NMe), 3.62 (3H, s, OMe), 4.19 (1H, t, J 
= 6.8, Fmoc-9), 4.31–4.44 (3H, m, Eα and Fmoc-CH2), 5.13 (1H, d, J = 8.4, NH- 
Eα), 6.51 (1H, d, J = 15.4, =CHCON(OMe)Me), 6.79 (1H, dd, J = 6.2 and 15.4, 
Qα-CH=), 7.29 (2H, app t, J = 7.4, Fmoc-2 and 7), 7.38 (2H, app t, J = 7.4, Fmoc-3 
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and 6), 7.57 (2H, d, J = 7.1, Fmoc-1 and 8), 7.74 (2H, d, J = 7.5, Fmoc-4 and 5); 
m/z, NMS (ES) 495 (70%, [M + H]
+
), 517 (100%, [M + Na]
+
).  
N-Methoxy-N-methyl-3-[Fmoc-L-Glu]-(E)-propenamide (69).TFA (0.6 mL) 
was added to a solution of 68 (173 mg, 0.35 mmol) in DCM (2.4 mL) at room 
temperature. The reaction mixture was stirred for 2 h, and then the volatiles were 
removed under reduced pressure. The residue was triturated with a 1:1 mixture of 
Et2O and hexanes (1 mL), after centrifugation the supernatant was discarded and 
the precipitate was thoroughly washed with cold Et2O–Hx (1:1, 2 mL) by 
centrifugation, the precipitate was dried in vacuo to afford 69 as a white solid 
(128 mg, 83% yield). Rf = 0.46 (10% MeOH in DCM); mp 114–116 °C; δH/ppm 
(400 MHz, CD3OD) 1.80 (1H, m, Eβ), 1.93 (1H, m, Eβ), 2.36 (2H, t, J = 7.4, Eγ), 
3.22 (3H, s, NMe), 3.65 (3H, s, OMe), 4.20 (1H, t, J = 6.8, Fmoc-9), 4.33 (1H, m, 
Eα), (2H, d, J = 6.8, Fmoc-CH2) 6.56 (1H, d, J = 15.5, =CHCON(OMe)Me), 6.78 
(1H, dd, J = 5.8 and 15.5, Qα-CH=), 7.29 (2H, app t, J = 7.4, Fmoc-2 and 7), 7.37 
(2H, app t, J = 7.4, Fmoc-3 and 6), 7.64 (2H, d, J = 7.0, Fmoc-1 and 8), 7.77 (2H, d, 
J = 7.5, Fmoc-4 and 5); m/z, NMS (ES) 439 (70%, [M + H]
+
), 478 (100%, [M + 
K]
+
). 
N-Methoxy-N-methyl-3-[Fmoc-L-Glu(RA(AM)-resin)]-(E)-propenamide 
(70). Following swelling in DMF (5 mL) and Fmoc deprotection of Rink amide-
AM-resin (27) (210 mg, 0.71 mmol/g, 0.15 mmol), compound 69 (128 mg, 
0.3 mmol), HOAt (41 mg, 0.3 mmol), HATU (115 mg, 0.3 mmol) and DIPEA (0.1 
mL, 0.6 mmol) in DMF were added to the resin at room temperature with a final 
volume of 2 mL. The suspension was mixed for 2 h. The resin was then washed 
with DMF, DCM and MeOH (3 ×  5 mL each) and was subsequently dried at 
reduced pressure. The yield of the coupling was 82% as determined by the Fmoc-
test (page 178). A capping (page 178) was performed to ensure a final loading of 
0.58 mmol/g. 
 General procedure for ethyl-3-[peptidyl-Q]-(E)-propenoates, route B.  
All compounds were obtained by building the corresponding peptide chain 
onto the loaded resin 28 (48 mg, 0.025 mmol/well) by automated standard SPPS. 
After N-terminal Fmoc deprotection, all compounds were acetylated on their 
N-termini as described in page 178, unless otherwise stated. Simultaneous cleavage 
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and side chain deprotection was achieved using the standard method (page 179). 
The crude peptidyl derivatives were obtained after addition of cold TBME and 
evaporation of the solvent mixture. The crude peptides were purified by RP-HPLC, 
and the final products were obtained after lyophilisation according to the previously 
described methods (page 180).  
Ethyl-3-[Ac-PAKQ]-(E)-propenoate (15). TFA salt obtained as a very pale 
yellow glassy solid (79% yield from resin 27). Rt = 10.4 min (2–98% MeCN in 
H2O over 25 min), purity > 98%; full characterisation of this compound can be 
found on page 189.  
Ethyl-3-[Tos-PAKQ]-(E)-propenoate (32). The corresponding pre-swelled 
N-deprotected peptidyl-resin (48 mg, 0.025 mmol) in DMF (1 mL) was capped by 
adding p-toluenesulphonyl chloride (48 mg, 0.25 mmol) and DIPEA (44 µL, 
0.25 mmol) and shaking the reaction mixture for 3h. The resin was then washed, 
dried and the peptide was cleaved from the resin and purified to afford the TFA salt 
of 32 as a colourless glassy solid (42% yield from resin 27). Rt = 10.4 min (2–98 
MeCN in H2O over 16 min), purity 96%; δH/ppm (400 MHz, CD3OD) 1.27 (3H, t, J 
= 7.1, Et-2), 1.46 (3H, d, J = 7.2, Aβ), 1.40–1.52 (1H, m, Kγ), 1.53–1.62 (3H, m, Pγ 
and Kγ), 1.67 (2H, m, Kδ), 1.80 (1H, m, Kβ), 1.44–2.10 (6H, m, Pγ, Kβ, Qβ and 
Pβ), 2.32 (2H, t, J = 7.2, Qγ), 2.46 (3H, s, Tos-CH3), 2.93 (2H, m, Kε), 3.23 (1H, 
m, Pδ), 3.65 (1H, m, Pδ), 3.98 (1H, dd, J = 5.4 and 8.0, Pα), 4.18 (2H, q, J = 7.1, 
Et-1), 4.30 (1H, m, Aα), 4.39 (1H, m, Kα), 4.56 (1H, m, Qα), 5.94 (1H, d, J = 15.7, 
=CHCO2Et), 6.88 (1H, dd, J = 15.7 and 5.2, Qα-CH=), 7.48 (2H, d, J = 8.3, Tos-3), 
7.78 (2H, d, J = 8.3, Tos-2), 7.82 (1H, d, J = 7.4, NH-Kα), 7.99 (1H, d, J = 8.4, 
NH-Qα), 8.52 (1H, d, J = 6.4, NH-Aα); m/z, NMS (MALDI) 651 ([M + H]+), 
HRMS (ESI) found 651.3198 (C30H47N6O8S, [M + H]
+
, requires 651.3176). 
Ethyl-3-[Bn-PAKQ]-(E)-propenoate (33). The corresponding pre-swelled 
N-deprotected peptidyl-resin (48 mg, 0.025 mmol) in DMF (1 mL) was capped by 
adding benzyl bromide (30 µL, 0.25 mmol) and DIPEA (44 µL, 0.25 mmol) and 
shaking the reaction mixture for 3h. The resin was then washed, dried and the 
peptide was cleaved from the resin and purified to afford the TFA salt of 33 as a 
pale yellow glassy solid (63% yield from resin 27). Rt = 8.6 min (2–98 MeCN in 
H2O over 16 min), purity 97%; δH/ppm (400 MHz, CD3OD) 1.24 (3H, d, J = 7.3, 
Aβ), 1.27 (3H, t, J = 7.1, Et-2), 1.44 (2H, m, Kγ), 1.68 (2H, m, Kδ), 1.63–1.89 (m, 
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3H, Kβ, and Qβ), 1.91–2.13 (3H, m, Qβ, Pγ and Pβ), 2.20 (1H, m, Pγ), 2.28 (2H, m, 
Qγ), 2.55 (1H, m, Pβ), 2.92 (2H, m, Kε), 3.36 (1H, m, Pδ), 3.70 (1H, m, Pδ), 4.10 
(1H, q, J = 7.2, Aα), 4.18 (3H, q, J = 7.1, Et-1), 4.21 (2H, m, Pα and Kα), 4.35 (1H, 
d, J =12.8, Bn-CH2), 4.46 (1H, d, J = 12.8, Bn-CH2), 4.51 (1H, m, Qα), 5.90 (1H, 
dd, J =15.7 and 1.6, =CHCO2Et), 6.85 (1H, dd, J = 15.7 and 5.6, Qα-CH=), 7.41–
7.54 (5H, m, Bn-Ar), 8.14 (1H, d, J = 6.9, NH-Kα), 8.25 (1H, d, J = 8.2, NH-Qα), 
8.43 (1H, d, J = 7.5, NH-Aα); m/z, NMS (MALDI) 587 ([M + H]+), HRMS (ESI) 
found 587.3534 (C30H47N6O6, [M + H]
+
, requires
 
587.3557). 
Ethyl-3-[Bz-PAKQ]-(E)-propenoate (34). The corresponding pre-swelled 
N-deprotected peptidyl-resin (48 mg, 0.025 mmol) in DMF (1 mL) was capped by 
adding benzoic anhydride (58 mg, 0.25 mmol) and a catalytic amount of DMAP 
and shaking the mixture for 1.5 h. The resin was then washed, dried and the peptide 
was cleaved from the resin and purified (according to the previously described 
methods page 179) to afford the TFA salt of 34 as a pale yellow glassy solid (67% 
yield from resin 27). Rt = 9.4 min (2–98% MeCN in H2O over 16 min), purity 
> 98%; δH/ppm (400 MHz, CD3OD) 1.27 (3H, t, J = 7.1, Et-2), 1.40 (2H, m, Kγ), 
1.44 (3H, d, J = 7.1, Aβ), 1.59 (2H, m, Kδ), 1.35–2.11 (7H, m, Kβ, Qβ, Pγ and Pβ), 
2.23–2.45 (3H, m, Qγ and Pβ), 2.82 (2H, m, Kε), 3.59 (1H, m, Pδ), 3.74 (1H, m, 
Pδ), 4.18 (2H, q, J = 7.1, Et-1), 4.24–4.42 (2H, m, Kα and Aα), 4.47–4.50 (2H, m, 
Qα and Pα), 5.92 (1H, dd, J = 15.7 and 1.6, =CHCO2Et), 6.86 (1H, dd, J = 15.7 and 
5.4, Qα-CH=), 7.36–7.56 (3H, m, Ph-3 and 4), 7.64 (2H, m, Ph-2), 8.04 (1H, d, J = 
8.3, NH-Qα), 8.08 (1H, d, J = 6.4, NH-Kα), 8.24 (1H, d, J = 5.7, NH-Aα); m/z, 
NMS (MALDI) 601 ([M + H]
+
), HRMS (ESI) found 601.3350 (C30H45N6O7, [M + 
H]
+
, requires 601.3350). 
Ethyl-3-[Bz-AKQ]-(E)-propenoate (35). TFA salt obtained as a pale yellow 
glassy solid (27% yield from resin 27). Rt = 9.8 min (2–98% MeCN in H2O over 
16 min), purity > 98%; δH/ppm (500 MHz, CD3OD) 1.28 (3H, t, J = 7.1, Et-2), 
1.43–1.58 (2H, m, Kγ), 1.50 (3H, d, J = 7.2, Aβ), 1.69 (2H, m, Kδ), 1.73–1.94 (3H, 
m, Kβ and Qβ), 2.00 (1H, m, Qβ), 2.22–2.35 (2H, m, Qγ), 2.93 (2H, m, Kε), 4.18 
(2H, q, J = 7.1, Et-1), 4.37 (1H, m, Kα), 4.48 (1H, q, J = 7.2, Aα), 4.54 (1H, m, 
Qα), 5.92 (1H, dd, J = 15.7 and 1.6, =CHCO2Et), 6.87 (dd, J = 15.7 and 5.6, Qα-
CH=), 7.47 (2H, app t, J = 7.9, Ph-3), 7.56 (1H, t, J = 7.4, Ph-4), 7.88 (2H, d, J = 
7.5, Ph-2), 8.25 (1H, d, J = 8.2, NH-Qα), 8.36 (1H, d, J = 7.3, NH-Kα), 8.62 (1H, 
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d, J = 5.6, NH-Aα); m/z, NMS (MALDI) 503 ([M]+), HRMS (ESI) found 504.2825 
(C25H38N5O6, [M + H]
+
, requires 504.2822). 
Ethyl-3-[Ac-PAGQ]-(E)-propenoate (36). Obtained as a colourless glassy 
solid (60% yield from resin 27). Rt = 8.7 min (2–98% MeCN in H2O over 16 min), 
purity > 98%; δH/ppm (400 MHz, CD3OD) 1.27 (3H, t, J = 7.1, Et-2), 1.40 (3H, d, J 
= 7.2, Aβ), 1.84 (1H, m, Qβ), 1.74–2.38 (4H, m, Qβ, Pβ and Pγ), 2.10 (3H, s, Ac), 
2.18–2.35 (3H, m, Qγ and Pβ), 3.64 (2H, m, Pδ), 3.80 (1H, d, J = 16.9, Gα), 3.96 
(1H, d, J = 16.9, Gα), 4.14–4.26 (3H, m, Et-1 and Aα), 4.35 (1H, m, Pα), 4.55 (1H, 
m, Qα), 5.95 (1H, d, J = 15.7, =CHCO2Et), 6.87 (1H, dd, J = 15.7 and 5.6, Qα-
CH=); m/z, NMS (ESI) 490 ([M + Na]
+
), HRMS (ESI) found 468.2451 
(C21H34N5O7, [M + H]
+
, requires 468.2458). 
Ethyl-3-[Ac-PAEQ]-(E)-propenoate (37). Obtained as an off-white solid (37% 
yield from resin 27). Rt = 8.7 min (2–98% MeCN in H2O over 16 min), purity 
> 98%; δH/ppm (400 MHz, CDCl3) 1.24 (3H, t, J = 7.1, Et-2), 1.36 (3H, d, J = 7.2, 
Aβ), 1.81 (2H, m, Qβ), 1.94–2.16 (5H, m, Eβ, Pβ and Pγ), 2.09 (3H, s, Ac), 2.17–
2.34 (3H, m, Qγ and Pβ), 2.33–2.53 (2H, m, Eγ), 3.47 (1H, m, Pδ), 3.65 (1H, m, 
Pδ), 4.14 (2H, q, J = 7.1, Et-1), 4.25 (1H, q, J = 7.2, Aα), 4.34 (1H, m, Eα), 4.42 
(1H, m, Pα), 4.55 (1H, m, Qα), 5.87 (1H, d, J = 15.7, =CHCO2Et), 6.81 (1H, dd, J 
= 15.7 and 5.6, Qα-CH=), 7.35 (1H, d, J = 8.3, NH-Qα), 7.55 (1H, d, J = 8.2, NH-
Eα), 7.79 (1H, d, J = 6.1, NH-Aα); m/z, NMS (ESI) 540 ([M + H]+), HRMS (ESI) 
found 540.2676 (C24H38N5O9, [M + H]
+
, requires 540.2670). 
Ethyl-3-[Ac-PAK(Ac)Q]-(E)-propenoate (38). Obtained as a white solid (21% 
yield from resin 27). Rt = 8.9 min (2–98% MeCN in H2O over 16 min), purity 
> 98%; δH/ppm (400 MHz, CD3OD) 1.27 (3H, t, J = 7.1, Et-2), 1.40 (3H, d, J = 7.2, 
Aβ), 1.33–1.44 (2H, m, Kγ), 1.51 (2H, m, Kδ), 1.67–1.94 (4H, m, Qβ and Kβ), 1.92 
(3H, s, K-Ac), 1.94–2.08 (3H, m, Pγ and Pβ), 2.11 (3H, s, Ac-Nt), 2.19–2.34 (3H, 
m, Pβ and Qγ), 3.15 (2H, m, Kε), 3.59 (1H, m, Pγ), 3.70 (1H, m, Pγ), 4.17 (2H, q, J 
= 7.1, Et-1) 4.21–4.37 (3H, m, Kα, Aα and Pα), 4.51 (1H, m, Qα), 5.91 (1H, d, J = 
15.7, =CHCO2Et), 6.86 (1H, dd, J = 15.7 and 5.6, Qα-CH=); m/z, NMS (ESI) 603 
([M + Na]
+
), HRMS (ESI) found 581.3301 (C27H45N6O8, [M + H]
+
, requires 
581.3299).  
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Ethyl-3-[Ac-PAQQ]-(E)-propenoate (39). Obtained as a colourless gummy 
solid (60% yield from resin 27). Rt = 8.4 min (2–98% MeCN in H2O over 16 min), 
purity > 98%; δH/ppm (400 MHz, CDCl3) 1.19 (3H, t, J = 7.1, Et-2), 1.33 (3H, d, J 
= 7.2, Aβ), 1.77 (1H, m, QβP1),1.85–2.08 (5H, m, Pγ, QβP1 and QβP2), 2.03 (3H, s, 
Ac), 2.07–2.32 (6H, m, Pβ, QγP1 and QγP2), 3.45 (1H, m, Pδ), 3.62 (1H, m, Pδ), 
4.09 (2H, q, J = 7.1, Et-1), 4.19 (1H, q, J = 7.2, Aα), 4.18–4.34 (2H, m, Pα and 
QαP2), 4.47 (1H, m, QαP1), 5.80 (1H, d, J = 15.6, =CHCO2Et), 6.76 (1H, dd, J = 
15.6 and 5.2, Qα-CH=), 7.52 (1H, d, J = 7.7, NH-QαP1), 7.62 (1H, d, J = 7.4, NH-
QαP2), 7.93 (1H, d, J = 6.8, NH-Aα); m/z, NMS (ESI) 561 ([M + Na]
+
), HRMS 
(ESI) found 539.2841 (C24H39N6O8, [M + H]
+
, requires 539.2829). 
Ethyl-3-[Ac-PAHQ]-(E)-propenoate (40). TFA salt obtained as a colourless 
glassy solid (79% yield from resin 27). Rt = 11.8 min (2–98% MeCN in H2O over 
30 min), purity > 98%; δH/ppm (400 MHz, CD3OD) 1.27 (3H, t, J = 7.1, Et-2), 1.34 
(3H, d, J = 7.2, Aβ), 1.87 (1H, m, Qβ), 1.91–2.09 (4H, m, Qβ, Pβ and Pγ), 2.12 
(3H, s, Ac), 2.27 (1H, m, Pβ), 2.30 (2H, t, J = 7.6, Qγ), 3.13–3.42 (2H, m, Hβ), 3.62 
(1H, m, Pδ), 3.69 (1H, m, Pδ), 4.12–4.26 (3H, m, Et-1 and Aα), 4.33 (1H, m, Pα), 
4.53 (1H, m, Qα), 4.62 (1H, m, Hα), 5.84 (1H, d, J =15.7, =CHCO2Et), 6.83 (1H, 
dd, J = 15.7 and 5.6, Qα-CH=), 7.35 (1H, s, Hδ), 8.80 (1H, s, Hδ); m/z, NMS (ESI) 
548 ([M + H]
+
), HRMS (ESI) found 548.2835 (C25H38N7O7, [M + H]
+
, requires 
548.2833). 
Ethyl-3-[Ac-PARQ]-(E)-propenoate (41). Cleavage from the corresponding 
extra-dry peptidyl-resin (48 mg, 0.025 mmol) was achieved upon treatment with 
TFA–Thioanisole-phenol-H2O-EDT-TIS (81.5:5:5:2.5:1) deprotection mixture 
(1 mL) for 3 h. Addition of cold TBME, evaporation of the solvent mixture and 
purification (according to the previously described methods page 180) afforded the 
TFA salt of 41 as a pale yellow glassy solid (35% yield from resin 27). Rt = 8.6 min 
(2–98% MeCN in H2O over 16 min), purity > 98%; δH/ppm (400 MHz, CD3OD) 
1.27 (3H, t, J = 7.1, Et-2), 1.41 (3H, d, J = 7.2, Aα), 1.57–1.73 (2H, m, Rγ), 1.74–
1.94 (4H, m, Rβ and Qβ), 1.94–2.08 (3H, m, Pγ and Pβ), 2.12 (3H, s, Ac), 2.20–
2.34 (1H, m, Pβ), 2.30 (2H, t, J = 7.8 Qγ), 3.21 (2H, td, J = 6.9 and 2.5, Rδ), 3.50–
3.76 (2H, m, Pδ), 4.18 (2H, q, J = 7.1, Et-1), 4.27 (1H, q, J = 7.2, Aα), 4.32 (1H, m, 
Rα), 4.36 (1H, m, Pα), 4.53 (1H, m, Qα), 5.92 (1H, d, J = 15.7, =CHCO2Et), 6.86 
(1H, dd, J = 15.7 and 5.6, Qα-CH=), 7.99 (1H, d, J = 8.3, NH-Rα), 8.03 (1H, d, J = 
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7.6, NH-Qα), 8.33 (1H, d, J = 4.7, NH-Aα); m/z, NMS (MALDI) 566 ([M]+), 
HRMS (ESI) found 567.3232 (C25H43N8O7, [M + H]
+
, requires 567.3255). 
Ethyl-3-[Ac-PAOQ]-(E)-propenoate (42). The TFA salt obtained as pale 
yellow gluey solid (74% yield from resin 27). Rt = 8.2 min (2–98% MeCN in H2O 
over 16 min), purity > 98%; δH/ppm (500 MHz, CD3OD) 1.27 (3H, t, J = 7.1, Et-2), 
1.41 (3H, d, J = 7.2, Aβ), 1.74 (2H, m, Oγ), 1.78–1.92 (3H, m, Qβ and Oβ), 1.92–
2.06 (4H, m, Qβ, Pγ and Pβ), 2.12 (s, 3H, Ac), 2.21–2.33 (3H, m, Qγ and Pβ), 2.96 
(2H, m, Oδ), 3.61 (1H, m, Pδ), 3.69 (1H, m, Pδ), 4.18 (2H, q, J = 7.1, Et-1), 4.27 
(1H, q, J = 7.2, Aα), 4.30–4.38 (2H, m, Oα and Pα), 4.53 (1H, m, Qα), 5.92 (1H, 
dd, J = 15.7 and 1.6, =CHCO2Et), 6.86 (1H, dd, J = 15.7 and 5.6, Qα-CH=); m/z, 
NMS (MALDI) 524 ([M]
+
), HRMS (ESI) found 525.3036 (C24H41N6O7, [M + H]
+
, 
requires 525.3037).  
Ethyl-3-[Ac-PABQ]-(E)-propenoate (43). Obtained as TFA salt a pale yellow 
glassy solid (51% yield from resin 27). Rt = 8.3 min (2–98% MeCN in H2O over 
16 min), purity > 98%; δH/ppm (500 MHz, CD3OD) 1.27 (3H, t, J = 7.1, Et-2), 1.41 
(3H, d, J = 7.2, Aα), 1.88 (1H, m, Qβ), 1.94–2.03 (3H, m, Pγ and Qβ), 2.03–2.15 
(2H, m, Pβ and Bβ), 2.12 (3H, s, Ac), 2.19–2.32 (2H, m, Pβ and Bβ), 2.30 (2H, t, J 
= 7.1, Qγ), 3.04 (2H, m, Bγ), 3.57–3.75 (2H, m, Pδ), 4.18 (2H, q, J = 7.1, Et-1), 
4.24 (1H, q, J = 7.2, Aα), 4.33 (1H, m, Bα), 4.41 (1H, m, Pα), 4.54 (1H, m, Qα), 
5.92 (1H, dd, J = 15.7 and 1.6, =CHCO2Et), 6.86 (1H, dd, J = 15.7 and 5.6, Qα-
CH=); m/z, NMS (MALDI) 510 ([M]
+
), HRMS (ESI) found 511.2854 
(C23H39N6O7, [M + H]
+
, requires 511.2880). 
Ethyl-3-[Bz-AOQ]-(E)-propenoate (57). TFA salt obtained as a colourless 
glassy solid (31% yield from resin 27). Rt = 10.4 min (2–98% MeCN in H2O over 
16 min), purity > 98%; δH/ppm (400 MHz, CD3OD) 1.28 (3H, t, J = 7.1, Et-2), 1.51 
(3H, d, J = 7.2, Aβ), 1.68–1.90 (4H, m, Qβ, Oβ and Oγ), 1.88–2.05 (2H, m, Qβ and 
Oβ), 2.27 (2H, t, J = 7.8, Qγ), 2.97 (2H, t, J = 7.0, Oδ), 4.18 (2H, q, J = 7.1, Et-1), 
4.40 (1H, m, Oα), 4.46 (1H, q, J = 7.2, Aα), 4.54 (1H, m, Qα), 5.93 (1H, d, J =15.7, 
=CHCO2Et), 6.87 (1H, dd, J = 15.7 and 5.6, Qα-CH=), 7.47 (2H, app t, J = 7.3–7.7 
Ph-3), 7.56 (1H, t, J = 7.5, Ph-4), 7.88 (2H, d, J = 8.0 Ph-2), 8.25 (1H, d, J = 8.2, 
NH-Qα), 8.36 (1H, d, J = 7.3, NH-Oα), 8.62 (1H, d, J = 5.6, NH-Aα); m/z, NMS 
(MALDI) 489 ([M]
+
), HRMS (ESI) found 490.2664 (C24H36N5O6, [M + H]
+
, 
requires 490.2666). 
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Ethyl-3-[Bz-ARQ]-(E)-propenoate (58). Cleavage from the corresponding 
extra-dry peptidyl-resin (48 mg, 0.025 mmol) was achieved upon treatment with 
TFA–Thioanisole-phenol-water-EDT-TIS (81.5:5:5:2.5:1) deprotection mixture 
(1 mL) for 3 h. Addition of cold TBME, evaporation of the solvent mixture and 
purification afforded the TFA salt of 58 as a pale yellow glassy solid (17% yield 
from resin 27). Rt = 10.6 min (2–98% MeCN in H2O over 16 min), purity > 98%; 
δH/ppm (400 MHz, CD3OD) 1.27 (3H, t, J = 7.1, Et-2), 1.50 (3H, d, J = 7.2, Aβ), 
1.70 (2H, m, Rγ), 1.80 (2H, m, Rβ), 1.85–2.07 (2H, m, Qβ), 2.27 (2H, m, Qγ), 3.22 
(2H, m, Rδ), 4.18 (2H, q, J = 7.1, Et-1), 4.37 (1H, m, Rα), 4.49 (1H, q, J = 7.2, Aα), 
4.54 (1H, m, Qα), 5.93 (1H, d, J = 15.7, =CHCO2Et), 6.87 (1H, dd, J =15.7 and 5.6, 
Qα-CH=), 7.47 (2H, m, Ph-3), 7.55 (1H, m, Ph-4), 7.88 (2H, m, Ph-2), 8.25 (1H, d, 
J = 8.2, NH-Qα), 8.32 (1H, d, J = 7.3, NH-Rα), 8.60 (1H, d, J = 6.0, NH-Aα); m/z, 
NMS (MALDI) 531 ([M]
+
), HRMS (ESI) found 532.2879 (C25H38N7O6, [M + H]
+
, 
requires 532.2884). 
N-Methoxy-N-methyl-3-[Ac-PAKQ]-(E)-propenamide (59). TFA salt obtained 
as a colourless glassy solid (45% yield from resin 27). Rt = 7.7 min (2–98% MeCN 
in H2O over 16 min), purity 97%; δH/ppm (500 MHz, CD3OD) 1.40 (3H, d, J = 7.1, 
Aβ), 1.49 (2H, m, Kγ), 1.69 (2H, m, Kδ), 1.77–1.95 (3H, m, Kβ and Qβ), 1.94–2.08 
(4H, m, Pβ, Qβ and Pγ), 2.12 (3H, s, Ac), 2.20–2.38 (3H, m, Pβ and Qγ), 2.93 (2H, 
m, Kε), 3.24 (3H, s, NMe), 3.62 (1H, m, Pδ), 3.71(1H, m Pδ), 3.74 (3H, s, OMe), 
4.25 (1H, m, Aα), 4.30 (1H, m, Kα), 4.32 (1H, m, Pα), 4.56 (1H, m, Qα), 6.57 (1H, 
d, J = 15.5, =CHCON(OMe)Me), 6.79 (1H, dd, J = 15.5 and 5.5, Qα-CH=); m/z, 
NMS (MALDI) 554 ([M + H]
+
), HRMS (ESI) found 554.3302 (C25H38N7O7, [M + 
H]
+
, requires 554.3302). 
 Preparation of guanidino derivatives  
The method was adapted from (Yong et al., 1997).  
Ethyl-3-[Ac-PAhR(Boc)2Q]-(E)-propenoate (47). To a solution of amine (15) 
(7.2 mg, 0.014 mmol), N,N′-bis(tert-butoxycarbonyl)thiourea (7 mg, 0.027 mmol) 
and triethylamine (6.5 µL, 0.045 mmol) in DCM (100 µL) was added Mukaiyama‘s 
reagent (7.0 mg, 0.027 mmol). The reaction was allowed to stir at room temperature 
until disappearance of the starting material as judged by HPLC (4 h of reaction 
time). DCM (200 µL) was then added to the reaction mixture and was washed with 
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water (3 × 200 µL). The organic layer was then evaporated and the crude recovered 
and purified by RP-HPLC to afford 47, as a colourless gluey solid, which was 
partially deprotected as judged by HPLC and NMR, (4.5 mg, 41%). Rt = 12.2 min 
(47-Boc, 25%) and 15.6 min (47, 75%) (2–98% MeCN in H2O over 30 min); m/z, 
NMS (MALDI) 580 ([M – Boc – Boc + H]+). 
Ethyl-3-[Ac-PAhRQ]-(E)-propenoate (48). Deprotection mixture TFA–H2O–
TIS, 95:2.5:2.5, (200 µL) was added to compound 47 (4.5 mg) and the resulting 
solution was stirred for 1.5 h. After addition of cold TMBE the solvent mixture was 
evaporated and the crude was purified by RP-HPLC (according to the previously 
described methods page 180) to afford the TFA salt of 48 as a pale yellow glassy 
solid (2.3 mg, 61% yield). Rt = 8.7 min (2–98% MeCN in H2O over 16 min), purity 
> 98%; δH/ppm (500 MHz, CD3OD) 1.28 (3H, t, J = 7.2, Et-2), 1.40 (3H, d, J = 7.3, 
Aβ), 1.45 (2H, m, hRγ), 1.62 (2H, m, hRδ), 1.68–1.93 (3H, m, hRβ and Qβ), 1.94–
2.07 (4H, m, Pγ, Pβ and Qβ), 2.11 (3H, s, Ac), 2.19–2.38 (3H, m, Qγ and Pβ), 3.18 
(2H, m, hRε), 3.61 (1H, m, Pδ), 3.68 (1H, m, Pδ), 4.18 (2H, q, J = 7.2, Et-1), 4.27 
(1H, q, J = 7.3, Aα), 4.30 (1H, m, hRα), 4.36 (1H, m, Pα), 4.52 (1H, m, Qα), 5.91 
(1H, dd, J = 15.7 and 1.6, =CHCO2Et), 6.86 (1H, dd, J = 15.7 and 5.4, QαCH=); 
δC/ppm (125 MHz, CD3OD) 14.8 (Et-2), 17.3 (Aβ), 22.7 (Ac), 24.1 (hRγ), 26.0 
(Pγ), 29.3 (hRδ), 30.7 (Pβ), 31.2 (Qβ), 32.3 (hRβ), 32.8 (Qγ), 42.4 (hRε), 49.7 (Pδ), 
51.3 (Aα), 51.4 (Qα), 54.8 (hRα), 61.8 (Et-1), 62.1 (Pα), 122.4 (=CHCO2Et), 148.7 
(QαCH=), 158.8 (NH-C(NH)=NH), 168.0 (CO2Et), 173.0 (CO), 174.0 (CO), 175.4 
(CO), 175.5 (CO), 178.0 (CONH2); m/z, NMS (MALDI) 581 ([M + H]
+
), HRMS 
(ESI) found 581.3411 (C26H45N8O7, [M + H]
+
, requires 581.3411). 
Ethyl-3-[Ac-PAnR(Boc)2Q]-(E)-propenoate (71). To a solution of amine (43, 
6.1 mg, 0.012 mmol), N,N′-bis(tert-butoxycarbonyl)thiourea (4.2 mg, 0.014 mmol) 
and triethylamine (3.3 µL, 0.024 mmol) in DCM (100 µL) was added Mukaiyama‘s 
reagent (3.7 mg, 0.014 mmol). The reaction was allowed to stir at room temperature 
until consumption of the starting material as judged by HPLC (3.5 h reaction time). 
DCM (200 µL) was then was added to the reaction mixture and was washed with 
water (3 × 200 µL) and the organic layer was evaporated and the crude peptide was 
used without further purification. Rt = 12.5 min (2–98% MeCN in H2O over 
16 min); m/z, NMS (MALDI) 552 ([M – Boc – Boc + H]+).  
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Ethyl-3-[Ac-PAnRQ]-(E)-propenoate (53). Deprotection mixture (TFA–H2O–
TIS, 95:2.5:2.5, 200 µL) was added to crude 71 and the resulting solution was 
stirred for 1.5 h at room temperature The solvent was evaporated and the crude was 
then purified by RP-HPLC to afford the TFA salt of 53 as a colourless glassy solid 
(3.2 mg, 40% yield from 43). Rt = 8.6 min (2–98% MeCN in H2O over 16 min), 
purity > 98%; δH/ppm (500 MHz, CD3OD) 1.27 (3H, t, J = 7.2, Et-2), 1.42 (3H, d, J 
= 7.3, Aβ), 1.89 (1H, m, Qβ), 1.93–2.08 (5H, m, nRβ, Pβ, Pγ and Qβ), 2.12 (3H, s, 
Ac), 2.15 (1H, m, nRβ), 2.23–2.33 (3H, m, Pβ and Qγ), 3.21–3.37 (2H, m, nRγ), 
3.63 (1H, m, Pδ), 3.69 (1H, m, Pδ), 4.18 (2H, q, J = 7.2, Et-1), 4.23 (1H, q, J = 7.3, 
Aα), 4.34 (1H, m, Pα), 4.39 (1H, m, nRα), 4.53 (1H, m, Qα), 5.92 (1H, dd, J = 15.7 
and 1.7, =CHCO2Et), 6.86 (1H, dd, J = 15.7 and 5.5, QαCH=); δC/ppm (125 MHz, 
CD3OD) 14.7 (Et-2), 16.9 (Aβ), 22.7 (Ac), 26.0 (Pγ), 30.6 (nRβ), 31.1 (Pβ), 32.2 
(Qβ), 32.8 (Qγ), 39.6 (nRγ), 49.6 (Pδ), 51.5 (Qα), 51.7 (Aα), 52.6 (nRα), 61.8 (Et-
1), 62.2 (Pα), 122.4 (=CHCO2Et), 148.6 (QαCH=), 158.8 (NH-C(NH)=NH), 168.0 
(CO2Et), 173.2 (CO), 173.3 (CO), 175.6 (CO), 175.7 (CO), 178.0 (CONH2); m/z, 
NMS (MALDI) 553 ([M + H]
+
); HRMS (ESI) found 553.3081 (C24H41N8O7, [M + 
H]
+
, requires 553.3098). 
 Preparation of N-hydroxyguanidino derivatives  
The method was adapted from (Martin et al., 2006) and required the 
preparation of N-Cbz-isothiocyanate (50) (see below). The representative protocol 
is presented for the synthesis of compound 49. Compounds 54, 55 and 56 were 
obtained following the exact protocol adapted to the different amounts of starting 
materials.  
N-Cbz-Isothiocyanate (50). Compound 50 was obtained following the 
previously described method (Martin et al., 2006). Potassium isothiocyanate (2 g, 
23 mmol), stirred vigorously in tetrachloroethene (50 mL), was treated with 
18-crown-6 (241 mg, 1.15 mmol) and benzyl chloroformate (2.6 mL, 17.3 mmol). 
The flask was fitted with a condenser and the mixture warmed to 85 °C overnight 
and complete consumption of the benzyl chloroformate was confirmed by TLC 
analysis (Rf = 0.57, DCM–Hx, 1:1). The mixture was then diluted in hexane 
(50 mL) and cooled on ice, which lead to the formation of a suspension. The 
suspension was filtered though celite and washed with DCM–Hx, 1:1. The solvent 
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of the filtrate was removed under vacuum and compound 50 was obtained as a 
bright yellow oil which solidified upon standing (3.5 g, 70% yield). NMR analysis 
of this material indicated that the desired product 50 (Linton et al., 2000) was 
present in major proportion along with traces of side products (benzyl thiocyanate 
and benzyl isothiocyante) and crown ether. These impurities were found not to 
interfere in the subsequent use of CbzNCS and were easily removed during the later 
RP-HPLC purification of the final N-hydroxyguanidine products. Rf = 0.45 (DCM–
Hx, 1:1); mp 41–43 °C; δH/ppm (400 MHz, CDCl3) 5.05 (2H, s, PhCH2O), 7.15–
7.32 (5H, m, Ph); δC/ppm (100 MHz, CD3Cl) 70.5 (CH2), 128.6 (Ph-2 and 6), 128.6 
(Ph-3 and 5), 128.9 (Ph-4), 133.9 (Ph-1), 147.0 (NCS), 149.5 (NCO2); m/z, NMS 
(ESI) 194 ([M + H]
+
). 
Ethyl-3-[Ac-PAhR(OH)Q]-(E)-propenoate (49). CbzNCS (55 µL of a 0.5 M 
solution in DCM, 0.02 mmol) was added to a solution of primary amine 15 
(12.8 mg, 0.02 mmol) and triethylamine (3 µL, 0.02 mmol) in DCM (0.4 mL). 
Once the amine was completely consumed as judged by HPLC (usually after 2 h), 
intermediate thiourea was treated directly with EDCI (3.8 mg, 0.02 mmol), 
triethylamine (3 μL, 0.02 mmol) and H2N-OTHP (2.4 mg, 0.02 mmol). The 
reaction was followed by HPLC. To drive the reaction to completion additional 
half-equivalents of EDCI, triethylamine and H2N-OTHP, were added at 30 minute 
intervals until complete consumption of the intermediate was observed on the 
HPLC trace (typically 2.5 h). The reaction mixture was partitioned with H2O 
(0.5 mL) and the solvent of the organic layer was removed under N2 pressure. RP-
HPLC purification of the fully protected guanidino derivative (Rt = 11.7 min, 2–
98% MeCN in H2O over 16 min) yielded to a mixture with the partially deprotected 
product (Rt = 10.5 min, 2–98% MeCN in H2O over 16 min) due to the presence of 
0.1% TFA in the solvent system. A deprotection mixture of TFA (778 μL, 
10 mmol) and thioanisole (117 μL, 1 mmol) was then added to the mixture and the 
reaction was followed by HPLC. The solvent was evaporated upon disappearance 
of the partially protected intermediate (generally after 4 h). The solvent was 
evaporated and the crude was purified by RP-HPLC to afford the TFA salt of 49 as 
a colourless glassy solid (9.0 mg, 63% yield from 15). Rt = 8.5 min (2–98% MeCN 
in H2O over 16 min), purity > 98%; δH/ppm (400 MHz, DMSO-d6) 1.21 (3H, t, J = 
7.1, Et-2), 1.24 (3H, d, J = 7.1, Aβ), 1.20–1.34 (2H, m, hRγ), 1.47 (2H, m, hRδ), 
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1.54–1.78 (4H, m, Qβ and hRβ), 1.79–1.96 (3H, m, Pβ and Pγ), 1.99 (3H, s, Ac), 
2.01–2.10 (3H, m, Pβ and Qγ), 3.09 (2H, m, hRε), 3.50–3.62 (2H, m, Pδ), 4.11 (2H, 
q, J =7.1, Et-1), 4.09–4.20 (2H, m, Aα and hRα), 4.23 (1H, m, Pα), 4.39 (1H, m, 
Qα), 5.81 (1H, d, J = 15.7, =CHCO2Et), 6.76 (1H, bs, CONH2), 6.79 (1H, dd, J = 
15.7 and 5.5, QαCH=), 7.22 (1H, bs, CONH2), 7.64 (1H, bs, =NH), 7.73 (1H, d, J = 
8.2, NH-hRα), 7.83 (1H, d, J = 8.6, NH-Qα), 7.85 (1H, bs, hRε-NH), 8.14 (1H, d, J 
= 6.8, NH-Aα), 9.71 (1H, bs, NH-OH), 10.20 (1H, bs, OH); δC/ppm (125 MHz, 
CD3OD) 14.7 (Et-2), 17.4 (Aβ), 22.7 (Ac), 24.2 (hRγ), 26.0 (Pγ), 29.4 (hRδ), 30.6 
(Pβ), 31.2 (Qβ), 32.3 (hRβ), 32.8 (Qγ), 42.0 (hRε), 49.7 (Pδ), 51.3 (Qα), 51.5 (Aα), 
54.9 (hRα), 61.8 (Et-1), 62.2 (Pα), 122.4 (=CHCO2Et), 148.7 (QαCH=), 160.7 
(NHC(NH)=NH), 168.0 (CO2Et), 173.2 (CO), 173.8 (CO), 175.5 (CO), 175.6 
(CO), 178.0 (CONH2); m/z, NMS (MALDI) 597 ([M + H]
+
) and 581 ([M – OH + 
H]
+
), HRMS (ESI) found 597.3364 (C26H45N8O8, [M + H]
+
, requires 597.3360). 
Ethyl-3-[Ac-PAR(OH)Q]-(E)-propenoate (54). TFA salt obtained as a pale 
yellow glassy solid (47% yield from 42). Rt = 8.4 min. (2–98% MeCN in H2O over 
16 min), purity > 98%; δH/ppm (400 MHz, DMSO-d6) 1.20 (3H, t, J = 7.1, Et-2), 
1.24 (3H, d, J = 7.2, Aβ), 1.35–1.63 (5H, m, Rγ, Rβ and Qβ), 1.66–1.91 (4H, m, Pβ, 
Pγ and Qβ), 1.99 (3H, s, Ac), 2.00–2.11 (3H, m, Qγ and Pβ), 3.12 (2H, m, nRδ), 
3.46 (1H, m, Pδ), 3.56 (1H, m, Pδ), 4.11 (2H, q, J = 7.1, Et-1), 4.09–4.20 (2H, m, 
Aα and nRα), 4.23 (1H, m, Pα), 4.39 (1H, m, Qα), 6.77 (1H, bs, CONH2), 6.78 (1H, 
dd, J = 15.7 and 5.5, Qα-CH=), 7.21 (1H, bs, CONH2), 7.62 (1H, bs, =NH), 7.77 
(1H, d, J = 7.8, NH-nRα), 7.83 (1H, d, J = 8.0, NH-Qα), 7.84 (1H, bs, nRδ-NH), 
8.13 (1H, d, J = 6.8, NH-Aα), 9.70 (1H, bs, NH-OH), 10.19 (1H, bs, OH); δC/ppm 
(125 MHz, CD3OD) 14.7 (Et-2), 17.2 (Aβ), 22.8 (Ac), 26.0 (Pγ), 26.5 (Rγ), 29.9 
(Rβ), 30.8 (Pβ), 31.2 (Qβ), 32.8 (Qγ), 41.9 (Rδ), 49.9 (Pδ), 51.4 (Qα), 51.5 (Aα), 
54.6 (Rα), 61.8 (Et-1), 62.2 (Pα), 122.5 (=CHCO2Et), 148.6 (QαCH=), 160.6 
(NHC(NH)=NH), 168.0 (CO2Et), 173.1 (CO), 173.6 (CO), 175.4 (CO), 175.6 
(CO), 178.0 (CONH2); m/z, NMS (MALDI) 582 ([M]
+
); HRMS (ESI) found 
583.3231 (C25H43N8O8, [M + H]
+
, requires 583.3204). 
Ethyl-3-[Ac-PAnR(OH)Q]-(E)-propenoate (55). TFA salt obtained as a 
colourless glassy solid (29% yield from 43). Rt = 8.5 min (2–98% MeCN in H2O 
over 16 min), purity > 98%; δH/ppm (400 MHz, DMSO-d6) 1.20 (3H, t, J = 7.1, 
Et-2), 1.24 (3H, d, J = 7.2, Aβ), 1.33–1.65 (3H, m, Qβ and nRβ), 1.67–1.95 (4H, m, 
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nRβ, Pβ and Pγ), 1.99 (3H, s, Ac), 2.03–2.08 (3H, m, Qγ and Pβ), 3.08–3.26 (2H, 
m, nRγ), 3.40–3.60 (2H, m, Pδ), 4.10 (2H, q, J = 7.1, Et-1), 4.05–4.22 (m, 2H, Aα 
and nRα), 4.25 (1H, m, Pα), 4.39 (1H, m, Qα), 5.82 (1H, d, J = 15.7, Qα-CH=), 
6.77 (1H, bs, CONH2), 6.79 (1H, dd, J = 15.7 and 5.5, Qα-CH=), 7.23 (1H, bs, 
CONH2), 7.66 (1H, bs, =NH), 7.79 (1H, d, J = 7.8, NH-nRα), 7.75–7.85 (1H, bs, 
nRγ-NH), 7.87 (1H, d, J = 8.0, NH-Qα), 8.25 (1H, d, J = 6.8, NH-Aα), 9.74 (1H, 
bs, NH-OH), 10.25 (1H, bs, OH); δC/ppm (125 MHz, CD3OD) 14.7 (Et-2), 16.9 
(Aβ), 22.7 (Ac), 26.0 (Pγ), 30.5 (nRβ), 31.1 (Pβ), 32.2 (Qβ), 32.8 (Qγ), 39.4 (nRγ), 
49.8 (Pδ), 51.5 (Qα), 51.8 (Aα), 52.6 (nRα), 61.8 (Et-1), 62.3 (Pα), 122.5 
(=CHCO2Et), 148.5 (QαCH=), 160.7 (NHC(NH)=NH), 167.9 (CO2Et), 173.2 
(CO), 173.3 (CO), 175.6 (CO), 175.7 (CO), 178.0 (CONH2); m/z, NMS (MALDI) 
568 ([M]
+
); HRMS (ESI) found 569.3051 (C24H41N8O8, [M + H]
+
, 569.3047). 
Ethyl-3-[Bz-AR(OH)Q]-(E)-propenoate (56). TFA salt obtained as a pale 
yellow glassy solid (30% yield from 57). Rt = 10.5 min (2–98% MeCN in H2O over 
16 min), puritiy > 98%; δH/ppm (400 MHz, DMSO-d6) 1.21 (3H, t, J = 7.1, Et-2), 
1.36 (3H, d, J = 7.2, Aβ), 1.41–1.62 (3H, m, Rγ and Rβ), 1.63–1.84 (3H, m, Rβ and 
Qβ), 2.06 (2H, t, J = 7.8, Qγ), 3.14 (2H, t, J = 7.2, Rδ), 4.12 (2H, q, J = 7.1, Et-1), 
4.24 (1H, m, Rα), 4.35–4.48 (2H, m, Qα and Aα), 5.84 (1H, d, J = 15.8, 
=CHCO2Et), 6.76 (1H, s, CONH2), 6.79 (1H, dd, J = 15.8 and 5.7, QαCH=), 7.22 
(1H, bs, CONH2), 7.47 (2H, app t, J = 7.7, Ph-3), 7.55 (1H, t, J = 7.5 Ph-4), 7.62 
(bs, 1H, =NH), 7.85 (1H, bs, Rδ-NH), 7.89 (2H, d, J = 7.4, Ph-2), 8.02 (1H, d, J = 
8.2, NH-Qα), 8.06 (1H, d, J = 7.9, NH-Rα), 8.56 (1H, d, J = 6.7, NH-Aα), 9.71 
(1H, bs, NH-OH), 10.21 (1H, bs, OH); δC/ppm (125 MHz, CD3OD) 14.7 (Et-2), 
17.7 (Aβ), 26.5 (Rγ), 30.0 (Rβ), 30.7 (Qβ), 32.9 (Qγ), 42.1 (Rδ), 51.4 (Qα), 52.1 
(Aα), 54.6 (Rα), 61.8 (Et-1), 122.5 (=CHCO2Et), 128.8 (Ph-2), 129.7 (Ph-3), 133.2 
(Ph-4), 148.5 (QαCH=), 160.6 (NHC(NH)=NH), 167.9 (CO2Et), 170.7 (PhCO), 
173.6 (CO), 176.1 (CO), 177.9 (CONH2); m/z, NMS (MALDI) 547 ([M]
+
), HRMS 
(ESI) found 548.2830 (C25H38N7O7, [M + H]
+
, requires 548.2833).  
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 Note on the characterisation of N-hyroxylated guanidies 
Due to solubility issues and the requirement to recover the compounds 
synthesised for their evaluation against FMDV 3C
pro
 the NMR characterisation of 
most of the compounds synthesised was carried out in CD3OD. Whereas the amide 
protons could occasionally be identified in such spectra, the protons of primary 
amines and glutamine were never observed due to proton-deuterium exchange with 
the deuterated solvent used (CD3OD). Therefore, to monitor the transformation of 
the primary amines to the corresponding N-hydroxylated guanidine derivatives 
these compounds were further analysed by 
13
C-NMR and 
1
H-NMR with an aprotic 
solvent such as DMSO-d6. Figure 6.5 illustrates the modification of the primary 
amine in compound 57 to the corresponding N-hydroxylated guanidine in 
compound 56. 
The phenomenon of proton–deuterium exchange can be clearly observed 
comparing the 
1
H-NMR spectra for compound 57 in CD3OD and DMSO-d6. In 
deuterated methanol the signal of the backbone amide protons is very weak and no 
signal for Orn-NH3
+
 or Gln-CONH2 can be observed (Figure 6.5, A); in contrast, in 
deuterated DMSO each amide proton integrates for one and the protons for 
glutamine and ornithine can be clearly identified (Figure 6.5, B). In the spectra of 
the product of the guanidinylation (Figure 6.5, C) the Gln-CONH2 protons 
remained at the same position but the signal for Orn-NH shifted downfield and 
three new signals, corresponding to the OH and NH protons of the N-hydroxylated 
guanidino group, appeared. Therefore, it could be established that the modification 
through the synthetic routes described in section 4.2.2 (page 141) specifically 
occurred on the P2 position. 
 
 
Figure 6.5 Characterisation of N-hydroxyguanidines.  
Amplification of the 
1
H-NMR spectra at 400 MHz (next page) of compounds 57 and 56 (above). 
Compound 57 in CD3OD (A) and compounds 57 (B) and 56 (C) in DMSO-d6 DMSO-d6.  
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6.3 FMDV 3C
pro
 Enzymatic Assays 
6.3.1 General assay methods 
Recombinant FMDV 3C protease subtype A1061 was prepared as indicated in 
section 6.1. DMSO, DTT, EDTA, TCEP, glycerol and mono and di-basic sodium 
phosphate, were all purchased from Sigma-Aldrich. Ultrapure water (page 174) was 
used to prepare all solutions. 
Initial FRET substrate hydrolysis rates were determined using a Cytofluor 
Series 4000 microplate reader (PerSeptive Biosystem), with Titertek microtitration 
96-well plates. Fluorescence was always recorded at the absoption/emmission 
windows allowed by the plate reader closer to the fluorophore requirements. For 
both AMC and FRET substrates the windows used corresponded to 340–360 nm for 
sample irradiation and 440–460 nm for fluorescence detection. All assays were 
performed at 37 °C and pH 7.4 using a twelve channel multi-pipette (Finnpipette, 
from Labsystems). 
 Peptidyl and FMDV 3Cpro solutions  
Assay buffer solution. All peptide, fluorophores and enzyme working solutions 
were made up for every set of experiments by dissolving stock solutions into a fresh 
pH 7.4 buffer solution with sodium phosphate (0.1 M), TCEP (0.1 mM), EDTA 
(1 mM) and glycerol (5% v/v), ensuring that the final working solution contained 
less than 5% by volume of DMSO.  
Stock solutions. The stock solutions for the fluorophores, fluorogenic 
substrates and peptidyl inhibitors were kept at –20 °C. They were made by 
accurately weighing the dry mass of requisite compounds and adding the minimal 
amount of DMSO required to ensure solubility in the buffer solution. The FRET 
substrate (1) (1 mg) required the highest amount of DMSO (100 μL), resulting in a 
5 mM stock solution and the final concentration was confirmed by measuring its 
absorbance at 453 nm using εDABCYL 453nm = 32,000 M
–1
 cm
–1
. The stock solutions of 
FMDV 3C
pro
 A1061 mutants were kept at –80 °C straight after purification in small 
aliquots (generally 100 μL at 8 mg/mL, page 172).  
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Calibration of 3C protease enzyme concentration. Enzyme concentration was 
estimated from total amount of protein based on absorbance at 280 nm using the 
extinction coefficient determined from the sequence of the protease using 
ProtParam from EXPasY tools (Gasteiger et al., 2003). For Mutant A ε280nm = 
9200 M
–1
 cm
–1
 and for a MW = 23.032 kDa, Abs = 0.413 corresponds to a 0.1% 
solution of protein (= 1 g/L). Calibration of enzyme activity assays was achieved by 
identifying a concentration which gave a control value for initial rates of substrate 
hydrolysis: 6 AFU/min for Mutant A (0.6 μM) and FRET substrate 1 (50 μM). 
Then, as an internal control, the IC50 of compound 15 was determined for every 
new set of experiments and variation of the IC50 value was found within the 
standard error for the determination. 
6.3.2 Characterisation of AMC and FRET substrates 
 Calibration curves  
To establish the relationship between fluorescence of an assay solution and 
product concentration a calibration curve was determined for both AMC and FRET 
fluorogenic substrates. Fluorescence was recorded for 200 μL of twelve different 
concentrations in the range 0–100 μM of the intact substrates 1 and 2 and the 
corresponding free fluorophores (AMC-NH2 and EDANS-NH2). The fluorescence of 
the intact substrates provided the fluorescence background value at each substrate 
concentration. Increase of fluorescence with [EDANS-NH2] allowed a linear fit. The 
calibration curve for the protease activity assays was obtained from triplicates for 
the exact substrate working concentrations for every set of experiments providing 
the relationship AFU = slope [EDANS-NH2]/μM + background, with an R² of 
around 0.995.  
 Hydrolysis 
For the fluorogenic substrates 1 and 2 fluorescence was recorded for one hour 
after the addition of 100 μL of enzyme (0.6 μM) to 100 μL of fluorogenic substrate 
at four different concentrations (250, 200, 125 and 75 μM).  
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6.3.3 FRET hydrolysis assays 
Hydrolysis rates for the different 142 mutants (section 2.3.1, Figure 2.16) were 
determined as previously described (Sweeney et al., 2007). Dilutions of a fresh 
solution of FRET substrate (1) in assay buffer were performed on a microplate 
providing a range of 12 substrate concentrations (100 μL, 0–180 μM) and were 
incubated at 37 °C for 5 min. Subsequently 100 μL of a fresh enzyme solution in 
buffer (1.6 μM for Mutant T and Mutant S and 0.8 μM for Mutant A, Mutant L and 
Mutant V), also at 37 °C, was added to the different substrate concentrations. The 
increase in fluorescence units with time (AFU/min) was then recorded at 37 °C for 
30 minutes. Initial hydrolysis rates were obtained from the linear part of the 
hydrolysis curves (typically from 0–5 minutes) for each substrate concentration 
(Figure 2.8). Initial rates were corrected with the experimental correction factor 
(below) and transformed to concentration units (μM/s) using the calibration curve 
(above). Finally, the specificity constants (kcat/KM) for each mutant were calculated 
from triplicates by plotting the initial rates (v) against increasing substrate 
concentrations ([S]). Since Vmax = kcat [E]0 and [E]0 is the known initial enzyme 
concentration, kcat/KM was calculated for each mutant from the slope of the straight 
line obtained (Vmax/KM) (section 2.1.1, Figure 2.2). The values of kcat/KM obtained 
for the different 3C enzyme mutants and range from 10 to 1500 m
–1
 s
–1
 (section 
2.3.1, Figure 2.16). 
 Calculation of the correction factor (C) 
In order to account for the inner filter effect and prior to transforming the AFU 
into concentration units a correction factor (C) was experimentally determined 
(section 2.1.5). 100 μL of a solution of EDANS-NH2, at the same substrate 
concentrations used in the determination of kcat/KM and the corresponding 
calibration curves (0–90 μM, see above), was mixed with 100 μL of buffer or 
100 μL of an equimolar solution DABCYL-COOH. The fluorescence readings 
obtained for both types of solutions were compared to provide an experimental 
correction factor for each substrate concentration (section 2.1.5).  
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6.3.4 Enzyme–inhibitor complex  
In two spin columns with a 5 kDa cut-off (Vivaspin 500) a solution of Mutant 
A FMDV 3C
pro
 (25 μL, 430 µM in buffer A with 10% glycerol) was mixed with 
assay buffer (75 μL) and an excess of compound 15 in assay buffer (75 μL, 3 mM, 
final E–I, 1:21). Both solutions were incubated at 37 °C for one hour. The solution 
containing inhibitor was washed with five cycles of buffer exchange by adding 
assay buffer (200 μL), letting the solution stand for a minute and centrifuging to a 
final volume of 100 μL. Both solutions were then analysed by ESI-TOF MS by M. 
Sutton-Smith from Biopolymer Mass Spectrometry Group at Imperial College 
London and the m/z of the samples were obtained with an accuracy of ± 3.7 Da. 
6.3.5 Inhibition assays 
All inhibition assays required the determination of a relative rate, which was 
achieved comparing the initial rate of the free enzyme [Mutant A (50 µL, 2.4 μM) 
plus FRET substrate (1) (100 µL, 100 μM) and assay buffer (50 µL)] with the initial 
rate in the presence of the inhibitor at different concentrations and incubation times 
(depending on the experiment, see below) under the same conditions of time and 
temperature.  
 Determination of the IC50 
Mutant A (50 µL, 2.4 µM) was incubated with the inhibitor (50 µL) at twelve 
different concentrations (obtained by doubling dilution) for 30 minutes at 37 °C and 
readings of fluorescence were obtained upon addition of substrate (100 µL, 
100 µM) to the enzyme–inhibitor mixture. The first time an inhibitor was tested the 
initial inhibitor concentration was 1000 times the enzyme concentration (solubility 
permitting). For accurate IC50 determination the concentration was adjusted and the 
experiment was repeated three times for obtaining triplicates. The relative rates 
were plotted against inhibitor concentration in a log scale and the results were fitted 
to IC50 curves in GraFit (Leatherbarrow, 2003), the IC50 values and standard errors 
were obtained from the fit of the curves to the main values of the triplicates with a 
weighting based on their standard deviation (see section 3.3.2 for a graphic 
example). 
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 Determination of inhibition constants 
After the determination of the corresponding IC50 value experiments for the 
inhibition rates were performed according to the incubation method (Kitz and 
Wilson, 1962). Mutant A (50 µL, 2.4 µM) was incubated with the inhibitor (50 µL) 
at different inhibitor concentrations and readings of fluorescence were obtained 
upon addition of substrate (100 µL, 100 µM) at different incubation times (5 minute 
intervals up to 30 minutes). Time zero values were calculated by adding the enzyme 
(50 µL, 2.4 µM) to a mixture of the substrate (100 µL, 100 µM) with the 
corresponding inhibitor (50 µL). For curves defined with [I]0 ≥ 10[E]0 apparent first 
order kinetics were used, kobs were obtained from fitting the plot of the main 
relative rate from triplicates at each incubation time using the single exponential 
decay equation in GraFit (Leatherbarrow, 2003). kobs/[I] values were obtained from 
the slope of the straight line obtained from the plot of kobs against [I] for five 
different inhibitor concentrations and were expressed in M
–1
 s
–1
 units. The error 
stated corresponds to the fit of the straight line with a weighting defined by the 
standard errors from the kobs values. For values determined with less than 5 
concentration values the error stated corresponds to the deviation from the main 
value.  
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7.1 Amino Acid Nomenclature 
 
 
 
Table 7.1 Full names, side chains and 3 and 1 letter codes for natural and unnatural L-α-amino acids.  
R = H except for the cyclic amino acid proline. When referring to D-amino acids the name or code of 
the corresponding amino acid is preceded by a ―D-‖. 
Amino acid Side chain (R1) 3 letter code 1 letter code 
Alanine -CH3 Ala A 
Arginine -(CH2)3-Gnd Arg R 
Asparagine -CH2-CONH2 Asn N 
Aspartic acid -CH2-COOH Asp D 
Cysteine -CH2-SH Cys C 
Glycine -H Gly G 
Glutamic acid -(CH2)2-COOH Glu E 
Glutamine -(CH2)2-CONH2 Gln Q 
Histidine -CH2-(2-Imd) His H 
Isoleucine -CH(CH3)CH2-CH3 Ile I 
Leucine -CH2-CH(CH3)2 Leu L 
Lysine -(CH2)4- NH2 Lys K 
Methionine -(CH2)2-S-CH3 Met M 
Phenylalanine -CH2-Ph Phe F 
Proline -(CH2)3- Pro P 
Serine -CH2-OH Ser S 
Threonine -CH(OH)CH3 Thr T 
Tryptophan -CH2-(3-Ind) Trp W 
Tyrosine -CH2-(4-Ph-OH) Tyr Y 
Valine -CH(CH3)2 Val V 
Diaminobutiric acid -(CH2)2-NH2 Dab B 
Homoarginine -(CH2)4-Gnd hArg hR 
Norarginine -(CH2)2-Gnd nArg nR 
Norleucine -(CH2)3-CH3 Nle nL 
Ornithine -(CH2)3-NH2 Orn O 
OH
O
RHN
H R1
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7.2 The pET system 
In Figure 7.1 all the elements involved in a pET expression system are 
represented. With the presence of a T7 promoter upstream of the target gene, 
expression in pET vectors is induced by providing a source of T7 RNA polymerase 
in the host cell. The production of the polymerase is under control of a lac 
promoter, which remains inactive by binding of the lac-repressor protein and can 
be activated in the presence of galactose or its analog isopropyl-β-D-thiogalactoside 
(IPTG). After plasmids are introduced into a host bearing the T7 RNA polymerase 
gene (such as the DE3 E. coli strains) the transformed cells can be efficiently grown 
in absence of IPTG without expression of recombinant protein. Some strains also 
contain pLys plasmids which encode T7 lysosyme to suppress any basal expression 
of target protein. Subsequent addition of IPTG will cause expression of T7 
polymerase, and consequently, the target gene. The optimisation of FMDV 3C
pro
 
expression required the use of the BL21(DE3)pLysS cells presumably due to 
toxicity of active 3C
pro
 in normal DE3 hosts.  
 
Figure 7.1 Control elements of the pET expression system.  
In DE3 cells the T7 RNA polymerase gene is under the control of the lacUV5 promoter. The 
inherent leakiness of the lac promoter allows some degree of transcription in the uninduced state. 
Hosts carrying pLys plasmids (such as BL21(DE3)pLysS) encode T7 lysozyme, which is a natural 
inhibitor of T7 RNA polymerase reducing its ability to transcribe target genes in uninduced cells. 
Scheme taken from (Novagen, 2004).  
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7.3 The pET-28 vector  
The original construct, which was provided by Chris Proud, used for the 
expression of recombinant FMDV 3C
pro
, and the production of mutants, was built 
in a commercial pET-28b vector from Novagen. The different restriction sites 
present in the vector can be identified in the circular schematic representation 
(Figure 7.2). 
 
Figure 7.2 Commercial pET-28a-c(+) vectors.  
Unique restriction sites are shown on the circle map. The cloning/expression region of the coding 
strand transcribed by T7 RNA polymerase is represented by the black arrow. The three pET-28 
vectors (a, b and c) only differ on part of the expression region in that they contain different bases 
for the same restriction sites. From the distinctive regions ―ori‖ represents the origin for double 
stranded replication and ―f1 origin‖ the origin for single stranded replication in phage systems. Kan 
indicates the gene for the Kanamycin resistant marker, lacI is the coding region for the lac repressor 
(Figure 7.1). The the T7 promoter and lac operator (Figure 7.1) are at the begining of this expression 
region. Note the presence of an EcoR V site on the lacI region and Nco I on the expression region. 
Scheme taken from (Novagen, 2004).  
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7.4 Peptide–enzyme interactions 
 
Table 7.2 Enzyme–peptide interactions.  
Distances between peptide and enzyme residues found in the co-crystal structure of FMDV 3C
pro
 
Mutant iL and substrate 9 (section 2.3, Figure 2.18). Distances were ameasured between the atoms 
highlighted in bold. 
Pept. Res. Atom Enz. Res. Atom Distance (Å) Interaction 
P1′-Leu CH3 L47 CH3 3.29 hydrophobic 
P1′-Leu CH3 C31 SH 3.57 hydrophobic 
P1′-Leu CH3 C31 β-CH2 3.47 hydrophobic 
P1-Gln NH S182 CO 3.12 H-bond 
P1-Gln CO G161 NH 2.83 H-bond 
P1-Gln CO C163 NH 4.24 H-bond 
P1-Gln δCO H181 δ-CH-NH 2.58 H-bond 
P1-Gln δCO T158 OH 3.68 H-bond 
P1-Gln NH2 T158 CO 3.22 H-bond 
P2-Lys NH3 D146 CO 2.76 electrostatic 
P2-Lys NH3 D144 CO 3.59 electrostatic 
P2-Lys ε-CH2 L142 δ-CH3 3.88 hydrophobic 
P2-Lys γ-CH2 L142 δ-CH3 3.59 hydrophobic 
P2-Lys δ-CH2 H46 β-CH2 3.91 hydrophobic 
P2-Lys δ-CH2 H46 δ-CH-NH 3.44 hydrophobic 
P2-Lys δ-CH2 H46 NH 3.42 hydrophobic 
P3-Ala CO G184 NH 2.91 H-bond 
P3-Ala NH G184 CO 2.95 H-bond 
P3-Ala β-CH3 M143 S-CH3 4.06 hydrophobic 
P3-Ala β-CH3 M143 S 3.94 hydrophobic 
P3-Ala α-CH M143 β-CH2 4.16 hydrophobic 
P4-Pro CO M143 NH 2.67 H-bond 
P4-Pro α-CH G185 α-CH2 4.52 hydrophobic 
P4-Pro β-CH2 Y190 δ-CH 3.77 hydrophobic 
P4-Pro β-CH2 Y190 ε-CH 3.42 hydrophobic 
P4-Pro β-CH2 L142 δ-CH3 3.90 hydrophobic 
P4-Pro γ-CH2 L142 δ-CH3 3.57 hydrophobic 
P4-Pro γ-CH2 V140 γ-CH3 3.76 hydrophobic 
P4-Pro δ-CH2 Y190 ε-CH 4.40 hydrophobic 
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7.5 FMDV 3Cpro sequence alignments 
In order to identify the conservation of key residues involved in peptide 
recognition (Table 7.2 and section 2.3.3) the alignment of 3C protease sequences 
was performed with Clusal X (Thompson et al., 1997). The sequences were 
obtained from Genbank (Benson et al., 2005) for 107 genomes of FMD viral 
strains, from all seven sereotypes (section 1.2.1). The alignment is presented in the 
following pages as described below.  
The name of the viral strain to which the sequence belongs (first column) 
includes its sereotype (O, A, C, Asia1, SAT1, SAT2 and SAT3) and its genbank 
identification number (AY-------). The mutants used in this thesis correspond to the 
A10 viral strain (AY593751, indicated with an arrow). The symbols in the first row 
indicate the degree of conservation of the residue in that position: ―*‖ for a strictly 
conserved residue, ―:‖ for a strongly conserved residue and ―.‖ for a weakly 
conserved residue. The last row is a ruler that indicates the position of the residue 
within the sequence by numbering every 10 residues. 
Most of the residues interacting with the substrate (Table 7.2) are found 
between residues 140–213 (page 222), including C142 (L142 in the enzyme–
substrate co-crystal structure) and D144 and D146 (sections 2.3 and 4.2), and they 
are strictly conserved among the different viral strains.  
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